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Summary THE MECHANISM AND SITE OF ACTION OF CLONIDINE IN THE RAT
The inactin anaesthetized rat shews cardiovascular reflex
responses. Heat rate is under sympathetic but not vagal control.
Clonidine reduces the heart rate and blood pressure in the
inactin anaesthetized rat. The reduction in heart rate involves
reducing sympathetic cradiac drive. The fall in blood pressure
includes a reduction in peripheral resistance.
Using a newly developed "delayed" hindlimb perfusion the
reduction in peripheral resistance was seen to be neurally mediated.
A peripheral vasodilator action was not seen with clonidine.
Clonidine was administered by four different routes which were
expected to provide access to selected areas in the brain.
Intravenous, intracarotid artery, intraventricular and
intravertebral artery. Administration into the ventricular system of
the brain was slighty more potent in reducing arterial pressure than
intravenous injection. Intracarotid and intravenous were equipotent.
Intravertbral was by far the most effective, requiring 5% of the
intravenous dose to cause an equivalent cardiovascular response.
3
Autoradiography with H-clonidine was used to locate the
injected clonidine. The new CEA Verken tritium sensitive film was
used and proved able to detect very low levels of tritium. Each
route of administration resulted in a different pattern of
distribution.
Clonidine administered intravenously distributed evenly
throughout the CN3.
Intacarotid administration selectively reached rostral areas.
Intraventricular administration had the spread limited to
periventicular areas.
Intravertebral clonidine reached the medulla, pons, areas of
the cerebellum and upper areas of the 3pinal cord.
Comparison with the different hypotensive affects led to the








Abbreviations and Drug List
Chapter
1 Introduction And General Methods
Introduction 1-2
Current Status Of Clonidine 3
The Actions Of Clonidine 3-10
Cardiovascular 3- 4
Gastric Secretion 4- 6
Salivary Secretion 6- 7
Sedation 7- 3
Analgesia/Opiate Withdrawil 3-10
The Pharmacokinetics Of Clonidine 10-14
The Pnarmacology Of Clonidine 14-23
Alpha Adrenoceptor Interaction
Adrenoceptors 14-16
Clonidine As An Alpha Adrenoceptor Agonist 16-20
Clonidine As An Alpha Adrenoceptor Antagonist 20-21
Uptake 2 Antagonism 21
Purinergic Antagonist 22
Local Anaesthetic 22
Histamine H2 Agonist 22-27
Conclusions 27-23
Clonidine and Renin 28-29
The Site Of The Hypotensive Action Of Clonidine
Methodology 29-33
Peripheral Action 33-35
Indications For A Hypotensive Action Involving The CNS55-33
Biochemical Consequencies 33
Mechanism Of Bradycardia 39
Action On Baroreflex Arc 39-41
Central Catecholamines And Clonidine's
Cardiovascular Actions 41-
Microionophoretic Studies 42-
Purther Localization Of The Site Of Action
Porebrain 43-
Medulla/Pons 45
Ventral Surface Of Brainstem 45-
Medullary Reticular Formation 47
Floor Of Fourth Ventricle 47
Nucleus Of Solitary Tract 43
Spinal Cord 48-
Conclusions 51
Anaesthetics Different Hypertensive Models And Clonidine 51 -
General Methods 54-
2 IV Clonidine And The Inactin Anaestheitized Rat 8
3 "Delayed" Hindlimb Perfusion 8
4 Central Administration Of Clonidine 7
5 The Autoradiographies! Location Of Clonidine 20
6 Plasma Concentrations Of Clonidine 6
7 Conclusions And Suggestions For Further Work 4
Appendix
1 "Pulseless" Roller Pump 8
2 Neurophysiologies! Spike Discriminator And Counter 7
References 30












n nano. As in ng nanogram
p pico. As in pg picogram
pA2 log (1/concentration). Concentration of an antagonist requiring
doubling of the agonist concentration to restore the original
response.
SC subcutaneous
SHR spontaneously hypertensive rats
T1/2 half life, time taken for decline to half initial level




1) Mean blood pressure is obtained from systolic and diastolic:
2) Points on graphs are given with the standard error of the mean.
In its abscence the point represents only one result.
3) Only pages containing text and tables are numbered. Numbering
appears at the top right corner of each page and appears as a
chapter number followed by a page number. Page numbering starts anew
for each chapter.
4) Tables of results appear at the end of the relevent chapter. The
times noted are given with respect to the experimental manipulation
concerned e.g. -5 is five minutes before. The number given at time 0
is the absolute value and those given at other times are deviations
from the time 0 figure.
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The remit of this research project was to study the site and
mechanism of action of centrally acting antihypertensive drugs.
Centrally acting antihypertensive drugs have their locus of
action within the CN3 in contrast to diuretics, ganglion blockers,
alpha adrenoceptor antagonists, vasodilators, angiotensin converting
enzyme inhibitors, catecholamine depleters and Beta adrenoceptor
blockers. Centrally induced hypotension is characterized by a
reduction in vasoconstrictor nerve activity despite the fall in
blood pressure. This condition if generated peripherally classically
leads to a reflex increase in vasoconstrictor nerve tone.
Clonidine (Kobinger 1978), alpha methyldopa (Scriabine et al
1976) and certain Beta adrenoceptor blockers (Lewis et al 1975 and
1976) have central actions and find a clinical role in the treatment
of hypertension. Some B blockers cross the blood brain barrier
(Garvey & Ram 1975) and have central actions but as a class their
action is peripheral although the hypotensive mechanism is poorly
understood (Scriabine 1979). The hypotensive effect of alpha
methyldopa only becomes apparent over several hours (Kenning & van
Zwieten 1953), however clonidine acts within minutes making it
easier to manipulate experimentally. Therefore clonidine was the
centrally acting antihypertensive used in this research project.
Clonidine causes a fall in blood pressure and heart rate in man
and animals that is rapid in onset and persists for several hours.
The active dose is small, in the low aicrogram/Kg range, whilst Beta
blockers and methyl dopa are given in the low milligram/Kg range.
Despite being a very potent pharmaceutical clonidine's clinical use
is limited by side effects which are apparent at the
antihypertensive dose. They are a hypertensive action at high doses,
rebound hypertension when a course of treatment is precipitously
ended, sedation and reduced salivary secretion.
If the pharmacological properties associated with clonidine's
hypotensive action were established it would increase the
possibility of designing a new agent devoid of side effects. This
would have important clinical implications.
To separate the pharmacological properties from those
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attributable to pharmacokinetics it is necessary to establish the
3ite of action and then proceed with the application of
electrophysiological, biochemical and pharmacological techniques to
reveal the requirements for an antihypertensive action. Looking at
clonidine's pharmacological properties in isolation from the
hypotensive action is of U3e but does not necessarily demonstrate
those required for hypotension. Therefore the establishment of the
site of action i3 of prime importance in the understanding of the
hypotensive effect.
This study investigated the mechanism and site of action of
clonidine in the anaesthetized normotensive rat.
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A REVIEW OF THB CURRENT -STATUS OF GLONIDINE
Clonidine, also known as St 155, Catapres, Catapresan and DCAI
was developed as an alpha adrenergic agonist for use as a nasal
decongestant in the early sixties by Boehringer Ingelheim and
serendipitously proved to have antihypertensive properties. An
alternative story (Bowman £ Rand 1930) has clonidine proposed as an
additive for shaving cream, its alpha agonist action serving to
constrict severed vessels reducing bleeding and also to contract the
erector pili muscles making for a closer shave.
Clonidine has seen limited clinical use in blood pressure
control, has served as a tool in understanding the cardiovascular
system, played an important role in the subdivision of alpha
adrenoceptors, aided in the recognition of presynaptic receptors,
seen use in the treatment of glaucoma and shown a potentially
important interaction with opiates in analgesia and withdrawal. This
multiplicity of roles has led to clonidine's representation in
around 2000 papers becoming a minor research area in its own right.
The Actions of Clonidine
1 ) Cardiovascular
Clonidine is used as an antihypertensive in man for both
chronic and acute cases. Given acutely, systolic, diastolic and mean
arterial pressure fall, heart rate is reduced, cardiac output drop3
and variable changes in peripheral resistance are seen [Kroetz et al
(l9o9), Brest (1969), Bock et al (1959), Kho (1976)]. In the supine
position no consistent alterations in peripheral resistance appear,
measured standing a reduction is seen (Brest 1969). The reduced
cardiac output is not spread equally among tissues, skin blood flow
falls while that to muscle is unchanged (Bock et al 1969). Responses
to exercise, tilting and the valsalva manoeuvre are maintained
although the tilt response is reduced [Muir (1969), Dollery et al
(1976)]. The cold pressor response is attenuated but this may relate
to the analgesic properties of clonidine (Dollery et al 1976).
Orthostatic hypotension and exercise syncope are not seen with
clonidine. A pressor response is seen after rapid IV dosing (Bock et
al 1959), in patients already receiving hypotensive therapy (Kroetz
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et al 1969) and in patients given large doses (Wing et al 1977),
(Saarima 1976). Given rapidly IV a high plasma level is briefly
attained and a direct peripheral action of clonidine causes
vasoconstriction. In patients already on hypotensive therapy
clonidine may be unable to reduce blood pressure further and a
sustained rise may appear in arterial pressure reflecting a direct
action on the vasculature. When high doses are administered a
peripheral vasoconstrictor effect is superimposed on central
hypotensive action resulting in an increase in blood pressure. A.
physician when faced with an inappropriate response may increase the
dose, further compounding the problem. Longterm therapy leads to a
restoration of cardiac output and a fall in peripheral resistance
(Reubi et al 1 959).
On the cessation of clonidine therapy rebound hypertension and
withdrawal symptons may occur. Geyskes et al (1979) and Hunyor et al
(1973) reported tachycardia, hypertension, headache, nervousness,
palpitations and nausea. An increase in noradrenaline excretion also
occurred. Withdrawal is not reported in all patients (Conolly et al
1969). The distinction between rebound hypertension and a return to
pretreatment blood pressure and heart rate is unclear but may be
assumed to occur when the levels on withdrawl exceed those prior to
treatment. The non-cardiovascular manifestations are similar to
those encountered with opiates.
Discussion of the mechanisms involved appears in the sections
on the site of action and pharmacology of clonidine, in this
chapter.
2) Gastric Secretion
Gastric acid secretion is reduced in man (Kaess 8a Von Mikulitz-
Radecki 1971) by clonidine but under experimental conditions
alterations in either direction are possible.
In anaesthetized rats clonidine 30-1000ug/Kg IV (Walz & van
Zwieten 1970), 625-5000ug/Kg IP (Cheng et al 1931), 1000ug/Kg IV
(Jennewein 1977) and 500ug/Kg IV (Karppanen & Westermann 1973)
increased gastric acid secretion. This action is shared by histamine
and both are antagonized by similar doses of histamine H2
antagonists [Karppanen & Westermann (1 973), Jennewein (1 973),Parsons
(1973),Cheng et al (1931 )] intimating that histamine H2 receptors
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are involved. Phentolamine leaves the stimulant action of cloniiine
unaltered showing that adrenoceptors are not involved (Cheng et al
1931). Atropinisation does not reduce clonidine-induced acid
secretion indicating that this action is not vagally mediated.
In unanaesthetized dogs and rats clonidine 1O0Oug/Kg (Walz d
van Zwieten 1970), 3-1000ug/Kg (Jennewein 1977), 30ug/Kg SC (Pascaud
& Roger 1976), reduced gastric acid secretion. Clonidine injected
into the lateral ventricles is more potent than IV administration
suggesting a central site of action . This is also implicated by
clonidine's ability to reduce insulin and 2-deoxyglucose induced
acid secretion, which are centrally mediated whilst the effects of
the peripherally acting agents histamine, carbachol and bethanechol
are unchanged or enhanced.
Clonidine reduces acid production resulting from vagal
stimulation and in this role is itself antagonized by phentolamine
revealing the presence of adrenoceptors, probably presynaptic. The
importance of this peripheral action is hard to assess since the
experimenters did not use a range of doses and stimulation
frequencies.
The differences found in anaesthetized and unanaesthetized
animals become explicable when it is appreciated that anaesthesia
greatly reduces basal acid production by reducing vagal tone and
that increased acid secretion only occurs at high doses of
clonidine. Jennewein (1977) found acid production reduced in a dose
related manner 3-100ug/Kg and that further increases up to 1000
ug/Kg ware no more effective, Pascaud & Roger (1976) report an BT)50
of 20 ug/Kg. In anaesthetized animals low doses are inactive as
there is no vagal tone to reduce but as the dose rises an increase
mediated by H2 receptors is seen. In unanae3thetized animals
clonidine acts centrally to reduce acid secretion, as the dose rises
a peripheral action on the vagus further decreasing secretion would
be anticipated. However Boissier et al (1970) could not demonstrate
this effect with a do3e of 100ug/Kg, a dose found to reduce acid
production maximally. Therefore a vagal presynaptic action probably
has no role in unanaesthetized animals. A stimulant action has not
been reported in unanaesthetized animals probably because
sufficiently high doses have not been employed.
Clinically clonidine has not been used to treat gastric
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ulceration and investigation of this area has received little
attention. Some anecdotal refences were made at the 1959 symposium
"Catapres in Hypertension" which suggested that clonidine was
ineffective clinically (p213-214).
In conclusion clonidine acts centrally to reduce gastric acid
secretion and at high doses stimulation is apparent.
3) Salivary Secretion
A. dry mouth is reported by 44$ of patients receiving clonidine
(Houston 1931). Bock et al (1969) found salivation reduced
maximally, by 80$, 50 mins after 150 ug clonidins IV in 3 subjects.
In addition to the reduction in flow the sodium concentration fell
slightly and that of potassium nearly doubled. The increase in
potassium was progressive over the 100 mins after clonidine whilst
the reduction in flow was maximal at 50 mins recovering thereafter.
Dollery et al (1976) gave 300 ug orally to five subjects, salivary
flow was reduced maximally at 1 and 2 hrs after administration and
progressively recovered over the next 6 hours though to only 1/3 of
the original level. The reduction in flow correlated extremely well
with plasma concentration. Parotid pain is reported by a small
proportion of patients taking clonidine, generally at the start of a
meal, and may be related to the reduction in saliva production and
the increase in viscosity.
Davis and Maury (1978) found clonidine to reduce the adrenaline
mediated efflux of potassium from isolated rat parotid cells.
Clonidine alone was inactive but in receptor binding studies
antagonized dihydroergotamine. This antagonism was found with a
number of imidazoles. In vivo clonidine increases potassium levels
in saliva (Bock et al 1969) suggesting that a direct action on
salivary glands is not involved clinically.
Patients report that dryness of the mouth is worst over the
first few days of treatment and often subsides completely over 2-3
weeks (Kellett and Hamilton 1969).
Rand et al (1969) in the dog found that peripherally induced
increases in salivation, by pilocarpine, were unaltered by clonidine
but that increases as part of conditioned reflexes were reduced,
implicating a central site of action.
Sweet et al (1977) similarly found that clonidine reduced
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conditioned salivation and that St 91 , an alpha agonist unable to
penetrate readily the blood brain barrier, had no effect. In
consequence the reduction in salivation appears to involve a central
action.
4) Sedation
Sedation is the most commonly reported side effect of
clonidine, occurring in 50$ of patients (Houston 1931). Dollery et
al (1976) with a 300 ug/Kg oral dose found peak sedation after 2
hours after a slow onset, leading to a steady recovery over the next
6 hours, but not to the predose level. Elkeles et al (1969) found
that the reported level of sedation was greatest during periods of
inactivity and with continual treatment tolerance appeared over 4
weeks. Kellet & Hamilton (1959) with 12 patients reporting sedation
as a side effect, out of 26, also found tolerance appearing over
several weeks. With one exception the affected group found no
trouble concentrating during the day but fell asleep on relaxing.
Hoobler & Sagastume (1959) in a longterm study found transient
drowsiness 2-3 hours after dosing, tolerance appeared but an
increase in the dose led to a brief reappearance.
Sedation is unlikely to be the cause of the hypotension seen
with clonidine, although the time courses correlate well. Sedation
is not present in all patients, tolerance to sedation is more marked
than to hypotension and sedation is 3een at doses in excess of the
minimum hypotensive concentration.
Sedation can be demonstrated in young chicks with 20 ug/Kg IM
clonidine but lasts only a few minutes (Zaimis 1969). This sedation
is not reduced by phentolamine which is effective in reversing
sedation produced by adrenaline, suggesting different sites of
action.
Delbarre d Schmitt (1973) in chicks and mice found that of a
range of adrenoceptor antagonists employed only yohimbine reduced
sleeping time. Yohimbine is an alpha adrenoceptor antagonist but
other alpha antagonists were ineffective or prolonged sleeping time.
Phentolamine was not used in this study.
Cavero & Roach (1977) found phentolamine but not prazosin, an
alpha 1 adrenoceptor antagonist, effective in reducing clonidine
sleeping times in chickens.
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Timmermanns et al (1931 ) measuring sleeping times in mice found
rauwolscine and yohimbine to be effective antagonists of clonidine
but reported no action for corynanthine.
In the cat clonidine suppresses paradoxical sleep (REM sleep)
which is sensitive to alpha 2 but not alpha 1 adrenoceptor
antagonists. In the rat yohimbine and phentolamine were ineffective
and failed to alter the clonidine sleeping time (Makela & Atkonen
1930). However the dose of clonidine was high, 100 ug/Kg, and
effects of yohimbine were reported between four and eight hours
after treatment.
The work with antagonists suggests that the receptor involved
has the characteristics of an alpha 2 adrenoceptor. Central
hypotensive actions are thought to be mediated by the same receptor
but Clough et al (1978) were able to alter the ratio of
sedative/hypotensive action in a series of clonidine like compounds,
suggesting that the two actions do not share a common receptor.
5) Analgesia/Opiate Withdrawal
Clonidine shows analgesic properties in a variety of tests on
rats and mice. Paalzow (1974) using rats found that clonidine caused
a dose dependent increase in the vocalization threshold and
vocalization after discharge in response to electrical stimulation
of the tail. No change in the motor response was noted except with
10mg/Kg whilst 79 ug/Kg of clonidine produced the analgesic effect.
Mice required higher doses 2.5-10 mg/Kg. Fielding et al (1979) in a
battery of tests found reactions to doses as low as 30 ug/Kg SC,
phenylquinone induced abdominal constriction in the mouse, but
required 2.5 mg/Kg SC for a rat tail withdrawal. In man studies on
analgesia do not appear to have been undertaken, however Dollery et
al (1975) using a cold pressor test found that 2 out of 5 subjects
thought that the painful stimulus was reduced after clonidine and in
all subjects the pre33or response was reduced.
Clonidine is more potent than morphine (Fielding et al 1979)
(Spaulding et al 1979a & b). The two drugs act synergistically, the
combined effect is more than additive (Spaulding et al 1979a).
However clonidine analgesia is distinct from opiate induced. It is
insensitive to naloxone (Fielding et al 1979) (Spaulding et al
1979a), and receptor binding studies (Golembiowska-Nitikin et al
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1930) do not show an action of opiates at clonidine binding sites in
the cortex. Clonidine analgesia is sensitive to yohimbine but not
prazosin showing that alpha 2 adrenoceptors are involved (Hoefke Sc
Jannewein 1931). Phenoxybenzamine failed to block the tail flick
induced by heat in the mouse, showing the non involvement of alpha 1
adrenoceptors (Fielding et al 1979).
Tolerance develops to clonidine analgesia (Paalzow 1973) but
cross tolerance to morphine is not seen (Spaulding et al 1979a).
Paalzow (1978) does not support this contention. However this is not
the only possible interpretation of the data presented. The absence
of cross tolerance has clinical implications with clonidine 5 ug/TCg
being used to treat opiate withdrawal in man (Gold et al 1978).
Conversely morphine suppresses the cardiovascular manifestations of
clonidine withdrawal in the 3HR, although the withdrawal-induced
tachycardia was not abated (Thoolen et al 1 931 ). This action of
morphine is naloxone sensitive. Naloxone pretreatment is reported to
reverse the hypotensive response to clonidine in the 3HR (Farsang Sc
Kunos 1979) but in man Watkin3 et al (1930) found no interaction.
This may reflect the different doses of naloxone used, 0.2 mg/Kg IP
in the SHR study and 0.3 mg IV in the human study. There is much
evidence for a role of opiates within the cardiovascular system: in
spinal shock (Holaday & Faden 1930), with inhalation anaesthetics
(Arndt # Freye 1979), endotoxin 3hock (Holaday & Faden 1978), vagal
bradycardia (Laubie et al 1979), in central control (Feldberg Sc Wei
1977) (Wallenstein 1979), raised blood pressure is one of the
manifestations of opiate withdrawl. Blood pressure in experimentally
induced hypertension develops alongside an increase in pain
threshold (Zamir and Segal 1979). This appears at odds with the
observation that SHRs become progressively more irritable but
suggests that the relationship between the cardiovascular system and
analgesia is worth investigating
The analgesic action of clonidine is thought to be mediated by
both spinal and supraspinal sites (Spaulding 1979). Aghajanian
(1978) recording from locus coeruleus neurones found both clonidine
and morphine to reduce the number of action potentials recorded,
piperoxan (alpha 2 adrenceptor antagonist) antagonized clonidine and
naloxone antagonized morphine but the antagonists were specific to
each agonist. Further clonidine reduced the enhanced rate of
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discharge seen in morphine dependent rats given naloxone. This
indicates that a common receptor does not exist in the locu3
coeruleus (LC) and suggests the LC as a possible central site of
clonidine analgesia. The failure of either yohimbine to effect
morphine analgesia or naloxone to alter clonidine analgesia implies
that the separate sites of action are not sequentially located in an
analgesic neuronal system or that if this is the case the rostral
site is quiescent in the absence of clonidine or morphine.
Overall clonidine has analgesic properties to which tolerance
develops, is used to treat opiate withdrawal, has spinal and
supraspinal actions and involves alpha 2 adrenoceptors.
The Pharmacokinetics of Clonidine
The pharmacokinetics of clonidine have proved difficult to
investigate because its potency results in low tissue levels with
consequent problems of detection. To overcome this problem early
investigators used large doses of clonidine. This assumes that
extrapolation to lower doses is valid.
In man clonidine is well absorbed orally. It is equipotent when
given IV or orally although the rate of onset of action is much
faster by the former route (Davies et al 1977). Plasma levels
correlate well with sedation and reduced saliva production (Dollery
et al 1976). But for hypotension the correlation only holds for
plasma levels up to 3 ng/ml (Frisk-Holmberg & Paalzow 1979)(Reid et
al 1930). However Frisk-Holmberg (1930), using continuous infusions
to maintain a steady plasma concentration of clonidine, found that
the decrease in blood pressure was progressive, showing that plasma
concentration alone is not the only determinant of hypotensive
activity. In man the reported plasma half lives are similar: 20 hrs
(Rehbinder 1959, Rehbinder & Deckers 1969), 11 hrs (Davies et al
1977), 13 hrs (Dollery et al 1975), 11 hrs (Frisk-Holmberg & Paalzow
1979). Though a wide range is found between subjects studied
between 6-24 hrs after administration of clonidine (Dollery et al
1975). The plasma T1/2s have led to twice or thrice daily dosing. 4s
noted in the sections on sedation and salivation these unwanted
effects appear most markedly shortly after oral administration,
corresponding to the peak in plasma concentration. To reduce these
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fluctuations a slow release preparation is available, Catapres PL
Perlongets (Boehringer Ingelheim Ltd.)? intended for administration
once a day. Tolerance develops to the sedative action of clonidine
and to reduce its occurence the dosage is built up slowly (Velasco
et al 1976). Similarly to avoid withdrawal symptoms dosing is
curtailed slowly. Excretion occurs in both urine and the faeces with
4-0-60$ appearing in the urine unchanged and 15-50$ in the faeces
(Houston 1931) (Rehbinder & Deckers 1969) (Davies et al 1977).
Rehbinder (1969) and Rehbinder & Deckers (1969) using C
labelled clonidine found clonidine to be readily absorbed after oral
administration in the dog, rat, monkey and man. In the rat peak
plasma levels of radioactivity were found after one hour and
declined with a half life of ten hours. In the other animals
absorbtion was slower but the half lives were of a similar order of
magnitude. Excretion was investigated by recovering G—14 from urine
and faeces. Over 72 hrs urine accounted for between 65 (rat) and 33$
(monkey) of the given dose with the remainder appearing in the
faeces. Metabolites in the urine were separated chromatographically
and detected autoradiographically. This exposed differences between
the species studied in respect of metabolites and the perecentage of
the original dose excreted unchanged. In the rat 53$ was present
unchanged in the urine with 22$ as para hydroxy clonidine whilst in
the monkey only 14-$ appeared as clonidine with the balance as one of
six metabolites that did not include 6 hydroxy clonidine.
In a similar study (Cho & Curry 1969) using 500 ug/Kg IP in
rats 40$ of the C-1 4 was recovered from the urine over 72 hrs of
which 35$ was clonidine. The plasma T1/2 was 3-25 hrs whilst it was
2 hrs for the stomach and heart. This study also reported binding to
plasma proteins of between 40-62$ and to tissue homogenates 15-30$.
Jarrott & Spector (1978) 100 ug/Kg IV in the rat found T1/2 of
90 mins for plasma and 25 mins for the brain, with peak levels in
the latter appearing after 2 mins. Pour hydroxy clonidine (also
known as St 666) was detected in the plasma after 60 mins and after
90 mins was present in a higher concentration than clondine. This
metabolite was noted by (Rehbinder 1969) in urine. It is a potent
alpha adrenoceptor stimulant.
Conway & Jarrott (1930) using a sensitive radioimmunassay for
clonidine were able to use doses in the hypotensive range, 20 ug/Kg
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IV in the rat. They found T 1/2 3 to be similar for all tissues,
around 1 hr although that of the corpus striatum in the brain was
longer. As clonidine is lipophylic, movement between tissues should
be easy and therefore T1/2s similar.
There are major differences between the T1/2s reported by
authors for the rat which may be related to the period over which
tissue levels were monitored and/or the different dose used.
Clonidine is a lipophylic drug whose plasma levels drops very
rapidly after bolu3 dosage. Therefore the initial distribution is
likely to reflect the blood flow to the tissue or organ. Areas with
a high blood flow might be expected to exhibit an initially high
drug level which would decline as the pattern of distribution comes
to reflect lipid content and specific binding. It follows that the
T1/2s for different areas will vary in the first few minutes after
administration but become more uniform later when changing drug
levels reflect excretion and metabolism rather than redistribution.
Nerve discharge in the locu3 coeruleus was briefly inhibited by
clonidine IV, the inhibition lasted for only a few minutes (Svensson
et al 1975). This probably follows the concentration of clonidine in
the CNS, the brief inhibition occurring at a time when concentration
reflects tissue blood flow and the rapid offset following
redistribution to tissues with lower blood flow3. If the rate of
metabolism follows first order kinetics or is altered by the
anaesthetics used the different T1/2s become explicable. Larger
values would reflect larger doses if metabolism was rate limiting.
Metabolic studies do not appear to have been undertaken with this in
mind though Frisk-Holmberg St Paalzow (1 979) refer to dose related
alterations in the pharmacokinetics.
Clonidine is a basic drug with a pKa of 8.05 (Struyker Boudier
et al 1974). It follows that at pH 7.4 18'^ is present in an
unionized form. At this pH clonidine has an apparent partition
coefficient of 3.0 (Hoefke et al 1975) or 9.3 (Jarrott et al 1979)
in octanol/water or 4-95 between chloroform/water (Struyker Boudier
1974) and a true partition coefficient of 27- The true partition
coefficient is independent of pH and only concerns the differential
distribution of the unionized form of the drug. Therefore at the pH
found in plasma clonidine is a lipophylic drug and as such would be
expected to rapidly equilibrate across lipid barriers. It follows
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that equilibration will occur across the kidney tubules and that the
rate of excretion will be exponential, which is found. Further it
would be expected that the rate of excretion will reflect urinary
flow and pH. These do not appear to have been investigated but might
explain the wide range of plasma T 1/2s found in man.
Lipophilicity is a requirement for movement from plasma into
the CN3. In the absence of active secretion the blood brain barrier
reduces penetration by ionized molecules and poorly lipophilic
substances. It is not an absolute barrier but combined with removal
of substances from the cerebral extracellular fluid by bulk C3F flow
it leads to much lower CN3 than plasma concentrations.
Timmermans et al (I977a,b) using clonidine and clonidine
analogs found that the brain concentrations, measured at the time of
maximum blood pressure fall, were proportional to the doses given
IV. The slope of the brain/plasma concentration graph was linear and
reflected the lipophilicity of each substance. The study concluded
that "the brain concentration is a measure of the hypotensive
effect". It may be developed as an argument for a central site of
action, that the brain concentration determines the hypotensive
effect. This is specious as the concentration at any time is likely
to be dose dependent and as the hypotensive effect is similarly dose
dependent the argument may be ma^e for any tissue. Measuring the
concentration at the time of maximal blood pressure fall does not
enhance the case. Struyker-Boudier et al (1975) compared clonidine
with St 666, finding that the latter is a potent alpha adrenceptor
agonist but ineffective in lowering blood pressure when given IV.
Applied by injection into the hypothalamus it has a similar potency
to clonidine in reducing heart rate. The apparent partition
coefficients are 4-95 for clonidine and 0.003 for St 666, suggesting
that St 666 is unlikely to penetrate the blood brain barrier and
explaining the discrepancy between IV and intrahypothalamic dosing.
Tnis is an argument for a central site of action for clonidine,
assuming that alpha adrenoceptor stimulation is the mechanism. St
666 is an important metabolite of clonidine in the rat but is
unlikely to have central actions. As an alpha adrenceptor agonist it
may exert peripheral actions on pre and post synaptic receptors and
contribute to the progressive recovery in arterial pressure seen
with clonidine after a single IV dose. Jarrott and Spector (1978)
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measured the plasma levels of St 666 and found appreciable levels 30
mins after clonidine. Conway and Jarrott (1930) found that the T1/2
for clonidine levels and the hypotensive effect were similar in the
rat, however no account was taken of possible pressor actions of St
666.
Hoefke et al (1975) compared the partition coefficients of St
91, a clonidine analog, and clonidine with the hypotensive potency
when given IV or ICV. St 91 has an apparent partition coefficient of
0.06 and given IV fails to reduce blood pressure, given ICV it is
active. Comparison with clonidine, lipophilic and potent IV and ICV
establishes the importance of lipophilicity for IV antihypertensive
potency and points to a central site of action.
Overall lipophilicity is a requirement for IV potency. It is
important to note that though lipophylic only about 2% of the
clonidine given IV is present in the brain (Timmermans et al 1977,
Conway & Jarrott 1930).
The Pharmacology Of Clonidine
This section examines pharmacological effects of clonidine. It
is generally regarded as an alpha adrenoceptor agonist with a
preferential alpha 2 action but a variety of other actions have been
suggested: purinergic antagonist, uptake 2 blocker, histamine H2
agonist, alpha adrenergic antagonist and membrane stabiliser.
Alpha Adrenoceptor Interaction
1. Adrenoceptors
Adrenoceptors were divided into two groups, alpha and beta by
Alhquist (1943) and by Lands et al (1957) into beta 1 and beta 2.
More recently alpha receptors have been separated into alpha 1 and
alpha 2 on the basis of agonist and antagonist potency. Starke et al
(1975) using rabbit pulraomary artery strips found differences in
pre and post synaptic adrenoceptor actions in a range of alpha
adrenoceptor agonists: methoxamine and phenylephrine were
preferential post synaptic agonists, noradrenaline, adrenaline and
naphazoline were of similar potency and oxymetazoline, alpha
methylnoradrenaline and tramazoline more potent on pre synaptic
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receptors. Using antagonists Doxey et al (1976) found yohimbine and
phentolamine more potent antagonists at presynaptic receptors and
phenoxybenzamine and prazosin more active on postsynaptic receptors.
The antagonist with the largest pre/post ratio is rauwolscine (alpha
yohimbine) (Tanaka et al 1978).
Alpha adrenoceptors occur pre and postsynaptically. Presynaptic
receptors serve to modulate transmitter release. The initial
subdivision into two classes, alpha 1 and 2, coincided with the two
locations but the discovery of postsynaptic alpha 2 receptors in the
vasculature has invalidated this arrangement (Draw et al 1979),
(Kobinger & Pichler 1931), (Timmermanns 4 Van Zwieten 193Qa,b).
This may be related to the two populations of excitatory receptors
for noradrenaline found in arteriolar smooth muscle (Hirst 4 Neild
1930). Kobinger 4 Pichler (1931 ) found each type of alpha 2
adrenoceptor pre and postsynaptically.
Within the GN3 two types of alpha adrenoceptors have been
identified. Miach et al (1978), using H-dihydroergotamine
displacement from rat brain homogenates, demonstrated two binding
sites with differential preferencies for prazosin and yohimbine.
U'Prichard et al found two binding sites for prazosin and two
separate binding sites were noted by Sreenberg 4 Snyder (1977) and
Peroutka et al (1977). Hammer et al (1930) identified two clonidine
binding sites with Kds of 0.4 and 6.1 nM as did Vetulani et (1979),
but Jarrott et al (1978) found only one with a Kd of 1.7 nM and
U'Prichard et al (1979) located a high affinity site with a Kd of
0.4 nM. Hill plots indicate no cooperative binding. The binding at
the two sites generally conforms with pharmacologically identified
alpha adrenceptors found in the periphery. Binding studies alone are
insufficient to establish the presence of pharmacologically active
receptors, which further requires a physiological response. Anden et
al (1976) provide functional evidence for two classes of central
adrenoceptors and Aghajanian 4 Van der Maelen (1932), using
ionophore3is of drugs close to neurones, clearly established the
existence of central alpha 2 adrenoceptors. Anden et al (1976)
found clonidine le3S potent in stimulating the hindlimb flexor
refLex and potentiating the apomorphine induced locomotor activity
than in reducing the alpha-methyl-tyrosine mediated disapperance of
noradrenaline from the brain and spinal cord. The former occurred
Chapter 1 16
with 0.4 mg/Kg IP and the latter at only 0.1 rag/Kg IP.
Phenoxybenzamine and haloperidol were more effective than yohimbine
and piperoxane at abolishing the functional effects whilst the
potencies were reversed for the biochemical changes consequent on
clonidine.
Central alpha adrenoceptors appear both presynaptically and
postsynaptically, Helder et al (1931) found an alpha 2 adrenceptor
mediated reduction in electrically evoked catecholamine release from
cortical slices, a presynaptic effect. U'Prichard et al (1979)
destroyed noradrenergic nerve terminals in the rat corpus striatum
without reducing either alpha 1 or alpha 2 binding, indicative of a
postsynaptic location for each in this area of the brain. Dausse et
al (1932) in cerebral cortex found a 20$ reduction in alpha 2
adrenceptors after le3ioning with 5 hydroxydopamine whilst alpha 1
adrenoceptors increased slightly, locating alpha 2 pre and
postsynaptically and limiting alpha 1 to postsynaptic sites. This
pattern of distribution is the same as that commonly reported in the
periphery, with alpha 1 appearing only post and alpha 2 at both
locations. Presynaptic alpha adrenoceptors within the CN5 are not
confined to catecholamine-containing neurons and are seen on
serotonergic nerve terminals (Maura et al 1932).
In the periphery alpha adrenoceptors of cardiovascular
importance are found in the vasculature mediating vasoconstriction
(alpha 1 & 2), in presynaptic nerve terminals in the autonomic
nervous system reducing transmitter release (alpha 2) and in the
myocardium causing a positive inotropic effect (receptor
uncharacterized) (Williams et al 1973). The latter appears of little
physiological importance, is antagonised by phentolamine and i3
distinct from B 1 adrenoceptor mediated inotropism.
Within the CN3 alpha adrenoceptors are widely distributed and
are discussed further in the section on the site of hypotensive
action of clonidine, later in thi3 chapter.
To establish that central and peripheral alpha adrenoceptors
are the same would be of great use. A binding study using a
3
homogenate of central and peripheral tissue and H clonidine could
be used. If only the two binding sites found with brain tissue were
found in the mixed homogenate then it might be reasonably be
concluded that the receptors are the same. This study does not
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appear to have been undertaken.
2. Clonidine ae an alpha adrenoceptor agonist.
In the isolated aorta, whole animal and eat nictitating
membrane elonidine shows alpha adrenoceptor activity.
The action on the aorta is constrictor, similar to adrenaline
and noradrenaline. It is sensitive to phenoxbenzamine (Constantino $
McShane 1968) and phentolamine (Boissier et al 1963). However it is
not a full agonist having a lower maximal effect than adrenaline and
noradrenaline (Medgett et al 1978), a less steep drug response
curve, shows greater receptor protection against phenoxybenzamine
than adrenaline and reduced the constrictor response to a dose of
adrenaline othrerwise able to evoke the maximal response.
Phenoxybenzamine binds covalently to alpha adrenoceptors but binding
is prevented if an agonist is present. The implication behind
clonidine's greater protective role than adrenaline, despite a
smaller constrictor action, is that it occupies the receptor but
only stimulates it weakly, i.e. it acts as a partial agonist.
A bolus injection IV produces a brief pressor response in
perfused limbs, intact and spinal animals, which IV phentolamine
abolishes (Constantine and McShane 1969) showing it to involve aloha
adrenoceptors. Immunosympathectomy (Zaimis 1963) and reserpinization
(Autret et al 1971) do not diminish the pressor action which
therefore does not involve catecholamine release. Low doses of
clonidine, 20 ug/Kg, potentiate the pressor effect of IV adrenaline
and noradrenaline, whilst dose3 greater than 100 ug/kg, reduce the
pressor effect, revealing an intrinsic activity of less than one.
Tne pressor effect in pithed rats is of short duration, following
the rapid decline in plasma level seen with bolus administration
(Docherty & McGrath 1930) and the peak effect depends upon the
rapidity of the injection. It is assumed that the pressor effect
involves alpha 1 adrenoceptors but the establishment of postsynaptic
alpha 2 adrenoceptors (Drew et al 1979) in the vasculature
necessitate a reappraisal.
Bentley et al (1977) noted the ability of prazosin (competitive
alpha 1 adrenoceptor antagonist) to reduce noradrenaline induced
contractions in human visceral arteries but its failure in
peripheral arteries where phentolamine was efficacous (preferential
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alpha 2 adrenoceptor antagonist, with some alpha 1 action). Using
cats and pithed rats marked differences were seen in the
effectiveness of each antagonist in reducing the vasoconstricting
actions of phenylephrine, noradrenaline and nerve stimulation.
Prazosin was ineffective with nerve stimulation, moderately
effective with noradrenaline and potent with phenylephrine, while
phentolamine antagonized all three well. Clonidine in the pithed rat
(Autret et al 1971) is less potent as a vasoconstrictor than
noradrenaline but has a similar maximal response, phentolamine
causes a parallel shift in the log dose response relationship,
suggesting competitive antagonism. Clonidine is more potent at alpha
2 adrenoceptors, which are clearly established in the vasculature,
but in the pithed rat very different time courses are found for
actions on the vasculature and presynaptic inhibition (Docherty &
McGrath 1930). Both should involve alpha 2 adrenoceptors and
therefore have a similar time course. The central hypotensive action
of clonidine is also attributed to alpha 2 adrenoceptor stimulation
yet the hypotensive dose does not display a concomitant pressor
action. In doses above therapeutic levels a pressor effect is seen
Wing et al (1977) and at plasma levels above 3 ng/ml the correlation
with hypotensive activity falls. But if both actions stem from a
similar receptor a pressor action should be discernible. It could be
that a peripheral action is masked by pressor action of circulating
catecholamines, or that clonidine may act as an antagonist. Boissier
et al (1958) in cats, dogs and rats found potentiation by low doses
of clonidne of the pressor actions of adrenaline and noradrenaline
but antagonism by high, showing a partial agonist action.
Noradrenaline is slightly more potent, ratio 1.3, at alpha 1 than 2
adrenoceptors (Starke et al 1975) and active on alpha 2 at similar
concentrations to clonidine. In the pithed rat clonidine (Autret et
al 1971) appears as a full agonist, although competition with
noradrenaline was not researched. In the pithed rat levels of
catecholamines will be low and a maintained pressor effect of
clonidine expected. It's absence needs to be explained. Fla-136, a
clonidine analog, lowers blood prressure when applied ICV and like
clonidine has its cardiovascular effects reduced by yohimbine ICV
(Hamilton & Longman 1979). Given IV Fla-136 has no pressor actions
which may be indicative of differences between central and
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peripheral alpha adrenoceptors.
In a close arterial infusion tachyphylaxis to clonidine but not
noradrenaline appeared (Zaimis 1968) a confusing finding not
supported by later workers on the cardiovasclar system (Ruffolo et
al 1977). Tachyphylaxis is seen with imidazole alpha agonists
(clonidine, oxmetazoline etc) on the rat vas deferens and not with
phenylethylamine alpha agonists (adrenaline, noradrenaline etc).
Further, imidazole-induced tachyphylaxis does not extend to the
phenylethylamines, suggesting that different sites of action are
involved. Binding studies with dihydroazetepine reveal antagonism by
imidazoles but potentiation with phenylethylamines. The p.A? with
phentolamine is similar for each group of agonists. The authors
propose that each class of agonist acts at a separate location on
the receptor and explain the similarity between pA^s as occurring at
a part of the receptor shared by both families of alpha agonists.
Kobinger et al (1931) found tachyphylaxis to the vasoconstricting
effect of clonidine in the perfused rat hindquarters preparation,
cross tolerance was seen with noradrenaline. Although the repeated
application of noradrenaline did not not lead to a diminution in
response. Tachyphylaxis does not appear with the pressor response in
the pithed rat and this discrepancy needs to be explained. Kobinger
et al (1931 ) refer to loss of intrinsic tone in the hindlimb
vasculature but do not explain why this is not apparent in the
pithed rat. Zaimis (1963) found tachyphylaxis with clonidine after
close arterial infusion and loss of intrinsic tone is unlikely in
this preparation.
Presynaptic alpha 2 adrenoceptors reduce transmitter release
from autonomic nerve terminals (Langer 1977, 1977), conversely
antagonists increase release (Docherty & McGrath 1979)- Clonidine is
active at this sits. Starke et al (1975) compared the reduction in
D3
H noradrenaline efflux after electrical stimulation of an isolated
pulmonary artery with the postsynaptic constrictor action. Clonidine
has a pre/postsynaptic agonist ratio of 6 and phenylephrine 0.03 a
major discrepancy in the prevailing assumption of alpha adrenoceptor
homogeneity. The PA^ of phentolamine with a range of agonists also
differed markedly pre and postsynaptically but not between agonists
at each location, two receptor types. The net effect of an agonist
on the constrictor response to nerve stimulation depends on the
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pre/poet ratio. If it has preferential presynaptic actions
transmitter release will be reduced and so therefore will the
postsynaptic response whilst the opposite holds if the ratio is
reversed.
The action of clonidine on presynaptic receptors is
concentration-dependent between 10pM and 10uM. The effect on
transmitter release also varies with stimulation frequency. At low
frequencies of nerve stimulation (les3 than 5 Hz) transmitter
release is attenuated but above 5hz it is enhanced (Medgett et al
1 978). This is used to establish clonidine as a partial agonist at
this site. At low stimulation frequencies the concentration of
noradrenaline would be low and clonidine stimulates presynaptic
recptors thereby reducing transmitter release but at higher
concentrations noradrenaline and clonidine compete for the receptor.
If both had an intrinsic activity of one, greater stimulation would
result with a progressive reduction in transmitter release per
impulse, there finally being no difference between the control and
clonidine treated preparation. The reported clonidine/noradrenaline
ratios at the presynaptic alpha adrenoceptor are similar 1.2
(Berthelsen *k Pettinger 1977) and 0.8 (Starke et al 1975).
Clonidine also reduces actylcholine release at parasympathetic
nerve terminals (Werner et al 1972).
3- Clonidine as an alpha adrenoceptor antagonist.
Noradrenaline acting on alpha and beta receptors, increases
cyclic AMP levels in rat cerebral slices. Clondine has no agonist
action, 1-100uM, but reduces the evoked response to that resulting
from beta stimulation at only O.luM.s i*henox,ybenzamine is also an
antagonist but does not further enhance clonidine blockade,
suggesting a common site of action (Skolnick & Daly 1975). In
addition clonidine potentiates the effect of beta agonists.
In dispersed rat parotid cells adrenaline evokes potassium
release. Clonidine does not and it reduces the level of response to
adrenaline. In addition clonidine reduces dihydroergotamine binding
to receptors in parotid cells, an action seen with other imidazoles
(Davis & Maury 1978).
An excitatory effect of iontophoreticly applied noradrenaline
on a bulbar cardiovascular neurones was blocked by iontophoreticly
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applied clonidine which alone was inactive (Sharma et al 1978). The
authors conclude "it is apparent that clonidine and noradrenaline
act upon the 3ame adrenergic receptors". No use of selective alpha
or beta antagonists was made making the conclusion less
authoratative, but it is nonetheless quoted as a case of alpha
antagonism in the literature.
Human blood platelets aggregate when exposed to adrenaline or
noradrenaline, while clonidine and yohimbine antagonise the response
suggesting an action at a similar receptor. Vasopressin, 5HT and ADP
also cause aggregation but for these agents clonidine is a
potentiator, an action opposed by yohimbine (Grant £ Scrutton 1979).
Clonidine can act as an antagonist to noradrenaline evoked
vasoconstriction in the perfused rat hindquarters (Kobinger et al
1 931 ). The concentration in the perf\isate used to demonstrate this
effect was 10 ug/ml, far higher than that encountered during
antihypertensive therapy.
In each case clonidine appears to exhibit an alpha adrenoceptor
antagonist action, but they could be interpreted as partial agonist
actions. Clonidine potentiated the isoprenaline induced rise in
cyclic AMP in the rat cerebral slices and platelet aggregation
caused by non adrenergic agents. It is well established that
clonidine has an intrinsic activity of less than unity producing a
less than maximal response in some preparations and acting as an
antagonist in the presence of more potent agonists. It is assumed
that agonists only activate a small fraction of the available
receptors when producing a maximal response, the idea of spare
receptors. A partial agonist may produce a full response but needs
to stimulate more receptors. With a smaller receptor pool the
partial agonist will produce a submaximal response and a further
reduction in receptor numbers may lead to no end organ response. In
the presence of a agonist this appears as antagonism. Where there
are agonists with similar actions but mediated through a different
receptor the subthreshold stimulation is revealed by potentiation of
the second agonist. This is seen with clonidine.
Uptake 2 Antagonism
Clonidine reduces noradrenaline uptake (Starke et al 1972,
Katsuragi 1978). In a more detailed paper (Salt 1972) this was shown
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to involve extra neuronal tissue (uptake 2) and no action on uptake
1 was reported. In view of the high concentration required, 50uM, a
role in the hypotensive response seems unlikely.
Action As A Purinergic Antagonist
Stone & Taylor (1978a and 1978b), in two remarkably similar
papers, found that the iontophoretic application of adenosine or
aienosine-5-monophosphate reduced the frequency of discharge of
neurons in the rat motorsensory cortex. Clonidine in doses having no
overt action, antagonised this effect whilst failing to reduce the
responses to iontophoretic adrenaline, 5 hydroxytryptaraine or GABA
which were depressant. The ability to antagonise the response to one
group of agonists but not others having similar actions suggests
that in this preparation at least clonidine functions as a
purinergic antagonist. Purines have a role in reducing catecholamine
release from nerve terminals acting through presynaptic receptors
(Su 1975, Su & Tsuru 1978) but there appears to be no work on
possible interactions with clonidine. It is hard to assess the
importance of these results as the concentration of clonidine
achieved during iontophoretic application is unknown, a problem with
all iontophoretic experiments.
Local Anaesthetic Action
Clonidine is as potent as procaine in the guinea-pig wheal test
(Hoefke & Kobinger 1966), slightly more potent in reducing
conduction in the isolated frog sciatic nerve (Starke et al 1972)
and more potent in the rabbit corneal reflex test. A concentration
of approximately 1x10~^M is required for these actions. At high
concentrations and in the presence of burimamide, a histamine H2
antagonist, a negative chronotropic effect i3 seen on the isolated
rabbit heart (Csongrady & Kobinger 1972) which is probably due to a
local anaesthetic action.
Action As A Histamine H2 Agonist
In many tissues clonidine appears to act as an H2 agonist:
1. Clonidine 50 ug/Kg IP induced hypothermia in the conscious
rat is reduced by ICV phentolamine 5-1 Oug and cimetidine 25-50ug but
not by propranolol 50ug. Administered IV clonidine is ineffective
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(Bugajski et al 1980). Noradrenaline ICV also cau3es hypothermia
which is antagonized by phentolamine bat not by cimetidine or
propranolol. This suggests that hypothermia involves both central
histamine H2 and alpha adrenergic receptors and that clonidine but
not noradrenaline acts on both.
2. A positive inotropic action of both histamine and clonidine
is seen on the isolated perfused rabbit heart (Csongrady and
Kobinger 1974) that is antagonized by burimaraide, a histamine H2
antagonist, the PA2 is similar with each agonist implicating a
common receptor. Parsons (1973) shows similar actions on the guinea-
pig atrium with histamine and clonidine, the latter is however much
less potent and only able to exert 13% of the maximal response
possible with histamine, making clonidine a partial agonist. To show
an inotropic action Csongrady & Kobinger added 1Oug of clonidine to
an isolated perfused heart probably achieving a concentration
greatly in excess of that required to lower blood pressure where 10
ug/Kg IV is effective.
3. On the isolated rat uterus cimetidine show3 a similar PA2
against clonidine and histamine but clonidine has a low relative
potency and functions as a partial agonist (Parsons 1973).
r
4. Clonidine 5x10" M and histamine have a lipolytic action in
isolated dog adipocytes and stimulate cyclic AMP o^oduction,
cimetidine but not mepyramine, a histamine H1 blocker, shows
antagonism (Berlan et al 1931 ). These actions are at variance with
those of an alpha adrenocentor agonist which exhibit anti-lipolytic
properties on adipocytes.
5- Sastry d Philips (1977) showed that iontophoretic
application of clonidine, noradrenaline and histamine depressed rat
cerebral cortical neurons and that metiamide blocked the actions of
clonidine and histamine but not noradrenaline. However in a further
population of neurons clonidine was excitatory, histamine inactive
and noradrenaline depressant, metiamide had no action. Sastry \
Philips (1976) show histamine acting via H1 and H2 receptors and a
divergence in the actions of histamine and clonidine may be
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explicable in these terms, the ability of metiamiie to antagonise
clonidine but not noradrenaline implies an notion at histamine H2
receptors.
6. Receptor binding studies (Timmermans et al 1930) show that
clonidine reduces 3H prazosin, an alpha 2 adrenoceptor antagonist,
binding in brain tissue but that cimetidine only interacts at high
concentrations. This 3tudy only shows that cimetidine does not have
alpha 2 adrenoceptor actions and says nothing about clonidine having
a histamine H2 agonist action. Pile et al (1979) found that
cimetidine, metiamide and 4 methylhistamine, an H2 agonist, failed
to reduce 3H clonidine binding to rat cerebral cortical receptors in
concentrations less than 1x10~^"M and that alpha 2 adrenocentors
accounted for the clonidine binding. 4s clonidine shows many
examples of actions compatible with a histamine H2 agonist role the
results of these binding studies are surprising and may reflect the
artificial conditions under which these studies occur.
7. According to Audiger et al (1976) clonidine (lOOuM)
increases cyclic AMP levels in guinea-pig brain via histamine H2
receptors but at lower concentrations has no effect (Skolnick & Daly
1975). Cyclic AMP levels are also increased in gastric tissue
(Karppanen & Westermann 1973) using 1x10"" M clonidine which is
antagonized by burimamide and in adipocytes (Berlan et al 1931)
which is antagonized by cimetidine.
8. Histamine H2 receptor antagonists are reported to antagonise
the antihypertensive actions of clonidine: a) (Karpoanen et al 1976)
metiamiie (300 ug) ICV given before or after IV clonidine reduces
the fall in blood pressure but alone has no action on the
cardiovascular system, b) (Paakkari et al 1976) metiamide ICV
competitively reduces the effect of clonidine ICV but given alone
increases BP, c)Finch et al 1973 showed that ICV cimetidine and
metiamide reduce the antihypertensive action of IV cloaidine but
had a hypertensive action in high doses and a hyooten3ive action in
low doses, d) (Karppanen et al 1977) metiamide alone ICV raised BP
and reduced the action of clonidine, e) (Borkowski & Finch 1978)
metiamide and cimetidine ICV reduced the hypotensive action of
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clonidine, f) (Frisk-Holmbarg 1930) working on conscious rats in
contrast to the workers mentioned above who used urethane
anaesthetized animals found that IV ciraetidine (2.5-5 mg/Kg) reduced
the effect of low doses of clonidine. This paper is novel in that
cimetidine is given IV when it is generally reported not to cross
(Cross 1973) the blood brain barrier, that clonidine with
cimetidine increased BP whilst cimetidine alone was inactive, a
point not dwelt upon in the text, and that cimetidine given after
the establishment of clondine-induced hypotension was inactive.
Watkins et al (1930) using six normotensive human subjects showed no
interaction between clonidine (0.2 mg) IV and cimetidine (300 mg)
IV, doses compatible with those used by Frisk-Holmberg. The action
of H2 antagonists does not alter the hypotensive response to ICV
alpha methyldopamine (Finch et al 1978) and has not been tried
against alpha methyldopa. As a further complication Finch % Hicks
(1976) and Tadepelli & Mills (1978) found no evidence for a
clonidine histamine H2 receptor interaction in the cat.
9- Gastric acid secretion is increased in anaesthetized animals
by clonidine (Karppanen & Westermann 1973) (Walz %. van Zwieten 1970)
an action held in common with histamine. Walz & van Zwieten using
rats and guinea pigs found that clonidine (10-1OOOug/Kg) IV caused a
short lasting increase in acid secretion. This is blocked by
cimetidine (Parsons 1978) (Jennewein 1977) but not by phentolamine
(Cheng et al 1931). In all the se experiments clonidine was used in
high doses, up to 5mg/Kg, IP whilst cimetidine was used in doses
compatible with histamine H2 antagonism.
The proposition that clonidine has histamine H2 agonist
properties is supported by clonidine's actions in a variety of
preparations and the ability of histamine H2 antagonists to reduce
the effectiveness of clonidine.
Cardiovascular changes attendant upon the ICV administration of
histamine and histamine H2 agonists do not mimic those of clonidine
(Finch & Hicks 1977, 1978) (Hicks 1978), being in contrast to
clonidine pressor. The pressor action of dimaprit, a histamine H2
agonist, is antagonized by metiamide 400-830ug ICV (Ericksson 1930),
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a close sufficient to reduce the hypotensive action of clonidine. The
premise that clonidine and dimaprit act as agonists through the same
receptor is hard to reconcile with these results unless the
capriciousness of the ICV administration is invoked, mentioned in
more detail in the section on clonidine's site of action.
The cardiovascular effects of ICV H2 antagonists are variable
being reported as pressor, depressor and inactive, (Finch et al
1973) the action is dose dependent being pressor at high doses and
depressor at low doses.
Histamine H2 antagonists have actions not compatible with
histamine blockade. Catecholamine release by burimamide and
metiamide 2 mg/Kg IV was demonstrated (Brimblecombe at al 1976) in
the chronically denervated nictitating membrane and a pressor
response in the pithed rat (Ganellin & Owen 1977) involving the
adrenals shown with metiamide, burimamide and two other histamine H2
antagonists after IV dosing in the range 2-16 mg/kg. The pressor
effect was of short duration and probably related to the initial
high plasma levels encountered after bolus administration, Frisk-
Holmberg did not report a pressor response in conscious rats with IV
cimetidine. When used to reduce the hypotensive effect of clonidine
up to 800 ug/rat ICV are employed, as the volume of distribution is
3mall it is not impossible that catecholamine-releasing
concentrations are achieved within the brain. The 300 ug contrasts
with 25-50 ug U3ed to reduce the hypothermic action of clonidine
(Bugajski et al 1930) possibly reflecting a different mechanism.
There is evidence that metiamide acts as a presynaptic alpha
adrenoceptor antagonist (Griffin et al 197S)(Doxey & Everitt 1979)
in doses above 3mg/Kg IV. Cimetidine is reported to act as a
narcotic antagonist in the guinea-pig ileum at concentrations of
1x1 0'4M.
Pile et al (1979) report that high levels of cimetidine and
metiamide reduce clonidine binding to cerebral tissue and given the
large doses administered the unknown volume of distribution another
mechanism not involving histamine receptors is available to explain
the reduction of clonidine induced hypotension by histamine H2
antagonists.
Clonidine reduces the rate of central noradrenaline depletion
after Fla-63, a dopamine B hydroxylase inhibitor. Metiamide
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pretreatment did not alter this action of clonidine (Pugsley &
Lippman 1979) suggesting that H2 receptors are not involved. This
study is marred by the failure to report the effect of clonidine and
the interaction with metiamide on blood pressure.
However even if it is demonstrated that histamine H2
antagonists are acting in their named role this does not imply that
antagonism towards clonidine occurs at the level of the receptor, in
a complex system involving many neurons and receptors and containing
a feedback loops drugs have a superfluity of possible 3ites of
action and that two drugs exert opposing effects need not imply an
interaction at the molecular level.
Clonidine appears to exhibit a histamine H2 agonist action but
only when administered in high doses or concentrations, the action
of histamine H2 antagonists in reversing clonidine's hypotensive
effect is well established but reasonable doubt exists as to the
mechanism necessitating further research.
Overall it appears that clonidine's pharmacological actions are
concentration dependent. At low concentrations it acts as an alpha 2
partial agonist and as the concentration rises alpha 1 partial
agonist actions appear. Further increases lead to histamine H2
agonist/partial agonist properties, purinergic antagonism, uptake 2
antagonism and finally local anaesthetic properties. Therefore when
investigating the site and mechanism of the hypotensive effect care
must be taken to limit the concentrations used, to avoid results and
conclusions which though experimentally based are artifacts, real in
themselves but unrelated to the problem under investigation.
Lakdawala et al (1930) studied mast cell degranulation caused by
clonidine, concentrations of 10-30 ug/ml caused histamine release
yet 2 ng/ml is the concentration achieved in vivo, clearly this
study is unrelated to any clinical problem.The dose dependence of
responses is clearly seen in the work undertaken on acid secretion
where the quantity of clonidine used varied from 0.005 to 5mg/Kg and
both secretory and antisecretory actions may be seen. As the dose is
increased supsrimposition of actions occur, the experiments on acid
secretion all occurred with doses of clonidine that would alter
blood pressure yet the effect of this was rarely mentioned and not
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controlled for in the majority of studies.
Trie pharmacological data suggests that clonidine acts at alpha
2 adrenoceptors as a partial agonist. As a partial agonist the
result of its application depends upon the concentration of the
agonist already present. In the absence of an agonist clonidine
produces dose dependent stimulation with a maximum lower than that
of a full agonist. With high concentrations of agonist present the
addition of clonidine has an antagonist effect, reducing the level
of stimulation to that achievable with clonidine alone. It follows
that clonidine can act differently on systems containing alpha 2
adrenoceptors. The use of analogs with differing partial agonist
strength may be fruitful in the separation of hypotensive activity
from sedative and analgesic effects. Further complications involve
the intrinsic activity of the native agonist and spare receptors. To
develop clonidine analogs with differing ratios of
sedative/hypotensive/analge3ic actions a detailed knowledge of the
site of action and its pharmacology are necessary.
Glonidine And Plasma Renin Activity
Clonidine reduces plasma renin and the reduction correlates
well with the fall in blood pressure (Niarchos et al 1978). Though
in low renin hypertensive patients clonidine lowered arterial
pressure without a reduction in PRA (plasma renin activity) and was
effective in patients in whom saralasin was ineffective. Reports
exist of increased PRA during clonidine hypotension (Thananopavarn
et al 1976). Acutely PRA may increase but over a longer period a
reduction or no change is seen (Salvetti et al 1973). PRA increases
when arterial pressure is reduced therefore the maintenance of PRA
in the face of a reduction in arterial pressure represents a change
in this relationship.
In the conscious rat Pals (1975) could only obtain a reduction
in arterial pressure after sodium depletion which raised plasma
renin activity.
A central mechanism is involved. After spinal cord transection
an increase in PRA appears rather than the reduction seen in an
intact animal (Ganong et al 1978). A direct inhibitory action was
reported by Pettinger et al (1976), after ganglion blockade. The
failure to maintain renal perfusion pressure devalues this study.
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When perfusion pressure is maintained an increase follows clonidine
in ganglion blocked animals (Nolan & Reid 1977).
A reduction in plasma renin occurs within 15 minutes of IV
injected clonidine in the dog and the reduction increases over the
following thirty minutes (Ganong et al 1978). In many experiments
arterial pressure is seen to fall dramatically after clonidine,
often within seconds. It is unlikely that a a reduction in plasma
renin occurs within this brief period although it may contribute
over a longer period.
The Site Of Clonidine's Hypotensive Action
A definition of site of action of a drug is "the point where
the local concentration determines the duration and intensity of the
response".
A large number of sites have been proposed for clonidine's
hypotensive and bradycardic action. These include the ventral
surface of the brainstem, hypothalamus, spinal cord, presynaptic
receptors on sympathetic efferent nerves, forebrain and reticular
formation.
A Critique Of Methodology
Various methods have been used in the search for sites of
action. Those most frequently employed are local administration,
lesioning, biochemical and pharmacological.
Lesioning: Destroying part of the system under study and its
effect on the drug induced response is useful when the operation of
the lesioned area is well understood, including its inputs, outputs
and function but is otherwise confusing. Removal of areas rostral to
the pons alters the response to clonidine but this does not imply
that the 3ite of action is located in the lesioned area. A potential
site of action is presynaptically on projections from the
hypothalamus to the intermediolateral areas of the spinal cord. The
lesion would abolish the hypotensive action of clonidine by removing
descending neuronal activity. A site of action in the medulla that
projected to the hypothalamus and hence to the spinal cord would
also result in a loss of hypotensive activity after lesioning.
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Therefore interpretation of lesioning experiments is difficult. A
further problem involves ascertaining the size of a lesion, damage
may extend further than the anatomical limits or if performed
chronically (6-hydroxydopamine or imraunosympathectomy) denervation
supersensitivity will develops making interpretation difficult if
not impossible.
When a well understood lesion is employed eg deafferentation of
baroreceptors, useful results can be obtained.
Biochemical Methods: areas whose metabolism alters after
clonidine administration are potential sites of action. But
clonidine has multiple central actions, reduction in gastric
secretion, reduction in saliva production, sedation, analgesia and
hypotension. Therefore a change in metabolism is not necessarily
indicative of the hypotensive site. Further an action at a point in
a neuronal network will alter the metabolism at all sites peripheral
to it which increases the areas where changes occur. In the
cardiovascular system alterations in blood pressure lead to a change
in afferent neuronal input which will have metabolic consequences.
Taking a simplistic view of the cardiovascular system as a number of
sequentially connected neuronal groups with afferent input and
efferent output, clonidine will cause changes on the efferent side
of its site of action consistent with reduced efferent activity
whilst the consequent reduced blood pressure will alter afferent
input in the direction that in the absence of clonidine would lead
to an increase in sympathetic tone. Changes might be expected to
occur in all areas associated with the cardiovascular system thus
making interpretation of the results difficult.
The employment of adequate controls to compensate for
alterations in afferent input becomes of great importance. They
might include the use of peripheral vasoconstrictors and dilators.
Vasodilators would alter afferent input in a similar manner to
clonidine whilst efferent nerve activity would be expected to
increase, the opposite of the change found with clonidine.
Vasoconstrictors alter afferent input in a manner not found with
clonidine and efferent activity would be expected to decrease. Thus
the metabolic effects of clonidine on the cardiovascular system
ought to resemble on the afferent side those found with a
Chapter 1 31
vasodilator and on the efferent side those found with a
vasoconstrictor. The area where the changes switch from one mode to
the other is then likely to be the site of action.
Another approach would be to infuse a vasoconstrictor to
reestablish the original blood pressure, leaving afferent input
unchanged but output altered by clonidine, the site of action then
comes from a comparison with an untreated control animal. Or
afferent inputs could be removed: cut the vagi, destroy the
baroreceptors and chemoreceptors. This would leave afferent input
unchanged after clonidine except for afferents running in
sympathetic nerves.
Clearly metabolic studies are difficult to conduct usefully.
Pharmacological: having tentatively identified clonidine as an
alpha 2 adrenoceptor agonist it follows that the site of action will
contain the appropriate receptor. Therefore the class of sites with
the receptor will contain that for hypotensive action. Young & Kuhar
(1979,1930,1931) used a combination of autoradiographic and
receptor-binding techniques to locate central alpha adrenoceptors in
the rat.
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Spinal Cord
low even levels in the grey matter, moderate in lamina 2.
only cervical spinal cord studied.
However the number of activated receptors required to produce a
response may be very small, and the site of action contain only a
few neurons making the number of receptors involved too small for
identification autoradiographically.
Local Administration: it follows from the definition used for
site of action that local administration is a useful approach to
locating the site of action. The main problems are establishing the
spread and concentration after administration. With clonidine the
diversity and concentration dependent pharmacological actions
increase the importance of establishing both spread and
concentration.
A limited body of work exists on the quantitative aspects of
microinjection. Rech %. Domino (1959) found that a volume of 10 ul
causes disruption of the injection site and that spread of the
injectate up the cannula track occurred while Myers (1956) found
that the movement of injectate from the injection site was dependent
upon the volume used, molecular wt, solubility. Myers et al (1971)
noted variations in the distribution, metabolism and entry into the
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vasodilator and on the efferent side those found with a
vasoconstrictor. The area where the changes switch from one mode to
the other is then likely to be the site of action.
Another approach would be to infuse a vasoconstrictor to
reestablish the original blood pressure, leaving afferent input
unchanged but output altered by clonidine, the site of action then
comes from a comparison with an untreated control animal. Or
afferent inputs could be removed: cut the vagi, destroy the
baroreceptors and chemoreceptors. This would leave afferent input
unchanged after clonidine except for afferents running in
sympathetic nerves.
Clearly metabolic studies are difficult to conduct usefully.
Pharmacological: having tentatively identified clonidine as an
alpha 2 adrenoceptor agonist it follows that the site of action will
contain the appropriate receptor. Therefore the class of sites with
the receptor will contain that for hypotensive action. Young & Kuhar
(1979,1930,1931) used a combination of autoradiographic and
receptor-binding techniques to locate central alpha adrenoceptors in
the rat.
Location and Concentration of Alpha 2 Adrenoceptors
Thalamus hypothalamus: high supraotic nucleus
arcuate nucleus
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However the number of activated receptors required to produce a
response may be very small, and the site of action contain only a
few neurons making the number of receptors involved too small for
identification autoradiographically.
Local Administration: it follows from the definition used for
site of action that local administration is a useful approach to
locating the site of action. The main problems are establishing the
spread and concentration after administration. With clonidine the
diversity and concentration dependent pharmacological actions
increase the importance of establishing both spread and
concentration.
A limited body of work exists on the quantitative aspects of
microinjection. Rech & Domino (1959) found that a volume of 10 ul
causes disruption of the injection site and that spread of the
injectate up the cannula track occurred while Myers (1966) found
that the movement of injectate from the injection site was dependent
upon the volume used, molecular wt, solubility. Myers et al (1971)
noted variations in the distribution, metabolism and entry into the
cerebral circulation, Schubert et al (1970) found major differences
in the spread of morphine and fentanyl after ICV administration. In
2 animals (Myers 1971) very aberrant injections occurred, in one the
injectate passed into the general circulation and in a second a
cleavage of the cerebral tissue passed the injectate into the
ventricular system. These papers reveal the problems of
microinjection showing variations in soread between substances and
the effects of different injection volumes. Movement away from the
injection site into the blood and concentration differences within
the volume of distribution have not been considered. Many papers
compare the effects of microinjesting a number of drugs into the CNS
without reference to possible differences in metabolism or rates of
diffusion. In a comparison between clonidine and noradrenaline,
metabolism of noradrenaline but not clonidine and different rates of
diffusion would be expected but are very rarely taken into
consideration. Anderson d Stone (1974) found the response to
ionophoretic clonidine to be longer lasting than ionophoretically
applied noradrenaline this may indicate different rates of diffusion
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or metabolism. It then follow3 that work involving microinjection
is potentially flawed.
Microionophoresis applies drugs to discrete areas but the
problem of estimating the local concentration remains, this is only
partially offset by the ability to apply a range of doses. The
response of only a single neuron is recorded and there are no
attendant changes in blood pressure and heart rate. This makes
characterization of the neuron critical, although it is possible to
find changes in action potential frequency corresponding to
alterations in afferent input it is not possible unequivooably to
state that the neuron alters efferent nerve activity. The pH of the
solution and effects of different salts of the drugs used pose
further problems. Finding changes in discharge pattern after IV drug
application encounters the problems outlined in the section on
biochemical methods, altered afferent discharge. Neuronal recording
and iontophoresis are useful in studying identified sites of action
when the underlying pharmacology is of interest but are not useful
techniques for identifying potential sites of action.
Peripheral Action
A reduction in transmitter release by sympathetic
postganglionic neurons, diminished vascular reactivity and
stimulation of baroreceptors have been proposed as mechanisms for
the hypotensive and bradycardic affects of clonidine.
Zaimis (1953) and Zaimis & Hanington (1969) found reduced
responsiveness to exogenous vasoactive agents after chronic
clonidine administration. In three cats treated for a week the
vasoconstrictor response to adrenaline and noradrenaline were
attenuated and the dilator effect of isoprenaline similarly reduced.
Differences between the three animals used appear to be large and no
mention wa3 made of the effect of clonidine on blood pre3ssure and
heart rate. Lombardi et al (1976), with a low IV dose of clonidine,
noted a reduction in the local vasoconstrictor response to lumbar
sympathetic stimulation and a reduction in the pressor response to
femoral nerve stimulation. These occurred without alterations in the
spontaneous and evoked sympathetic discharge, measured at T3- This
is indicative of a peripheral mechanism operating after low doses of
clonidine. Shaw et al (1971) found a residual fall in peripheral
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resistance after autonomic blockade, with phenoxybenzamine, atropine
and propranolol. This was interpreted as a direct vasodilator action
of clonidine. In other studies clonidine was found to enhance the
action of vasoconstrictors when applied in submaximal doses (Kozelka
et al 1930). When given in large amounts clonidine antagonized the
action of catecholamines (Kobinger et al 1931) (Boissier et al
1958). Commonly antihypertensive therapy increases the
responsiveness of the vasculature making the work of Zaimis more
interesting.
An increase in the discharge in baroreceptor afferents is
reported [Aars (1972), Sleight et al (1975), Korner et al (1978),
Laubie et al (1976)]. Aar3 (1972) associated increased baroreceptor
discharge with an increase in the diameter of the aorta since the
relationship between the two was unaltered after clonidine.
Dilatation of the aorta appeared minutes after a reduction in renal
sympathetic activity. If reduced renal nerve activity is taken as an
indicator of sympathetic tone at the aorta the failure of the two
events to coincide shows that they are not related causally. The
reduction in efferent sympathetic nerve activity is therefore not
caused by the dilatation of the aorta and altered baroreceptor
discharge. However the reduction in sympathetic nerve activity is
progressive and varies between nerves (Krier et al 1979) reducing
the importance of a temporal separation between aortic dilatation
and reduced renal nerve activity. In vitro clonidine contracts
aortic strips, acting as a partial agonist in reducing the action of
adrenaline and noradrenaline an explanation for the in vivo action.
Antagonism to noradrenaline is also seen in the human saphenous vein
with concentrations above those associated with hypotension, 20
ng/ml, lower levels were not employed (Coupar & Kirby 1972).
Piperoxan, an alpha adrenoceptor antagonist, dilates the aorta
preventing further dilation by clonidine, supporting the partial
agonist idea. Noradrenaline given after clonidine is still able to
constrict the aorta. Korner et al (1974) found baroreceptor
discharge increased over a range of mean blood pressures with a
high, 20 ug/Kg IV, but not lower doses of clonidine. However
sectioning the baroreceptor nerves (Schmitt et al 1 963) (Laubie et
al 1976) and lesioning of the NTS doss not abolish the hypotensive
action of clonidine. Administration of clonidine into the carotid
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artery does not increase sinus nerve discharge and is no more potent
than IV administration in lowering blood pressure (Constantine &
McShane 1963). Yet this method of application would be expected to
reveal any direct effects of clonidine on carotid tone or directly
on the baroreceptors. Administration of clonidine IVert increaesed
baroreceptor discharge (Laubie et al 1976) again arguing against a
direct action on the baroreceptors. It is possible that the
enhancement of baroreceptor discharge involves efferent nerve
activity though the appropriate experiments have not been
undertaken. Increased baroreceptor discharge follows clonidine
administration but this is only a contributory hypotensive
mechanism, evidence exists for both a direct and indirect
enhancement of acivity.
Presynaptic receptors stimulation by clonidine reduces
transmitter release. The physiological role of presynaptic receptors
has been questioned (Chen %. Kalsner 1979) and a number of imidazoles
that are effective presynaptically and do not cross the blood brain
barrier fail to lower blood pressure when given IV, making the case
for the unimportance of this mechanism, (Pichler & Kobinger 1978).
Fla 136, a clonidine analog, with no presynaptic action lowers blood
pressure after oral administration to rats (Hamilton $ Longman
1930), again suggesting that peripheral actions are unimportant.
No action on sympathetic ganglia are reported (Schmitt et al
1968).
Indications For A Hypotensive Action Involving The CN3
Cross-circulation experiments and injection by intravertebral
and ICV routes establish a strong case for a central site of action.
The lack of hypotensive effect of agents that have similar
pharmacological actions to clonidine but do not pass the blood brain
barrier strengthens the case as does the reduction in sympathetic
nerve activity that follows clonidine treatment. Activity rises when
a peripherally acting agent is employed to reduce blood pressure,
mediated through the baroreceptor arc.
Infusion of clonidine into the vertebral artey in both dogs
(Constantine & McShane 1968) (Sattler & Van Zwieten 1967) and cats
(Sattler & Van Zwieten 1967), with doses that IV are ineffective or
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of greatly reduced efficacy, leads rapidly to a fall in blood
pressure and heart rate. The immediate pressor response that
normally accompanies IV dosing is not apparent with IVert though a
pressor action is seen when 200 ug is administered by this route. It
is proceeded by a brief hypotension. After the hypertensive episode
a sustained hypotension is seen. Intravertebral clonidine reduces
the resistance of a perfused brachial artery but with a denervated
paw a delayed vasoconstrictor effect appears (Constantino # McShane
1968).
A cerebral cross-circulation preparation (Sherman et al 1 959)
indicated that hypotension and bradycardia are centrally mediated.
Clonidine given to the donor dog led to a brief rise in the cerebral
perfusion pressure and a fall in blood pressure and heart rate in
the recipient. Removal of baroreceptor input in the recipient
increased the hypotensive effect but deafferentation increased the
pre clonidine blood pressure. Vagotomy did not prevent the
bradycardia revealing a sympathetic component. In the recipient dog
clonidine can only act within the brain and the concentration of
clonidine achieved will be similar to that in the donor animal.
Unfortunately the authors did not compare the cardiovascular
responses of the two animals, this might have indicated hypotensive
actions outside the brain.
Reduced sympathetic nerve activity is reported by many authors
(Schmitt et al 1958, Kobinger & Pichler 1976, Klupp et al 1970). The
reduction appears within seconds of an IV dose of clonidine and
slightly precedes the attendant hypotension and bradycardia (Schmitt
et al 1963). In a number of animals respiratory modulation of
efferent sympathetic discharge was more resistant to clonidine than
the continuous background activity (Schmitt et al 1953). The
magnitude of the reduction is dose dependent (Klupp et al 1970).
However not all sympathetic innervations are affected equally (Krier
et al 1979). Postganglionic efferents in the hypogastric nerve
running to the bladder and renal nerve were depressed by low IV
doses of clonidine whereas the lumbar colonic nerves were resistant
to high doses. Further renal efferents could be silenced with
clonidine yet in the hypogastric nerve 20-50$ of the pre-clonidine
activity remained in the face of large doses, 100-200 ug/Kg. Viscero
sympathetic reflexes in the colonic lumbar nerve were resistant to
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clonidine yet those appearing in the renal and hypogastric were
sensitive to low levels of clonidine. Intestinal sympathetic
discharge appears independent of bulbospinal control possibly
accounting for the minimal reaction to clonidine. In man muscle
sympathetic activity responded unpredictably and an increase or
decrease could follow a clonidine induced fall in blood pressure
(Frisk-Holmberg 3l Wallin 1979). Failure to obtain a uniform response
may have involved recording from an amalgam of muscle vasodilator
and vasoconstrictor fibres. Alternatively the new level of discharge
represents a shift in the relationship between blood pressure and
nerve activity, discharge is lower after clonidine than it would
have otherwise have been at the new reduced blood pressure. The
action of clonidine in reducing sympathetic tone and catecholamine
release is used as a clinical test to separate between essential
hypertension and phaeochromocytoma when plasma catecholamine
concentrations are high. Clonidine acts on sympathetic nerves but
not on the catecholamine secreting tumour and does not reduce
plasmsa levels in the latter case, the basis of the test (Bravo et
al 1 931 ).
ICV administration lowers blood pressure and heart rate
(Schmitt & Schmitt 1969, Kobinger d Walland 1967, Borkowski & Finch
1979, Bolme et al 1975, Orma et al 1930). The active dose is
generally lower than required IV but the speed of onset of the
hypotension is much reduced, appearing progressively over tens of
minutes. ICV administration is associated with a reduction in
sympathetic nerve activity and bradycardia. Further it is sensitive
to pretreatments with alpha antagonists. ICV administration limits
the spread of drug and as it is active at levels devoid of IV
activity a case is made for a central site of action. Clonidine acts
at a central site and ICV administration provides easy access
accounting for the potency of thi3 route. However emesis occurs with
ICV clonidine, an effect never seen with IV (Finch 1974,1975)-
Presumably a response to a concentration, in excess of that seen
after IV administration, acting on a periventricular site. Different
responses attend the administration of clondine by IV or IVert after
catcholamine depletion (Dollery & Reid 1974). The cardiovascular
effects of IV clonidine were reduced but those following ICV were
abolished. The differing sensitivities indicate that clonidine does
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not have the same actions when applied by the two routes,
attributing the residual IV action to peripheral action probably
overstates their importance. The emetic action of ICV clonidine
indicates the problems with localized dosing. The progressive nature
of the hyptotension is also interesting, does it represent
accumulation of drug at a site on the edge of the ventricles or
movement through the ventricular system to a site of action ?.
The case for a central action in the hypotensive response to
clonidine is overwhelming and a much effort has been made at further
localization.
Biochemical Consequences
Clonidine in antihypertensive doses has no effect on
noradrenaline, dopamine or 5HT concentrations in the central nervous
system (Anden et al 1970, Laverty & Taylor 1969, Anden et al 1976).
When noradrenaline synthesis is prevented, by giving alpha
methyl tyrosine, depletion results. Clonidine reduces the rate of
depletion and the rate of synthesis (Anden et al 1976). Similarly
•3
the T1/2 of tritium, after loading catecholamine nerves with H
noradrenaline, was increased by clonidine, 20 ug/Kg IV, in all
regions except the hypothalamus (Reid 1975). Further evidence for
reduced noradrenaline turnover is the reduction in noradrenaline
metabolites in CSF and reduced tyrosine hydroxlase levels, the
latter after one week of clonidine treatment (Reid 1975).
Clonidine reduces catecholamine and 5HT turnover in doses
lowering blood pressure making a prima facie case for the
involvement of these metabolic changes in the hypotensive response,
so does their increased turnover during clonidine withdrawal
(Svensson 4 Strombon 1977). The implications for the mechanism of
action are unclear (see discussion in earlier section on
methodology). These studies did not compensate for the effect of
altered blood pressure on catecholamine turnover, sectioning the
buffer nerves increases noradrenaline turnover in the spinal cord
(Chalmers 4 Wurtman 1971). Spatial discrimination is poor since
large sections of brain were used in the catecholamine assays,
therefore differential actions on tracts or nuclei within the
sections will be missed. Further clonidine has a number of actions
at low doses not involving the cardiovascular system and biochemical
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correlates of these are likely to appear.
In rats clonidine reduces adrenaline turnover in the medulla
oblongata without afffecting noradrenaline, the reverse occurs in
the hypothalamus (Bolme 1930). Central adrenergic mechanisms are
being increasingly considered in cardiovascular control.
Mechanism Of Bradycardia
Bradycardia invovles both the vagal and sympathetic nervous
systems. Pretreatment with propranolol or atropine reduces the
magnitude of clonidine evoked bradycardia but does not abolish it,
showing that it is mediated through both the parasympathetic and
sympathetic nervous system. The location of vagal preganglionic cell
bodies in the nucleus ambiguus, cuneate nucleus and dorsal motor
nucleus of the vagus requires that clonidine act3 at a supraspinal
site when causing bradycardia through a vagal action.
Clonidine reduces the cardioinhibitory effects of vagal
stimulation through an action on presynaptic receptors. However
there is one report of enhanced responsiveness of vagal efferents
(Lisander & Wennergren 1979). The mechanism was not pursued.
Action On Baroreflex Arc
clonidine reduces both mean arterial pressure and heart rate.
The normal operation of the baroreflex arc leads to a compensatory
increase in heart rate when blood pressure is reduced therefore the
appearance of bradycardia accompanied by a reduction in arterial
pressure indicates that clonidine has an action on heart rate in
addition to its hypotensive action.
After clonidine the slope of the heart rate/arterial pressure
relationship is altered, favouring a greater fall in heart rate for
a set change in in arterial pressure (Sleight et al 1975, Sleight &
West 1975, Korner1979).
In conscious rabbits Korner et al (1974) found a baroreceptor
dependent bradycardia involving vagal excitation and sympathetic
inhibition, a baroreflex ,independent bradycardia involving only
sympathetic efferents was also noted.
The increased responsiveness of the baroreflex arc can occur
before a reduction in arterial pressure or a change in sympathetic
nerve activity appear (Haeusler 1974). Clonidine 1-3 ug/Kg increased
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the response to sinus nerve stimulation.
A temporal separation between alterations in the response to
bilateral carotid occlusion and the fall in blood pressure were
reported by (Tadepelli & Mills 1978).
The enhancement of the baroreflex arc has peripheral
components, described in the section on peripheral sites of action
for clonidine, increasing baroreceptor discharge. An action
involving atrial receptors leading to a fall in heart rate was
reported (Lisander & Wennergren 1979). This appeared in the spinal
dog and had more to do with the pressor action of clonidine
increasing left atrial pressure than the pressure independent
activation reported for carotid baroreceptors. In clinical use left
atrial pressure falls and the involvement of atrial receptors in
clonidine invoked bradycardia is an artifact of the spinal
preparation.
Vagal bradycardia is widely reported to be enhanced by
clonidine (Kobinger & Pichler 1972) and depends on intact
baroreceptor afferents. Alternatively enhancement of the vagal
response by clonidine can be seen with sinus nerve stimulation
(Laubie et al 1976, Haeusler 1974). This occurs when clonidine is
administered IVert and therefore probably involves a medullary
structure. The response to electrical stimulation of the nucleus
ambiguus is not altered by IVert clonidine suggesting that it is not
the site of action (Laubie et al 1976).
The nucleus of the tractus solitarius, the first relay for
baroreceptor afferents, has bean considered as a site of action for
clonidine. Its acute destruction abolishes the vagally mediated
bradycardia seen with clonidine but in chronically lesioned dogs
vagal bradycardia again follows clonidine injection (Schmitt S
Laubie 1979). The reduction in heart rate seen with electrical
stimulation of the NTS is not altered by clonidine administered
IVert.
It appears that the vagal bradyacardia seen after clonidine
requires the existence of the NTS and the baroreceptor inputs. In
the NTS catecholamines reduce heart rate and arterial pressure (Reis
et al 1979, de Jong et al 1979).
Clonidine reduces the pressor response to bilateral carotid
occlusion but not in midcollicular decerebrate cats or when
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clonidine is confined to 3upracollicular areas (Tadepelli i Mills).
Farther the sympathetic response to increased and decreased
baroreceptor input was depressed. The authors reasonably suggest
that this is not an enhancement of the baroreflex arc. Clonidine was
administered by a variety of routes into the ventricular system and
access to the NTS should have been good. When clonidine was confined
to supracollicular structures a reduced but still marked fall in
blood pressure followed but without alterations in the response to
bilateral carotid occlusion. This was novel since it is widely
reported that IC administration of clonidine does not reduce
arterial pressure. It is possible that the response is due to high
concentrations of clonidine resulting from local administration and
does not represent the normal action of the drug.
The IVert administration alpha 2 adrenoceptor antagonists
enhances the response to carotid occlusion (Constantine at al 1932)
an action reversing that of clonidine.
Overall clonidine enhances vagal bradycardia probably through
an action within the NTS. After placing a lesion at this 3ite
clonidine is still able to lower blood pressure and heart rate
through the sympathetic nervous system suggesting that more than one
site of central action may be involved.
Central Catecholamines And Clonidine's Cardiovascular Actions
Depletion of central and peripheral catecholamines with
reserpine and alpha-methyltyrosine does not abolish the vagally
mediated bradycardia and the reduction in splanchnic nerve activity
seen after IV clonidine, though ICV clonidine was ineffective
(Kobinger & Pichler 1974,1976). A fall in blood pressure is
prevented by the lack of peripheral catecholamines. A difference in
IV and ICV actions is also reported by (Dollery h Reid 1973).
Catecholamine depletion was restricted to the brain by applying 5
OHDA ICV, resting heart rate and arterial blood pressure were
similar to control animals. The fall in heart rate and blood
pressure after IV clonidine were much reduced and the actions of ICV
clonidine abolished in 6 OHDA pretreated animals.
These results are equivocal on the role of central
catecholamines. Complete abolition of the actions of clonidine would
appear if its effect was mediated through " noradrenergic neurons,
Chapter 1 42
either an action on presynaptic receptors reducing tramiitter
release or postsynaptic effect leading to catecholamine release. A
partial reduction short of abolition suggests that central
catecholamines have a role in the cardiovascular response to
clonidine. A complication is the denervation supersensitivity seen
after S-OHDA (Ungerstedt 1971) which makes interpreting the reduced
effect of IV clonidine more difficult.
The difference in the susceptibility of IV and ICV clonidine
implies that the two mechanisms of action are different, see section
IGV dosing in "Indications for a hypotensive action involving the
CNS".
Ionophoretic Studies
Cedarbaum $ Aghajanian (1977) found that ionophoretic clonidine
reduced the rate of discharge of locus coeruleus neurons and in this
action was more potent than noradrenaline. A later study (Aghajanian
& Van der Jtaelen 1932) related the depressant effect of clonidine to
hyperpolarization of the cell membrane through the activation of
alpha 2 adrenoceptors.A depressant action of clonidine on locus
coeruleus neurons was also noted by (Svensson et al 1979).
Sharma et al (1978) looking at bulbar cardiovascular neurons in
the decerebrate cat noted opposing actions of clonidine and
noradrenaline, clonidine reduced the firing of 20 from a population
of twenty seven neurons all located within 2-3mm of the dorsal
surface of the medulla.
Champagnat et al (1979) saw a common action for noradrenaline,
adrenaline, isoprenaline and clonidine on bulbar respiratory
neurones.
Anderson & Stone (1977) ionophoretically applied clonidine and
noradrenaline to neurons in the medullary reticular formation and
found a common action in 13% of their population. Clonidine
depressed the firing of 61 % of the neurons tested and had a longer
lasting action than noradrenaline, this was also noted by (Cedarbaum
and Aghajanian 1977).
A number of iontophoretic studies have been undertaken but
offer little insight into the hypotensive site of action of
clonidine. The Aghajanian & Van ier Maelen (1932) study illustrates
the utility of iontophoretic experiments, showing the mechanism of
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action of clonidine in a well defined system but the studies are
hard to relate to the hypotensive site of action of clonidine. The
relevance of the iontophoretic study is brought into doubt by
Svensson et al (1975). A dose of clonidine was administered IV
whilst recording from LC neurons, a brief depression in firing
followed. However the dose was in the hypotensive range and a
prolonged reduction in blood pressure would be anticipated, not the
brief response noted in neuronal firing. The action on blood
pressure was not mentioned and a further complication is the effect
of altered arterial pressure on LC firing, also not mentioned in
this study.
Further Localization Of Central Site Of Action
Forebrain
Tadepelli & Mills (1978) and (Clevans et al (1 973) suggest a
role for the forebrain in the clonidine-induced reduction in heart
rate and blood pressure. Klevans et al evoked tachycardia and an
increase in blood pressure by stimulating the medullary reticular
formation, clonidine reduced the magnitude of both. Decerebration,
at the midcollicular level, increased the magnitude of the
stimulation evoked response but when undertaken in the absence of
clonidine was ineffective. This doss not necessarily require that
clonidine act in the forebrain, only that a pathway stimulated by
clonidine involves structures rostral to the pons. Tadepelli St Mills
compared the responses to clonidine in midcollicular decerebrate,
perfused third ventricle and brain intact anaesthetized cats. The
perfused third ventricle preparation involved the cannulation of the
aqueduct between the third and fourth ventricle, 30 that when
clonidine is administered into the third ventricle its spread is
limited to supracollicular areas. In the decerebrate and brain
intact cats clonidine was injected into the third ventricle, giving
access to the ventricular system. The brain intact cat produced the
greatest reduction in blood pressure and heart rate. Similarly the
reduction in the response to bilateral carotid occlusion was also
greatest in the intact animal. In the animals where the spread of
clonidine was restricted blood pressure and heart rate were reduced
substantially but the consequencies of bilateral carotid occlusion
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changed, heart rate increased and blood pressure failed to respond.
It then appears that an intact brain is required for the full
actions of clonidine. However in each preparation the same dose of
clondine, 25 ug, was given, despite a reduction in the volume of
distribution. It follows that in the areas to which clonidine had
access the concentration of clonidine will exceed that found in the
brain intact animal, making comparisons questionable.
A pressor action of clonidine in the forebrain is widely
supported. Bousquet # Suertzenstein (1973) obtained a hypertensve
response to ICV clonidine when spread into the fourth ventricle was
prevented by externalising the aqueduct between the 3rd and 4th
cerebral ventricles. This involved 100 ug of clonidine and the
pressor response appeared rapidly. Trolin (1975) compared conscious,
anaesthetized and decerebrate rats. In the conscious animals only a
brief hypertension appeared, in anaesthetized a pressor then
depressor action occurred and in decerebrate only a hypotensive
action was noted. A pressor response to clonidine still failed to
appear even with 100 ug/Kg IV. Trolin proposes that supracollicular
structures act to maintain blood pressure and generate the pressor
response to clonidine. His results are incompatible with the widely
held view that the brief pressor action of clonidine is a peripheral
effect. Shaw et al (1971) noted that the hypotension following
clonidine was greater in pontine animals than intact but that the
fall in heart rate was reduced, again arguing that the forebrain
operates to maintain arterial pressure.
Constantine $ HcShane (1963), Laubie et al (1976) and Katie et
al (1972) administered a small dose of clonidine into the internal
carotid artery. This led to no alterations in blood pressure.
Therefore no role for the forebrain as a site of action for
clonidine is indicated, pressor or depressor. This does not mean
that structures rostral to the pons are not involved in the changes
in blood pressure seen after clonidine, ,ju3t that clonidine does
not act in those areas.
Schmitt & Schmitt (1969) found the response to clonidine
unaltered in decerebrate cats and dogs, even when the decerebration
extended to the pons, in addition decerebration during the response
to clonidine did not restore blood pressure.
Struyker-Boudier & Van Rossum (1972,1974) and Struyker-Boudier
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et al (1974) microinjected clonidine into the rat hypothalmu3 and
produced a prolonged dose dependent fall in arterial pressure and
heart rate. The fall in heart rate appeared with 1 ug whilst 3-20 ug
progressively lowered blood pressure. Myers (1966) shows that 1 ul,
the volume used by Struyker-Boudier & Van Rossum, microinjected into
the hypothalamus is likely to spread no more than 2.2 mm. Further
the dose used is ug/animal not ug/Kg equivalent to perhaps 80 ug/Kg.
The prolonged response reported suggests that movement away from the
site of injection is slow and that in consequence levels of
clonidine are maintained. The most remarkable aspect of these two
papers is the dose dependent nature of the response. Timmermans et
al (1977) and Conway & Jarrott (1930) show that only 2% of the
clonidine given IV resides in the brain. Thus even if the 30 ug/Kg
was distributed thoughout the brain it is equivalent to 4 000 ug/Kg
IV, clearly of no relevance to the normal actions of clonidine.
Philippu et a (1979) found that clonidine enhanced the pressor
response to stimulation of the posterior hypothalamus and in higher
doses reduced the response. Philippu used superfusion to apply
_3
clonidine to the hypothalamus and concentrations of between 10 and
-5
10 M were employed, they are far in excess of the concentrations
likely to follow IV administration.
The evidence for a hypotensive action of clonidine in the
forebrain is poor.
Medulla/Pons
Decerebration experiments (Schmitt & Schmitt 1969) and IVert
experiments point very strongly to a site of action for clonidine
within the medulla. Microinjection and topical administration have
been used to further delineate the site.
Pons
Extending decerebrations below the level of the Pons does not
abolish the hypotensive action of clonidine. This suggests that the
site of action following IV administration of clonidine is likely to
be in an area caudal to the pons. Though the lesion may alter the
operation of the undamaged areas, by removing the influence or more
rostral structures, and hence the alter action of clonidine on these
areas.
Chapter 1 46
Ventral Surface Of The Medulla
A chemosensitive zone on the ventral surface of the brainstem
is a favoured site for clonidine's hypotensive action (Bousquet &
Guertzenstein 1973)- After cannulation of the aqueduct between the
third and fourth ventricles the hypotensive response to
intraventricular clonidine disappears and is replaced with a
hypertensive action, suggesting that the hypotensive site is outside
the lateral ventricles, cisterna magna and third ventricle, further
the site is accessible from the CSF. Topical application on the
ventral surface of the brainstem revealed the area S, lateral to the
pyramids caudal to the trapezoid body and rostral to the hypoglossal
roots. Bilateral but not unilateral application reduces blood
pressure. Lesioning abolishes the action of IV clonidine (Bousquet
et al 1975) and the ip3ilateral hypothalamic pressor response. Alone
lesioning leads to a reduction in blood pressure. Microinjection
of clonidine produces an immediate fall in blood pressure (Bousquet
et al 1979), reduction of the pressor response to electrical
stimulation of the posterior hypothalamus and in the fall in blood
pressure following stimulation of the anterior hypothalamus.
Piperoxan IV reestablishes both pressor and depressor effects of
hypothalamic stimulation following intracisternal clonidine.
Tne area S is associated with respiratory responses to
superfusion with solutions of different acidity (Loeschcke d
Koepchen 1958). The topical application of a variety of drugs gaba,
glycine, pentobarbitone, clonidine, carbachol, dopamine results in a
fall in blood pressure (Guertzenstein 1973). Anatomically it is
associated with the nucleus paragigantocellularis and nucleus
reticularis lateralis
Criticism of this body of work stems from the quantities of
clonidine employed. Topical application involved 10 ul of 0.05-1
mg/ml and microinjection 4 ug in 0.5 ul and ICV 100 ug/Kg. The
volume of distribution is likely to be restricted and a
concentration markedly in excess of that following IV administration
undoubtedly achieved. Until this is resolved the area 3 cannot be
considered seriously as the site of action.
Further the onset of action after topical application is rapid
yet that consequent on ICV dosing is widely reported to be 3low and
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progressive suggesting that topical administration does not mimic
the response obtained after ICV. However Bousquet S Cuertzenstein
(1973), the paper initially associating clonidine with the area S,
found a rapid fall in blood pressure after TCV administration. A
large quanitity of clonidine was employed which may be the key to
fast actions on the edge of the ventricular system.
Among other drugs acting on the area S is procaine, a local
aneasthetic. Clonidine can, in high concentrations act in this
manner, a possible explanation for this body of work. Bilateral
cooling of the area S causes respiratory depression and a reduction
in blood pressure, which recovers first (Schlafke S See
1930,Wennergren S Oberg 1930). This also argues for a nonspecific
action of clonidine at this site. Though Schlafke S See (1930)
recording electrical activity below the area S found two populations
of neurons, one was responsive to pH alterations and the second to
lofexidine, an imidazole presumably with a clonidine like action.
The imidazole increased neuronal activity and led to a concomitant
reduction in blood pressure, an effect not compatible with the local
cooling response. Electrical stimulation elicits a pressor response
(Trouth et al 1973), seemingly inconsistent with imidazole mediated
stimulation of neurons in the area.
There is evidence for the area S as a site of action for
clonidine but doubts, arising from the quantities of drug employed
and the presumed limited volume of distribution, exist.
Medullary Reticular Formation
Chen S Chan (1979) and Chan S Koo (1978) found that placing
lesions in the medial reticular formation, which in itself did not
alter blood pressure, prevented IV clonidine from lowering blood
pressure. Further local injection of 0.25 ug/Kg of clonidine caused
a prolonged fall in blood pressure. Electrical stimulation of this
area lowers blood presssure. Bousquet et al (1931 ) working with cats
bilaterally injected 75 ng/Kg clonidine into the nucleus reticularis
lateralis and found a rapid fall in blood pressur. Placing lesions
in this area lowers blood pressure whilst electrical stimulation is
pressor. The authors relate the microinjection to areas that may be
reached after topical application on the area S.
The iontophoretic study of Anderson S Stone (1977) is
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consistent with an action within the medullary reticular formation.
Floor Of The Fourth Ventricle
Schmitt 3l Schmitt (1969), Srimal et a (1977) and Dhawan et al
(1975) all obtained reductions in heart rate and blood pressure with
topical application of clondine on the floor of the fourth
ventricle. Concentrations of 0.1-1.0$ were employed and the
corresponding concentration achieved in the underlying tissue are
unknown but are likely to be high. The area contains alpha 1
adrenoceptors (Young & Kuhar 1930) which provide a mechanism of
action but not for low concentrations.
Nucleus Of The Solitary Tract
Antonaccio & Halley (1977) damaged the NTS which prevents
reflex bradycardia, the nucleus receives the baroreceptor inputs,
but did not prevent clonidine lowering blood pressure. Though it
seems that the enhancement of the baroreflex arc by clonidine
requires the integrity of this area. It is not fully established
that clonidine acts directly at this site.
Spinal Action
Clonidine has no hypotensive action after spinalization. In
tetraplegias bradycardia, reduced salivation and sedation follow
oral administration (Reid et al 1977). The bradycardia was probably
vagally mediated and the absence of blood pressure changes not due
to altered drug kinetics (Reid et al 1977). In cord transected dogs
(Ganong et al 1978) clonidine 30 ug/Kg IV was only pressor, in
spinal cats 10 ug/Kg IV similarly (Constantine 8l McShane 1963) or 30
ug\Kg IV (Schmitt & Schmitt 1969) produced no fall in blood
pressure. After transection blood pre33ure falls precipitously then
slowly recovers to the original level but even after recovery
clonidine is only pressor (Tangri et al 1977) (Petty et al 1976), 30
ug/Kg IV led to a prolonged and enhanced rise in pressure.
In spinal animals sympathetic tone is low and the influence of
descending systems removed. In consequence an action on descending
tracts, spinal interneurons or sympathetic efferents would not be
apparent. When sympathetic tone is stimulated a hypotensive action
in spinalized animals may be seen. Haeusler (1976) used strychnine,
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1 mg/Kg IV, or stimulated sympathoexcitatory tracts in the dorsal
lateral funiculus and showed inhibition of the evoked sympathetic
activity by clonidine 3-39 ug/Kg IV or alpha methyl dopa 100 mg/Kg
IV. Dhawan et al (1973) used spinal compression to elicit a pressor
response in spinalized cats which was attenuated by clonidine 1-2
ug/Kg IT. Koss (1976) found the centrally or peripherally evoked
electrodermal response reduced by clonidine. Sinha et al (1973)
evoked splanchnic nerve discharges by stimulating the central end of
sciatic nerve and found the response reduced by clonidine. Baum fk
Shropshire (1977) noted a reduction by clonidine of the sympathetic
nerve activity evoked by stimulation of descending tracts in the
spinal cord or afferent nerve stimulation. Franz et al (1978) found
clonidine reduced the evoked response in preganglionic sympathetic
nerves from either somatic afferent or intraspinal tracts.
In cord intact anaesthetized rats IT clonidine 0.4-10 ug/Kg has
a hypotensive action (Finch et al 1979, Connor & Finch 1931 ). The
onset of action is faster after IT than ICV administration
suggesting a spinal bite of action (Dhawan at al 1975), Lo Pachin k
Rudy (1931) found a reduction in nerve activity in the lumbar
sympathetic chain after IT clonidine. 6.8 ug/rat was employed and
the peak action appeared forty minutes after administration.
Walland (1978) questions the importance of the spinal site. A.
reduction in the pressor response evoked by tibial nerve stimulation
with high voltage and high frequency followed IV clonidine,
oxymetazoline or tramazoline. IVert, ICV and intralumbar clonidine
failed to alter the evoked response and as the two other agents
employed do not cross the blood brain barrier an arguement is
developed for a site of action outside the CNS.
Clearly clonidine can show a hypotensive action within the
spinal cord but this may not be involved in the responses following
IV dosing. The technique for IT administration (Yaksh 1976) results
in good localization with limited spread along the cord from the tip
of the cannula. The spread of the affective dose 0.4-10 ug/Kg is not
known but is likely to be 3mall and therefore may reach
concentrations in excess of those found after IV administration. A
few ug/Kg IV show a hypotensive effect and the dose is distributed
throughout the whole animal. In view of the delayed appearance of
the peak effect (La Pachin k Rudy 1930) and large dose adminstered a
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spinal action may not be invovled. The delay may reflect the time
taken to escape from a depot created in the spinal cord. The somatic
sympathetic response, seen with stimulation of the cut ends of
afferent nerves, has two components fast and slow (Sato & Schubert
1973), Coote & Downman 1956). The first involves only the spinal
cord while the second requires supraspinal structures. Their
susceptibility to clonidine differs, in low doses clonidine is more
effective in reducing the late component (Raum % Shropshire 1977,
Sinha st al 1973)- Conversely, higher doses are required to reduce
the spinal component of the reflex, the response evoked by
intraspinal stimulation and the pressor responsse to hypothalamic
stimulation (Sinha et al 1973). In other studies, where
discrimination between medullary and spinal actions could not be
made, clonidine was active at a spinal level in low doses (Franz at
al 1978, Haeusler 1976).
Clonidine appears to act postsynaptically, acting after
reserpinization (Franz et al 1978), IT 60HD\ and IT 5,6DHT (Connor $
Finch 1931). The latter two drugs damage catecholamine and
indolamine containing neurons. Clonidine is effective on the spinal
pathway which doe3 not contain catecholamines and presumably acts on
the preganglionic sympathetic cell body.
The action of clonidine is antagonized by IV alpha antagonists
intimating that the effect is mediated in this manner (Franz et al
1978, Haeusler 1976, Sinha et al 1973, Finch et al 1979). Finch
found antagonism of the hypotensive action by prazosin, an alpha 1
adrenoceptor antagonist, but no action with phenylephrine. Further a
range of alpha 2 adrenoceptor antagonists given IT lowered blood
pressure. This inconsistent with the idea of alpha receptors having
an inhibitory action on the sympathetic nervous system at the spinal
level. These results may reflect problems with the IT technique.
Franz et al (1978) proposes an action on 5HT receptors. This
dichotomy revolves around the action of descending tracts containing
noradrenaline and 5HT on preganglionic sympathetic neurons.
The consensus is that descending indolamine systems are
inhibitory (Coote & Maclean 1974, Franz et al 1978, Neumayr et al
1974. Hare et al 1972). Two positions exist on the role of
noradrenergic systems that they are inhibitory (Coote & Macleod
1974, Haeusler 1976) or that they are excitatory (Neumayr et al
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1974, Hare et al 1972, Taylor & Broiy 1976). Iontophoretic studies
show ail inhibitory role for noradrenaline on spinal preganglionic
sympathetic neurons (De Groat & Ryall 1957, Hongo & Ryall 1956,
Coote et al 1979), Blessing and Reis (1932) produced a hypotensive
response by stimulating, electrically and with L-glutamate, the 41
area in the ventrolateral medulla. This area contains catecholamines
and the stimulation experiments support the idea of descending
inhibition involving this type of neuron. The opposing view derives
from biochemical studies using drugs that may not have a single
action. The iontophoretic studies with 5HT show it to be excitatory
and in consequence the existence of an interneuron is postulated
(Coote et al 1 979)-
How important a spinal action is, in the hypotensive response
to clonidine is not clear. It is suggested that high doses are
required to reduce sympathetic tone through this site and the
concentrations resulting from IT administration are likely to be
excessive.
Conclusions
Despite a large body of work the origin of the hypotensive
effect of clonidine it is not unequivooably established. It is clear
that the acute response involves areas within the brain and spinal
cord and in all probability involves alpha 2 adrenoceptors. However
there is also evidence for an action outside the CHS on
baroreceptors, presynaptic receptors and vascular smooth muscle
senstivity.
A large body of work exists on the site of action but problems
with drug concentration and the multiple pharmacological actions of
clonidine surround each proposed site. The question is not whether
clonidine can act at a given site but if the site is involved in the
clinical response
The search for a unitary site of action may be misconceived and
the cardiovascular actions of clonidine result from the summation of
minor effects in a multiplicity of areas. Sufficient uncertainty
exists to justify yet more research in this field.
Anaesthetics Different Hypertensive Models And Glonidine
Tne absence of a hypotensive effect of clonidine has been
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reported in conscious rats (Trolin 1975, Pals 1975, Zandberg 1977,
Henning et al 1975)- In addition the brief hypertensive episode
associated with bolus IV clonidine administration was attenuated in
barbiturate anaesthetized rats and could not be demonstrated in
decerebrate animals even with large doses (Trolin 1975, Henning et
al 1975)- The authors suggest that supracollicular structures are
involved in the hypertensive action of clonidine . Their role is
likely to be permissive rather than as a site of action. A pressor
action mediated through these areas would require the hypertension
to involve increased sympathetic nerve activation, which has not
been reported during the hypertensive interlude, and that IC
administration should lead to hypertension, again not reported.
Further work on isolated tissues and pithed rats indicates that the
hypertension is peripherally generated. The role of the
supracollicular structures then must be assumed to be permissive,
allowing hypertension to appear by inhibiting the compensatory
mechanisms. This is also hard to accept as it requires that in the
anaesthetized and decerebrate animal the functioning of the
baroreflex arc is greatly enhanced, to such an extent that the
pressor action is overwhelmed. The baroreflex operates as as a
negative feedback loop and as such cannot operate to completely
eliminate the imposed stimulus, a load error should appear.
Anaesthetic can enhance the operation of the baroreflex arc,
decreasing the response to a pressor stimulus. Brezenoff (1975)
found that high levels of pentobarbitone reduced the effect of IV
noradrenaline on arterial blood pressure whilst lighter anaesthesia
increased the magnitude ot the response. A range of anaesthetics did
not have the a similar effect on the pressor response to
noradrenaline and may involve both central effects and alterations
in vascular responsiveness.
Pals (1975) found even large doses of clonidine ineffective in
in conscious rats but sodium depletion, with frusemide, which did
not alter arterial pressure made clonidine hypotensive.
Clonidine appears to cause catecholamine release from the
adrenal gland (Zandberg 1975) having a greater hypotensive action
after adrenalectomy in conscious and urethane anaesthetized rats,
only a slight enhancement appeared in pentobarbitone treated
animals. It is unclear whether a centrally-mediated or direct action
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is involved as denervation of the adrenals was not undertaken and no
reports on the actions on adrenal sympathetic efferents appear to
exist.
A differential effect on urethane and pentobarbitone
anaesthetized rats was not noted (Bousquet et al 1977) in whose
hands a reduction in arterial pressure was seen with these two
anaesthetics but not with ketamine, althesin or chloralose. In the
Bousquet et al study clonidine led to a prolonged hypertension with
althesin, work at ICI does not support this finding and instead a
reduction in arterial pressure appeared (P. Marshall personnel
communication). Bolrae et al (1974) were able to obtain a fall in
arterial pressure in the chloralose anaesthetized rat again
contradicting Bousquet et al (1977). In the rat Timmermans et al
(1977) found greater falls in arterial pressure when using
barbiturate anaesthetized than ether treated rats although no
pharmacokinetic changes were apparent.
Despite a faiure of a number of authors to find a reduction in
blood pressure in conscious rats it has been noticed (Meyer 1 977,
Salzman 1979, Finch St Hicks 1930, Christersson et al 1 979).
The effectiveness of clonidine varies in different hypertensive
models (Dadkar et al 1979). The action was greatest in SHRs and
smaller in renal and Doca/salt rats. At the end of the first day of
treatment the reduction in blood pressure was similar in all three
groups of rats. The new level of pressure was maintained in the
renal and Doca/salt animals but in the SHRs arterial pressure fell
further over the next few days. Differences in vascular reactivity
to clonidine are involved (Dadkar et al 1979). Plasma renin falls
with clonidine in animals and man and the pretreatment plasma
concentration is related to the subsequent reduction in arterial
pressure. Pals (1975) only found clonidine effective in conscius
rats after sodium depletion, this increases plasma renin activity
which fall3 after clonidine.
Overall clonidine can lower arterial pressure in conscious and
anaesthetized rats but the anaesthetic and type of rat used are
important. The failure of some authors to find a hypotensive
response in conscious rats suggests that the use of anaesthetized
animals is preferable. The reported differences between anaesthetics
and the failure of clonidine to interact with the adrenals in
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barbiturate treated animals suggest that this is the simplest
preparation in which to investigate the hypotensive properties of
clonidine. The diverse results reported with different anaesthetics




The hypotensive and bradycardic action of cloniiine is readily
demonstrated in anaesthetized rats which were used in all
experiments. Rats of both sexes within a weight range of 140-350 gms
were used.
Initially urethane was used to provide anaesthesia but as the
OASS award involved working at 101 Alderley Park where this
substance is deemed carcinogenic a switch was made to Inactin.
Inactin (thiobutobarbitone manufactured by BYX) is a barbiturate
anaesthetic that provides several hours of stable anaesthesia after
a single dose. Initially 10Omg/Kg IP wa3 given from a freshly made
up stock solution of 50mg/ml in water and the dose increased
progressively at 15 minute intervals until an acceptable level was
achieved, usually 115-155mg/Kg sufficed. Lower doses are reported in
the literature but those used are in the range used at TCI.
Blood pressure was-measured using standard Lectromed/CEC strain
gauge transducers connected to either the carotid artery or femoral
vein. Static calibration was made using mercury manometers and
dynamic calibration was not undertaken as suitable equipment was not
available and a detailed knowledge of the waveform was unncessary
for the experimates undertaken. Except where mentioned the femoral
artery was used in preference to the ca-otid as to use the latter
results in one set of baroreceptors operating at a nressure below
arterial pressure. Tnis was shown in a number of animals bv
cannulating both the central and peripheral end of a carotid artery.
Although changes in arterial pressure are followed by the centrally
located cannula the pressure recorded is always lower than that
recorded at the cardiac end of the carotid. This suggests that the
relevant baroreceptors and chemoreceptors are likely to be operating
differently from those on the contralateral side and femoral
arterial cannula were used to obviated this problem.
Cannulas were made from polythene tubing PP50 with the tins
stepped down to a size just sufficient to enable introduction into
blood vessels.
Heart rates were obtained from the arterial trace using
ratemeters triggered from the nressure pulse. Two rotameters were
used, a Devices instantaneous ratemeter used over a 0-500 min-1
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range and a ratemeter built at ICI that required several beats to
adjust to a change in heart rate, this machine could be offset
allowing a 200 beat interval to provide full scale deflection on
the pen recorders.
A variety of Devices/Lectromed hot wire recorders were used to
obtain a record of the experiment.
Once anaesthetized the animals had a rectal probe inserted to
record temperature. Using either a heating lamp or blanket
controller, of local design, rectal temperature was maintained
within 56.5-37.5 C.
IV administration was achieved by drawing the drug into a long
polythene cannula which was then connected to a venous cannula. The
syringe was replaced with one containing saline and drug flushed out
of the cannula with 0.2 ml of saline. A microlitre syringe was used
to draw up drugs which permitted the use of small injection volumes.
This was considered important as repeated drug injections could
otherwise involve large cumulative volumes of saline.
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Intravenous Clonidine And The Inactin Anaesthetized Rat
Clonidine lowers blood pressure and heart rate in anaesthetized
animals and as these animals are more amenable to experimental
manipulation they were used throughout the study.
The initial series of experiments were undertaken to establish
the nature of the clonidine-induced response in the inactin
anaesthetized rat.
Experiments
1) The effect of a carotid arterial cannula on carotid
pressure.
2) IV clonidine administration.
3) Control of resting heart rate.
4) The pathway for clonidine induced bradycardia.
5) Alterations in peripheral resistance after clonidine.
6) Sympathetic efferent activity in the anaesthetized rat.
7) Operation of the baroreflex arc.
Methods
Unless otherwise 3tated animals were prepared as outlined in
the general methods section.
1) One carotid artery was cannulated twice. One cannula was
inserted in the directiion of the heart and and second iin the
diirection of the head.
3) To remove vagal control of heart function 1 mg\Kg IV
atropine was employed. Sympathetic control was curtailed with 1
mg/Kg IV atenolol, a cardioselective beta blocker. Hexamethonium 30
mg/Kg IV was employed to remove neural control of the heart and
vasculature. An infusion at 20 ul/min of 90 mg/ml lasting several
minutes was used to administer heaxamethonium. Despite this slow
method of injection four of the twelve rats given hexamethonium died
during or just after administration. The quantity of hexamethonium
U3ed was established in a number of preliminary trials where
cumulative injections were made until no further reduction in heart
rate of blood pressure could be obtained.
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5) Peripheral resistance was measured using the pressure
generated downstream of a roller pump operating in the constant rate
mode. Perfusions were made of the hindquarters and of a hindlimb.
The method of Brody et al (1963) was employed for the hindquarters
perfusion. This involves double cannulation of the descending aorta.
Hindlimb perfusions were established as described in the next
chapter but without the large extracorporeal circuit. Flow rates of
between 1 and 2.5 ml/rain-^ were employed for the hindliimb
perfusions.
6) The renal and superior cervical nerves were dissected for
multiunit efferent recording. The renal nerve was approached with a
midline ventral incision, tissues above the nerve were retracted and
the peritoneal cavity used to hold the paraffin pool. The superior
cervical nerve was approached from the ventral surface of the neck
and the skin of the neck arranged to retain the liquid parrafin
pool. A. tracheal cannula was inserted through the mouth to avoid
cutting the trachea which could have acted as a drain for the
mineral oil bath.
Recordings were made using bipolar silver electrodes. The
signal was passed through a physiological amplifier with the filters
set to exclude frequencies above 10kHz and below 30Hz. Telttronix RH
122, Tektronix 3160 and a locally built amplifier were used. The
resulting signal was displayed on a Tektronix 5000 series cathode
ray osciilloscope (CRO) and a Telequipment M 64 CRO. A numerical
count of action potentials was obtained from a spike discriminator
and counter (see appendix 2). Facilities for obtaining taped records
of the nerve actiivity were not availible.
7) The baroreflex wa3 studied by perfusing the carotid artery
with blood at different pressures, looking for alterations in heart
rate and artrial pressure, measured from the femoral artery. The
vagi were cut in the neck to remove the influence of cardiac and
pulmonary receptors and aortic arch receptors.
The roller pump and feedback loop, described in appendix 1,
were used to perfuse the rostral end of the common carotid artery.
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Blood for the perfusion was obtained from the caudal portion of the
same common carotid. Once the double cannulation of the carotid had
been established the other carotid artery was ligated.
Results
1) The pressure recorded from the cranial end of the carotid
artery was always much lower than that from the cardiac side. In
three rats the arterial pressures were:
Systolic Diastolic Mean Cranial Carotid mmHg
135 100 112 44
145 104 118 51
120 106 111 24
The cranial pressure was not pulsatile and followed that recorded
from the cardiac cannula during changes in arterial pressure.
2) Clonidine produced a dose dependent reduction in both heart
rate and mean arterial pressure. Fig 2.1 a,b,c and tables 2T3-3. The
reduction in heart rate and blood pressure were prolonged. A brief
rise in blood pressure follows bolus IV clonidine, this is not shown
in Fig 2.1 a,b as it did not extend to the first point on the graph,
1 min post injection. After hexamethonium pretreatment the magnitude
and duration of the pressor effect were enhanced, from a peak rise
in systolic pressure of 31 mmHg and a duration of less than one
minute to a mean rise of 64- mmHg and a duration in excess of three
minutes Fig. 2.2.
3) Control of resting heart rate.
Atropine 1 mg/Kg IV did not alter heart rate or blood pressure,
Fig 2.3 a, table 2T.1.
Atenolol 1 mg/Kg IV reduced heart rate but not mean arterial
pressure, Fig 2.3 a,b, table 2T.1. In five of the six rats given
atenolol the heart rate was more stable after treatment than before,
in the sixth rat heart rate was stable at all times. Stability
refers to variations about the mean.
Heart rate was reduced by injections of pressor drugs, infusion



























IV clonidine given to an Inactin anaesthetized rat.
Note initial pressor response, subsequent fall in blood oressure and
bradycardia.
a) Acute response to a bolus IV injection. Readings taken at -10,-
5,-2,0,1,2,3,4,6,8 and 10 mins after injection.
1 ug/Kg N=6, 2.5 ug/Kg N=1 1 , 5 ug/Kg N=14, 10 ug/Kg N=1 2
d) Response of one animal to 5 ug/Kg. Note brief rise in ~rterial
pressure after bolus injection.
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IV Clonidine After Hexamethonium
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Effect Of IV Atropine And Atenolol On Blood Pressure And Heart Rate.
Administration IV bolus.












Atenolol 1mg/Kg I.V. 5 mins
Fig. 2.3b
Response To IV Atenolol 1 mg/Kg IV
Note fall in heart rate but not blood pressure and the stability of
heart rate after atenolol.
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baroreceptors (described in Appendix 1) Fig. 2.6b, 2.7, 3.1a, 3-1b,
3.3c & A1.6.
Hexamethonium, 30 mg/Kg IV, caused a mean reduction in heart
-1
rate of 95 beats min , reducing heart rate to 354, mean of 3.
Subsequent treatment with clonidine only reduced heart rate in one
of four rats and then by only 10 beats min ^ (Fig. 2.2.).
4) After pretreatment with atropine, clonidine still reduced
heart rate and blood pressure, Fig 2.4 a,b and table 2T.2.
Pretreatment with atenolol reduced heart rate and greatly attenuated
the action of clonidine on heart rate, Fig 2.4 a,b. Cumulative doses
of clonidine eventually do not lower heart rate further but a
reduction occurs during the brief rise in blood pressure following a
bolus injection, Fig 2.4 c,d,e
After treatment with clonidine and atenolol the injection of
atropine does not alter heart rate, similarly atenolol after
clonidine and atropine has no effect.
5) In two perfused hindquarters preparations clonidine reduced
peripheral resistance and heart rate. The preparation proved awkward
to establish and further work was discontinued in favour of the
perfused hindlimb, Fig 2.5 a,b,c show results from individual
experiments. Cumulative doses of clonidine were used, given every
seven minutes. Peripheral resistance, arterial pressure and heart
rate initially decline but as the dose is increased perfusion
pressure and arterial pressure increase though heart rate does not.
6) Sympathetic efferent nerve activity in the inactin
anaesthetized rat responds to a variety of stimuli, Fig 2.6. Raising
arterial pressure with either injection or infusion of phenylephrine
reduced efferent activity. Asphyxia raised nerve activity, arterial
pressure and heart rate. Acetylcholine lowered heart rate and
arterial pressure and raised sympathetic efferent activity. The
traces shown are typical results.
7) The operation of the baroreflex arc can be seen in Fig. A1
6.b (in appendix 1) and fig. 2.7. The latter shows alterations in
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Fig. 2.4a
Action Of Cionidine After Pretreatment With Atenolol Or Atropine
Clonidine was given cumulatively every 7 mins. The responses used in
the graph are those 6.5 mins after administration, this was employed
to avoid involving the response to the brief hypertensive episode
and include the full response to clonidine.
Atenolol N=6, Atropine N=8
Fig. 2.4b
Cumulative Clonidine After Atenolol or Atropine
Effects on two animals.
Note lower initial heart rate in the atenolol pretreated animal.
























































Heart Rate Response To Clonidine During The Pressor Episode
Fig. 2.4 c,d
Cumulative clonidine in two rats, dosed every 10 mins.
Note reduction in heart rate during pressor episode and prolonged
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Cumulative Clonidine And Peripheral Resistance
Peripheral resistance measured with a perfused hindlirab. Perfusion
at constant flow.



















































a) Phenylephrine infusion at two different rates. The reduction in
ner/e activity follows the onset and magnitude of the pressor
effect. Recovery is to the initial resting level of activity. A

















b) Phenylephrine bolus injection. Trie reduction in sympathetic
avtivity is related to the magnitude of the increase in blood




Sympathetic Efferent Activity In The Inactin Anaesthetized Rat
The counting method used, accumulation in one period and display on
the trace in the next period, means that nerve activity refers to














c) Asphyxia. The tracheal cannula was occluded to produce asphyxia.












I ACH IV f
d) Acetylcholine IV. Blood pressure and heart rate fall whilst nerve
activity increases. Recording from renal nerve.
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Fig. 2.7
Changes in blooi pressure and heart rate produced by the alteration
in pressure around the oarotid baroreceptor3. This was achieved by
cannulating both ends of a cut carotid artery andusing a roller pump
to drive blood from the cardiac end of the artery to the cerebral
end. The pump was controlled by a feedback loop allowing the
generation of a fixed pressure downstream of the pump (see Appendix
1).
Note reduction in heart rate and arterial blood pressure when the








perfusion pressure. Fig. A6.b only shows alterations in femoral
arterial pressure.
A similar experiment shown in Fig. A6.c used the feedback
controller to infuse phenyephrine which increased arterial pressure
and led to a corresponding fall in heart rate.
The results illustrated are anecdotal and this preparation was
not pursued.
Discussion
Blood pressure recorded from the cranial end of a carotid
artery follows arterial pressure recorded from the cardiac side of
the same blood vessel, but at a much reduced level. It follows that
one set of carotid sinus baroreceptors is exposed to a low pressure
and the animal is probably functionally equivalent to continuous
unilateral carotid occlusion. To avoid this the femoral artery was
used for the arterial pressure cannula in all subsequent
experiments. The Circle of Willis is unable to deliver sufficient
blood to the side of the head deprived of its arterial supply and
that side of the head i3 probably hypoxic (see autoradiographic
evidence, chapter 5)-
Clonidine reduced heart rate and blood pressure in a dose
dependant manner over the range of doses used, 1-10 ug/Kg. This
range was employed in later experiments, excluding higher
concentrations that produce prolonged hypertensive episodes. In fig
2.4d the last two injections of clonidine resulted in
a prolonged increase in arterial pressure. Two components are
apparent one a rapidly rising and falling following immediately
after IV adminstration of clonidine and a second hypertensive
episode with a longer duration that appears as the initial peak
declines. This pattern was seen in two of the animals pretreated
with hexaraethonium. The second hypertensive period may involve
release of catecholamines from the adrenal medulla, reported by
Zandberg (1977). That it occurred in a hexamethonium-pretreated
animal requires that it involve a direct action of clonidine.
Zandberg found that clonidine-e/oked catecholamine release was
reduced in barbiturate anaesthetized rats compared with urethane
anaesthetized or conscious animals. The suggestion that it is
occurring in the inactin anesthetized rat is speculative but the
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prolonged duration of the pressor effect seems to be at odds with
the very dramatic fall in plasma clonidine noted in chapter 6.
In the group of animals given 10 ug/Kg IV heart rate declines
more slowly than mean arterial pressure, possibly indicating that
the two effects are separate in some respects. It does not involve
the brief pressor effect following bolu3 IV clonidine which in these
experiments lasted less than one minute.
The cardiovascular actions of clonidine are maintained and only
a partial recovery appeared in a group of animals followed for 55
mins after injection. This lack of acute recovery justifies the use
of cumulative applications of clonidine in subsequent experiments.
Resting heart rate in the inactin anaesthetized rat appears to
be under sympathetic but not vagal control, since atropine leaves
the resting heart rate unaltered whilst atenolol reduced it by 60
beats per minute. This has been noted before in the pentobarbitone
anaesthetized rat Imms et (1976). This may be in part an anaesthetic
artefact since in the dog bradycardia due to sinus nerve stimulation
switches from the vagal to sympathetic evoked after barbituate
anaesthesia (Vatner et al 1971). The small variations in heart rats
around the mean also appeared to be under sympathetic control since
atenolol reduced them in all cases where they appeared. Atenolol led
to only a small reduction in mean arterial pressure, around 2 mmHg
and this suggests that heart rate is not an important controller of
blood pressure in this preparation. The temporal dissociation of
heart rate and blood pressure change seen with 10 mg/Kg clonidine IV
supports this idea.
When all nervous influences on heart rate are removed, by
hexamethonium, the residual rate is mainly that arising from the
cardiac pacemaker tissue. In these animals under inactin anaesthesia
this varied from 310 to 415 min"^ .
Resting heart rate responds to vasopressor and vasodilator
stimuli. The responses are in line with baroreflex actions, a
decrease after phenylephrine and an increase following glyceryl
trinitrate or acetylcholine. The reduction in mean arterial pressure
following clonidine would be expected to lead to a reflex increase
in heart rate. That this does not occur shows that clonidine alters
the operation of the baroreflex arc.
Clonidine has a much reduced action on heart rate after
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atenolol pretreatment. After atropine the magnitude of the reduction
is similar to that seen without atenolol suggesting that its cause
is a reduction in sympathetic tone. Although failing to alter heart
rate after atenolol pretreatment clonidine still lowered blood
pressure again showing the separation between these two effects.
When the cumulative dose of clonidine was of sufficient magnitude
that no further fall in heart rate or arterial pressure appeared, a
fall in heart rate occured during the brief hypertensive period
after each bolus IV injection. It al3o appeared after pretreatment
with atenolol which shows that a non-sympathetic pathway is
implicated, either a direct action or mediated through the vagus.
Ths could be seen as the enhancement of the baroreflex commonly seen
in dogs after the administration of clonidine.
The failure of atropine to alter heart rate after the
administration of clonidine and atenolol indicates that there is no
vagal cardiac tone. Similarly atenolol does not further reduce heart
rate when administered after clonidine and atropine, shewing that
sympathetic tone does not contribute to the final magnitude of heart
rate. When sufficient clonidine has been administered the heart is
devoid of all nervous tone, but acute increases in arterial pressure
can still evoke a further fall in rate. This must be attributed to a
vagal influence since the phenomena appears after atenolol
pretreatment which abolishes sympathetic tone.
Glonidine reduces peripheral resistance in the perfused
hindquarters and hindlimb. As the cumulative clonidine levels
increase peripheral resistance and arterial pressure cease falling
and increase. Heart rate does not increase. The technique employed
does not indicate whether nervous or humoral factors are involved,
this is further pursued in the next chapter. Since a pressor action
with clonidine appears where neural autonomic control is removed
using hexamethonium, this action is peripheral in origin. In the
pithed rat pressor responses to clonidine are obtained. They occur
with concentrations above those needed to alter transmitter release
from sympathetic nerve terminals, in clinical use the application of
large quantities of clonidine can lead to a paradoxical increase in
mean arterial pressure (Wing et al 1977, Saarima 1976).
In the inactin anaesthetized rat cardiovascular manipulations
led to alterations in sympathetic efferent activity. This suggests
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that the use of this anaesthetic in the investigation of
cardiovascular reflexes is feasible. It had been intended initially
to study the effect of clonidine on functionally identified
sympathetic efferent nerves but the difficulties in obtaining stable
single unit recordings led to the adoption of the "delayed" hindlimb
perfusion technique. This allowed the visualization of neural
control of the peripheral vasculature.
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Tables for Chapter 2
The lotion of Atropine and Atenolol on Blood Pressure and Heart Rate
atropine 1 m,g/Kg IV
Time Heart Rate
mins
10 -3 0 1 5 -4 -3 0 _2
-5 -5 -7 0 9 -9 -1 0 _2
-2 -6 -6 2 4 -2 1 1 -2
-1 -6 -4 0 5 0 0 0 _2
0 421 349 407 572 533 503 444 412
1 1 0 -2 -1 4 3 1 -5
2 -2 1 -2 -2 7 0 _2 -3
5 -9 2 -2 -4 -1 -5 -4 -3
10 -17 3 -7 -2 5 -6 -5 -14
Blood Pressure
-1 0 0.5 -2 -1 2.5 3.5 4-5 0 1
-5 0.5 -6 0 -1 -3 4.5 -1 1
-2 0.5 -4 0 -9.5 -0.5 2.5 1.5 1
-1 -2.5 -2 0 0 0 0.5 0.5 0
0 91 .5 113 91 83.5 90 106 94 103
1 -0.5 -1 -4 -2 -4 -5 0 -5.5
2 -0.5 0 -4 _2 -1 -5 -5 0 -6
5 1 .5 1 -4 0.5 0 -10 1.5 -6.5
10 4.4 _2 -3 3 0 -7.5 2 -7.5
Atenolol 1 mg/Kg IV
Time Heart Rate
mins .min-1 . . .
-10 0 _2 -4 -2 -1 4
-5 0 _2 -6 -2 2 2
-2 0 -1 0 -4 1 0
-1 0 0 0 -2 0 0
0 376 41 6 436 396 354 435
0-5 -36 -26 -60 -26 -24 -10
1 -54 -30 -63 -40 -34 -15
2 -53 -40 -78 -44 -57 -29
5 -64 -56 -33 -43 -36 -47
10 -63 -56 -90 -43 -44 -47
Blood Pressure
mmHg
-10 0 2.5 -1 2 1 .5 0
-5 2 2.5 1 2 1 0
-2 1 • 5 -0.5 0 1.5 1 0. 5
-1 0.5 0 0 1 .5 1 1
0 114.5 119 94 75 102.5 116
1 -2 -1 -3.5 0.5 -5.5 6. 5
2 -5 -0.5 -4-5 0 -1 .5 3
5 -4 -4 -5.5 0 0 2
10 -5 -14 -4.5 1 .5 -9 1
Chapter 2.T2
The Action of Glonidine oil Heart Rate
After pretreatment with Atropine or atenolol
Cumulative Clonidine IV After Atropine
Clonidine Heart Rate
ug/Kg 1
0 400 402 387 393 439 363 433 356
2.5 -43 -25 -25 -43 -33 -30 -68 -24
5 -50 -27 -23 -54 -103 -30 -33 -25
7.5 -43 -29 -23 -61 -11 7 -30 -95 -30
10 -42 -33 -22 -66 -123 -30 -119 -30
12.5 -33 -36 -24 -72 -131 -30 -129 -35
15 -32 -40 -27 -72 -133 -30 -143 -33
Blood Pressure
0 119 106 90 90 96 91 .5 103 113
2.5 -3 -5.5 -0.5 -3 -7 -6 -6. 5 -1 4
5 -11 -1 0.5 0 -7.5 -9 -9 -1 2 -25
7.5 -11.5 -1 2 0.5 -9 -12.5 -11.5 -15. 5 -25
10 -11.5 -13 -0.5 -13.5 -13.5 -14-5 -1 6 -25
12.5 -13.5 -14 -2.5 -17.5 -13 -18.5 -16 -26
15 -11.5 -15 -5.5 -19 -12.5 -1 6.5 -16. 5 -26
Cumulative Clonidine After Atenolol
Heart Rate
•min-1
0 318 360 346 350 300 435
2.5 2 -13 -4 -3 -9 -11
5 -6 -32 -6 -10 -10 -20
7.5 -7 -30 -3 -15 -10 -22
1 0 -3 -32 -6 -20 -9 -25
12.5 -7 -31 -1 -24 -9 -26
15 -6 -30 -3 -23 -9 -24
Blood Pressure
0 90 105 36 79 36.5 122.5
2.5 -1 4-5 -22.5 -7 _2 -3 -6.5
5 -21 -31 .5 -11 -3 -11-5 -10
7-5 -25 -34-5 -1 6 -4 -16 -1 1
10 -28 -34.5 -1 9.5 -5 -1 9 -1 2.5
12.5 -50 -34-5 -20.5 -5 -17 -13









































of Intravenous Clonidine on Blood Pressure and Heart Hate
Clonidine IV 1 ug/Kg
Heart Rate
■1 . . . . .
-3 -2 -10 -10 3 17
-10 -2 -1 8 -13 0 5
-6 1 -17 -3 2 3
-4 1 -1 2 -4 3 1
-2 0 -6 -2 4 1
0 -2 -2 -2 0 0
404 353 402 364 431 425
-16 -14 -17 -14 -21 -17
-20 -15 -12 -13 -28 -20
-21 -14 -9 -9 -32 -25
-23 -14 -3 -4 -33 -25
-30 -3 -3 -4 -33 -27
-36 -4 40 -15 -59 -29
-59 -2 4 -24 -42 -31
-41 7 -6 -24 -46 -36
-43 2 -17 -17 -42 -36
-51 -7 -32 -11 -35 -35
-53 -18 -37 -10 -33 -29
Blood Pressure
0 2 -2 0 -1 5
0 2 -3 0 -2 3
0 1 -4 0 -1 2
0 1 -3 0 -1 4
0 0 -3 0 0 0
0 0 0 1 -1 1
95 102 79 79 103 91
-2 -3 -4 -2 -5 -2
-5 -4.5 -3 -3 -7 -3
-4 -5 -3 -5 -7 -4
-3.5 -5 -1 -3 -7 -5
-6.5 -5.5 -1 _2 -7 -4
-7.5 -5 -2 -3 -7 -4
-3.5 -5-5 -3 -4 -7 -7
-13 -7 • 5 -4 -4 -7 -3
-16.5 -11.5 -3 -5 -7 -3
-19 -15 -9 -3 -7 -3
-20.5 -19 -9 -4 -6 -6
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Clonidine IV 2.5 ugAg
Time Blood Pressure
maris.
-10 -4 1 1 3 6 -3 5 -1 2 -1 3
-5 -5 1 0 -2 2 -1 5 -1 2 2 1
-4 -5 2 -1 -3 2 -2 2 -1 3 0 1
-3 -5 0 -1 -2 2 -1 1 0 3 0 1
-2 -5 0 1 -3 1 -1 1 0 4 1 1
-1 -1 -1 1 1 0 -1 0 0 2 0 1
0 99 32 92 37 103 104 101 102 37 88 101
1 -7 -3 -2 -9 -10 -5 -6 -6 -9 -16 -11
2 -11 _'7 -5 -11 -11 -6 -3 -1 0 -14 -23 -13
3 -11 -7 -5 -9 -12 -6 -9 -10 -17 -29 -13
4 -11 -7 -3 -11 -12 -6 -9 -1 1 -15 -28 -22
6 -12 -6 -7 -11 -16 -7 -10 -11 -1 3 -23 -21
8 -10 -6 -3 -11 -14 -6 -13 -1 2 -21 -28 -23
10 -9 -3 -9 -13 -1 2 -4 -14 -1 2 -20 -26 -24
15 -2 -3 -5 -1 2 -1 2 -1 -13 -1 2 -19 -25 -25
20 -5 -3 -3 -9 -13 3 -13 -1 2 -22 -17 -27
25 -7 -7 -3 -3 -13 4 -11 -1 2 -17 -14 -27
30 -3 -3 0 -5 -1 2 4 -3 -11 -15 -1 3 -26
35 -7 -3 -1 -5 -12 5 2 -1 2 -1 2 -10 -26
Heart Rate
-1 0 12 -1 5 -3 -1 13 -17 10 2 0 -5 0
-5 5 -5 -4 -1 5 -6 13 1 0 -7 0
-4 5 -3 -1 0 4 -7 9 0 0 0 0
-5 1 -5 -2 0 2 -4 3 0 0 -2 0
-2 1 -1 2 -1 1 -2 3 0 0 -2 0
-1 0 -3 2 0 0 0 1 0 0 0 0
0 435 1-53 435 407 467 427 447 400 375 370 330
1 -23 -13 -37 -6 -39 -11 -39 -45 -45 -50 -50
2 -27 -15 -53 -11 -50 -1 2 -45 -55 -60 -60 -66
3 -27 -11 -33 -12 -53 -16 -47 -60 -67 -65 -65
4 -25 -9 -35 -17 -52 -21 -51 -65 -67 -72 -70
5 -17 -5 -39 -17 -54 -24 -59 -62 -30 -77 -73
8 -13 -5 -43 -17 -56 -27 -61 -62 -36 -77 -32
10 -1 1 -47 -1 3 -57 -27 -61 -60 -35 -77 -37
15 19 0 -27 -1 3 -46 -30 -61 -53 -33 -75 -92
20 17 0 0 -17 -42 -29 -61 -53 -33 -75 -92
25 10 0 -4 -17 -36 -31 -61 -53 -30 -70 -90
30 1 0 6 -17 -50 -31 -35 -55 -75 -65 -37










































Clonidine IV 5 ug/Kg (1 )
Blood Pressure
tnraHg
2 3 2 3 4 4 0
1 2 2 3 4 2 0
2 1 1 1 3 1 1
1 0 1 1 -1 2 1
0 2 1 0 0 1 0
0 1 1 0 0 0 1
93 33 105 132 108 89 95
-11 -9 -10 -17 -30 -10 -9
-15 -16 -15 -20 -27 -19 -10
-14 -14 -16 -20 -25 -20 -1 2
-15 -1 8 -17 -21 -23 -20 -14
-1 6 -16 -13 -23 -24 -23 -17
-15 -17 -18 -26 -27 -24 -19
-15 -1 6 -21 -29 -28 -24 -21
-18 -15 -17 -31 -27 -25 -25
-14 -14 -17 -28 -33 -25 -25
-16 -16 -14 -27 -36 -24 -25
-16 -16 -1 2 -27 -40 -20 -26
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Clonidine IV 5 ug/Kg (2)
Blood Pressure
mmHg
-1 4 0 1 1 -1 0
1 2 0 1 1 1 1
-1 1 0 1 0 1 -1
0 0 0 1 0 0 0
0 0 0 2 -0. 5 0 0
0 0 0 0 0 0 0
103 104 102.5 100 31 100 102
-11 -7 -9.5 -11 -3.5 -13 -44
-18 -7 -13.5 -13 -13 -15 -43
-18 -7 -14 -17 -14 -17 -43
-19 -7 -15 -20 -15 -21 -47
-20 -7 -16 -26 -16 -25 -45
-20 -10 -16 -28 -17 -23 -41
-21 -1 2 -16.5 -31 -13 -23 -46
-23 -12 -17 -29 -18 -23 -36
-27 -1 2 -17.5 -27.5 -13 -21 -36
-26 -10 -16 -23 -13 -20 -34
-25.5 -3 -15-5 -23 -18 -1 9 -34

























Clonidine IV 10 ug/Kg (1 )
Time Blooi Pressure
un
-10 -1 4 10 5 0 2
-5 1 3 5 3 0 2
-4 1 1 5 1 0 2
-3 0 -1 3 2 1 1
_2 -1 0 2 1 0 1
-1 1 -1 1 0 0 1
0 107 39 103 110 94 37
1 -1 6 -11 -18 -44 -1 2 -15
2 -21 -15 -31 -43 -17 -20
3 -23 -17 -56 -42 -20 -20
4 -25 -1 3 -37 -36 -22 -19
5 -27 -17 -36 -36 -24 -20
8 -29 -18 -56 -40 -25 -21
10 -28 -1 8 -37 -33 -25 -21
15 -26 -17 -33 -57 -25 -23
20 -26 -1 6 -33 -40 -22 -23
25 -24 -11 -36 -37 -16 -20
30 -24 -1 1 -35 -58 -15 -17
35 -24 -1 0 -34 -39 -14 -18
40 -26 -11 -29 -39 -16 -17
45 -25 -10 -25 -58 -1 6 -16
Heart Rate
-10 -6 23 -7 -1 -3 10
-5 0 12 -9 -4 -1 6
-4 -1 3 -7 -6 1 5
-3 0 1 -5 -2 2 2
-2 0 0 -3 0 2 4
-1 0 1 0 0 1 1
0 427 442 415 404 413 441
1 -53 -45 -42 -42 -46 -52
2 -69 -54 -57 -59 -55 -53
3 -70 -53 -60 -63 -58 -64
4 -74 -61 -64 -67 -62 -71
6 -32 -64 -73 -72 -68 -76
8 -93 -67 -74 -77 -70 -30
10 -92 -66 -77 -31 -73 -35
15 -34 -63 -75 -33 -75 -100
20 -31 -63 -72 -69 -110
25 -30 -62 -54 -53 -1 11
30 -30 -59 -57 -46 -102
35 -78 -57 -39 -45 -83
40 -79 56 -44 -50 -69


















































t -1 -1 2 1 0
-7 -1 -2 -1 0 0
-3 1 -2 0 -2 0
-7 -1 -1 1 _2 0
-5 -1 0 1 -2 0
3 0 -1 0 0 0
140 101 122 121 93 115
-15 -42 4 1 -42 -52
-19 -45 -4 -1 2 -53 -50
-23 -54 -11 -17 -53 -47
-25 -57 -14 -20 -43 -47
-26 -56 -1 3 -25 -33 -43
-26 -53 -21 -31 -32 -43
-22 -59 -23 -37 -34 -31
-21 -60 -25 -37 -39 -39
-21 -61 -23 -35 -42 -40
-21 -60 -23 -35 -44 -43
-25 -60 -21 -37 -47 -40
-25 -53 -19 -39 -51 -34
-25 -57 -1 3 -40 -53 -45
-24 -57 -16 -40 -51 -45
Heart Rate
.. .Tain-1 ..
-5 0 -5 -3 0
5 0 -5 -3 0
3 0 -5 -3 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
365 332 390 403 475
-65 -50 -53 -63 -1 05
-30 -60 -62 -63 -110
-37 -62 -60 -63 -1 20
-95 -55 -60 -53 -1 20
-100 -55 -55 -73 -125
-102 -55 -65 -33 -135
-108 -62 -70 -33 -125
-1 22 -64 -55 -93 -140
-133 -67 -57 -93 -155
-140 -72 -53 -103 -1 60
-1 43 -72 -53 -1 03 -1 65
-143 -70 -60 -103 -1 60
-143 -70 -68 -103 -155
-1 43 -70 -68 -1 03 -1 20
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"Delayed" Hindlimb Perfusion
In the previous chapter clonidine was shown to reduce vascular
resistance in the hindlimh and hindquarters. Changes in vascular
resistance shown in constant rate or pressure perfusions may
involve:
1) direct action on the vasculature by blood borne agents.
2) changes in vasoconstrictor or vasodilator nerve tone.
3) action by blood borne agents on neurotransmitter
release, uptake or metabolism.
4) autoregulatory changes.
5) a net response of different portions of the
vasculature.
The interpretation of the mechanisms involved is therefore
difficult. To improve the utility of perfusion experiments the
vasculature may be denervated, cross circulation techniques employed
or drugs may be administered by close arterial injection.
Cross circulation experiments involve pumping blood from a
donor into the arterial supply of a vascularly isolated tissue and
returning the venous effluent to the donor. Changes in resistance
and capacitance represent nervous or blood-borne responses depending
on whether the stimulus is applied to the donor or the recipient. An
important variation utilises a vascularly isolated head and allows
separation of central from peripheral responses (Nowak et al 1935
for historical review). Taylor et al (1951 ) and Bickerton et al
(1961) perfected the technique with a relatively simple method for
occluding the venous sinuses under the ventral spinal cord but the
authors reported difficulty in maintaining the experimental animals
over several hours. Cerebral cross circulation experiments have not
been reported in rats probably because of the low historical cost of
dogs and the intricacy of the surgery.
Field et al (1953), Clark et al (1975) and Sakai (1973) report
using cross circulation procedures in the rat hindlimb. Returning
venous blood to the donor whilst maintaining venous pressure
constant appears to be a problem. Field and Sakai (1978) used a
venous reservoir and intermittent pumping whilst Clark used a second
pump without mention of a reservoir and may have encountered
problems with two pumps operating in series. A progressive build up
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"Inappropriate" responses to clonidine, glyceryl trinitrate and
phenylephrine in the perfused rat hindlimb.
* marks responses of interest.
a) Phenylephrine 10 ug/Kg IV. Top Left.
Causes an initial brief fall in perfusion pressure in the perfused
hindlimb, an unexpected effect for a vasoconstrictor drug. The
expected pressor effect follows of similar duration in both hindlimb
and on arterial blood pressure, the fall in heart rate mirrors the
increase in arterial pressure.
b) Phenylephrine 5 and 10 ug/Kg IV and Glyceryl trinitrate 10 ug/Kg
IV. Bottom Far Left.
As in a) a brief dilator action appears immiediately after
phenylephrine. This unlike the drop in heart rate and increase in
arterial pressure is unexpected. The slight increase in peripheral
resistance seen with glyceryl trintrate is similarly unexpected as
the drug is a vasodilator.
c) Clonidine 2.5 ug/Kg IV. Bottom Left.
The initial dilator effect in the hindlimb during the rise in
arterial pressure is unexpected from a drug with vasoconstrictor
actions after bolus IV administration.
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of fluid occurrs in part of the circuit if the rates of each pump
differ however slightly. Clark (1975) however avoids using a third
rat to fill the venous reservoir. A plausible solution requiring two
rats could involve using the second roller pump with a feedback loop
maintaining pressure downstream of the pump and by recording the
pumping rate capacitance changes could be ascertained.
This solution was not possible with the equipment availible and
a novel "delayed" hindlimb perfusion was developed. In some of the
hindlimb perfusion experiments blood temperature was considered a
problem and a heat exchanger was incorporated, necessitating an
increase in the extracorporeal volume. This slighly delayed the
arrival of blood-borne agents at the perfused hindlimb with respect
to the remainder of the vasculature. Intravenously applied drugs
produced "inappropriate" responses over this brief period, glyceryl
trinitrate producing vasoconstriction, phenylephrine and clonidine
vasodilation, before the expected effects manifested themselves, fig
3.1 a,b,c. The initial changes in perfusion pressure were
interpreted as being nervous in origin, rather than direct actions
of the drug, as the extracorporeal circuit has to be negotiated
before blood-borne agents can act on the perfused tissue.
Vasodilatation following clonidine or phenylephrine are then reflex
responses to the pressor actions apparent in the arterial blood
pressure trace. A method therefore presented itself for visualizing
nervous influences on the vasculature. The preparation was developed
by increasing the extracorporeal volume to between three and five
mis. giving a delay of at least one and a half minutes, fig 3-2.
Preparation
It is designed to distinguish between acute changes in
peripheral resistance mediated by humoral agents and those under
nervous control. Blood-borne responses are delayed because the large
external circuit takes time to negotiate and blood originating from
the pre-stimulus state is in the meantime perfusing the hindlimb.
There is no delay for nervously mediated effects and until post
stimulus blood reaches the hindlimb nervous effects are seen in
isolation. Changes seen concomitantly in arterial blood pressure
represent an amalgam of the applied stimulus and reflex responses.





The hindlimb is perfused with blood drawn from the carotid artery.
It passes through a long cannula containing several millilitres of
blood and its arrival at the hindlimb is delayed, allowing neural
responses to appear in the hindiimb separate from blood born
effects. A heat exchanger positioned just before the blood returns
to the animal restores the temperature of the perfusate to body
temperature.
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is superimposed on the existing level of nervous vasomotor tone. If
the cardiovascular effects of the initial stimulus have abated and a
new stable level of vasomotor tone become established then 1tHife
delayed response only reflects direct actions on the vasculature.
Finally changes in perfusion pressure represent a balance between
nervous and blood-borne responses.
It is a common practice to record the activity in sympathetic
efferent nerves and relate this to vasomotor tone. This requires
that sympathetic efferents are homogenous, if not in actions at
least in response. This is not justified as the work of Crosse %
Janig (1976) illustrates. Sympathetic efferents show different
response patterns therefore to use gross nerve activity as a measure
of vasomotor tone is unjustified. The "delayed hindlimb" avoids this
problem and alterations in vasomotor tone are seen without
contamination from sudomotor and piloerector activity. The
preparation does not differentiate between decreases in
vasoconstrictor activity and increases in vasodilator tone. Further
the vasculature studied involves muscles, skin and the foot with the
net response appearing. The foot could have been ligated to exclude
its involvement but was not, likewise the skin could have been
removed.
Blood volume in rats has been estimated at between 4--1 1 ral/100
gm (Muelheims at al 1959, Wang 1959) therefore an extracorporeal
circuit of 3-5 mis represents a substantial proportion of the blood
volume. If uncompensated for the volume required to fill the
external circuit would represent a substantial haemorrhage. To avoid
using a second rat a range of plasma substitutes were tried: saline,
Dextran 70, Haemacel. Replacement of both oxygen carrying capacity
and blood volume are required. Saline having no osmotic activity
proved to be of only short term utility. Dextran 70 was suprisingly
ineffective, a subsequent literature review revealed an
analphylactic reaction in rats (Edlund et al 1952, Auikier & Starr
1967, Voorhess et al 1951). A. retrospective look at earlier
experiments where dextran was used to increase blood pressure showed
it to be of questionable utility. Haemacel (Hoechst), a gelatin
based polymer with a molecular weight of around 37 000, reported to
have fewer allergic effects, (l3biter & Fisher 1980), did not appear
of great utility, although its use was not systematically
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investigated• Rather than invest a lot of effort in looking for
blood substitutes it was decided to use blood from a second animal.
Delay times were calculated from the volume of the external
circuit and tested using coloured solutions. The time taken for the
dye to appear at the outflow after a switch from saline to coloured
solution was shorter by several seconds than that calculated. This
is probably accounted for by diffusion along the tubing. To minimise
this PP50 polythene tubing was used, it has a narrow bore which
reduced the time difference.
The utility of the technique requires that the vascular bed
supplied by the femoral artery does not recieve a blood supply from
another artery. If this were the case immediate changes is perfusion
pressure could result from vasoactive agents delivered by a
collateral supply and not as the techniques requires from nervous
sources. To validate the technique perfusion pressures were measured
after stopping the pump, and were around 10 mmHg. If a second
arterial supply existed a higher pressure would be expected. Further
cutting the femoral vein after ligating the femoral artery does not
lead to sustained bleeding suggesting that the hindlimb blood supply
is predominantly derived from the femoral artery in these
preparations
Methods
1) Rats 250-500 gm prepared in the standard manner, tracheal
cannulation, femoral artery and vein of one leg cannulated for IV
injection and BP recording.
2) IV heparin 500 units. Carotid artery exposed, tied centrally
and cannulated on the cardiac side.
3) The other femoral artery tied centrally and cannulated
peripherally, taking care to avoid the adjacent nerve.
4) The perfusion apparatus filled with blood from the carotid
artery of a donor rat, 150-200 gm anaesthetized IP inactin and
heparinized.
5) The carotid artery and femoral arterial cannulae connected
to appropriate ends of the perfusion apparatus and the perfusion
started. After a few minutes the perfusion speed was adjusted to
provide a perfusion pressure approximating to the arterial BP.
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6) A. heat exchanger containing water at 38°C kept the perfusate
at body temperature. Warm water was obtained from a thermostatically
controlled water bath and pumped through the heat exchanger.
Heparin was given regularly, 200 units every hour. It is
important to fill the perfusion system with blood only when the
experimental animal is fully prepared. Otherwise the RBCs in the
tubing sediment and blockage of the perfusion system may occur. In
several experiments the perfusion pressures increased progressively,
suddenly returned to the initial level and then repeated the cycle.
It was assumed that a blood clot had lodged in the vasculature
leading to a build up of pressure which momentarily displaced the
obstruction and allowed blood to pa3s. The appearance of this
phenomenon signalled the useful end of an experiment.
Experiments
1) Responses to a variety of stimuli. Asphyxia, IV glyceryl
trinitrate, carotid occlusion, IV noradrenaline, IV isoprenaline and
IV phenylephrine were used to validate the technique and illustrate
reflex responses in the inactin anaesthetized rat.
2) Responses to IV clonidine. Looking for changes in peripheral
resistance resulting from reduced vasomotor tone and the direct
actions of clonidine on the hindlimb. The combined response was
studied after 9 mins when changes in peripheral resistance are due a
combination of central and peripheral actions, to asess the
importance of nervous and direct effects.
Results
1) Various Stimuli.
These are typical responses,they were not syteraatically applied
but used to establish that the preparation was functioning.
a) IV Phenylephrine, Fig. 3«3 a,b. An immediate increase in
arterial blood pressure and fall in heart rate and vascular
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.25 min asphyxia PHE 5 pg/Kg
Fig. 3.3 a
1/4 Minute Asphyxia And Phenylephrine 5 ug/Kg IV
1 min
Heart Rate











PHE 10pg/Kg i.v. PHE 1pg/Kg perfusate 1 min
Fig. 3.3b
Phenylephrine 10 ug/Kg IV And Phenylephrine Injected Into The
Perfusate.
The latter initially delivers the drug only to the hindlimb.
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resistance in the hindlimb. The delayed response was pressor and of
greater duration than that seen in arterial pressure, though the
rate of rise of pressure and peak effect were markedly reduced.
Diffusion within the delay tuhing would account for both phenomena,
reducing the concentration peak following bolus IV administration
and delivering phenylephrine over a longer period. An additional
factor reducing the duration of the arterial pressor response is the
neurally mediated reduction in peripheral resistanc, seen in the
hindlimb and presumably occuring in other vascular beds.
b) IV Adrenaline Fig. 3-3 h. Similar responses to IV
phenylephrine though no fall in heart rate occured.
c) IV Glyceryl Trinitrate Fig. 3-3 c,g. An immediate drop in
arterial pressure, increase in heart rate and increase in hindlimb
vascular resistance. Arterial pressure and heart rate return to
preinjection levels and a delayed fall in resistance appears in the
hindlimb. These results are compatible with a direct relaxant action
for glyceryl trinitrate and reflex responses by the anaesthetized
animal.
d) IV Isoprenaline Fig. 3-3 f. A vasodilator action explains
the drop in arterial pressure and rise in hindlimb resistance that
follow IV isoprenaline. The failure of heart rate to increase is
surprising.
e). Asphyxia Fig. 3.3 a,e,g. Asphyxia was achieved by covering
the tracheal cannula of spontaneously breathing animals. In each
instance hindlimb resistance increases immediately, in Fig. 3.3 a
arterial pressure did nor rise and in all three instances no
increase in heart rate was seen. The rise is perfusion pressure is
neural in origin and no delayed effect was seen. Possibly prolonging
the asphyxia would produce a delayed dilatation.
f). Bilateral Carotid Occlusion Fig. 3*3 d. An immediate
increase in arterial and hindlimb pressure resulted, heart rate did
not rise but the fluctuations around the mean abated for the
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Fig. 3.3 c,d,e,f
The "Delayed Hindlimb Perfusion With A Variety Of Stimuli
Fig. 3.3 c
Glyceryltrinitrate IV
Perfusion pressure increases in the hindlimb whilst arterial blood
pressure falls. A delayed decrease in perfusion pressure is
apparent.
Fig. 3.3 d
Carotid Occlusion Far Left.






pressure rise in unison, there is no temporal
Fig. 3.3 f Near Left
Isoprenaline IV

























ADR 6 ug/Kg IV mmI 1
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Fig. 3.3 g,h
The "Delayed" Hindlimb Perfusion With A Variety Of Stimuli.
Fig. 3.3 g
Glyceryltrinitrate IV And Asphyxia.
Perfusion pressure does not follow arterial pressure after GTN IV
but does in response to asphyxia.
Fig. 3.3 h
Adrenaline IV.
Perfusion pressure falls as arterial pressure rises in response to
ADR. After a delay perfusion pressure increases.
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2) Response to IV clonidine Fig. 3-4 a,b,c.
In all cases arterial pressure rose briefly following IV
clonidine. Heart rate fell as did perfusion pressure. The delayed
response was always pressor with its magnitude reflecting the dose
of clonidine. Comparison of the drop in perfusion pressure at 1.5
and nine minutes shows the former to be greater, though the final
pressure was lower than the predose level. Clonidine acutely reduces
perfusion pressure by in the first instance a neural action on
vasomotor tone. This is more than the reflex reductions in
peripheral resistance seen with phenylephrine and adrenaline as it
outlasts the increase in arterial pressure which is brief and small
compared to the responses to phenylephrine and adrenaline. The
prolongation of the dilator effect beyond the duration of the
arterial pressor action shows that this is not merely a reflex
effect but a neurally mediated action of clonidine.
The direct action on the vasculature is pressor. The final fall
in perfusion pressure is smaller than at 1 .5 mins. The pressor
effect in the perfused vasculature is of much longer duration than
the arterial action and of comparable magnitude. The explanation
offered for the prolongation of the action of phenylephrine in the
periphery is insufficient to explain the discrepancy in magnitudes
but accepting that clonidine is reducing vasomotor tone in excess of
that associated with a pressor action helps. The arterial pressor
action is overpowered by the accompanying reduction in vasomotor
tone whilst still existing at plasma concentrations mediating
vasoconstriction. In the hindlimb vasomotor tone has fallen when
clonidine arrives and does not attenuate the pressor effect,
prolongation arises from diffusion within the delay tubing and lack
of attenuation by falling vasomotor tone. That the overall
peripheral action (compare 1.5 mins with 9 mins) is not dilator
argues that an action at presynaptic nerve terminals reducing
transmitter release is unimportant. How important a contribution
this action makes cannot be derived from this experiment. Accepting
the argument for an arterial pressor action of short duration makes
part of the reduction in hindlimb resistance a reflex effect. Over a
few minutes plasma levels of clonidine fall and likewise the
suppressed pressor action. Vasomotor tone would rise a little in
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IV Cionidine And The Delayed Hindlimb Perfusion.
I.V. Cionidine and "Delayed" Hindlimb Perfusion
i . 1 > 1 1 1 1
0 5 10 15
Cumulative I.V. Cionidine pg/Kg
Compilation of results from five experiments.
The responses are measured 9.5 minutes after each administration.
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recognition of this. Therefore when comparing 1.5 with 9 mins after
IV clonidine vasomotor tone is likely to have risen and the overall
peripheral action of clonidine cannot be taken to be the difference.
Conclusions
A novel preparation for viewing the acute action on hindlimb
vasomotor tone has been developed and, by showing predictable
responses to known vasoactive agents, has been validated.
Clonidine was shown to cause an immediate fall in vasomotor
tone and when the net effect of peripheral and central actions is
viewed, at nine minutes after IV injection, an overall reduction in
vascular resistance is seen. The magnitude of each action cannot be
determined with this preparation. This would require a cross
perfusion of the vasculature, administration of clonidine to the
donor animal would allow direct vasoconstrictor and presynaptic
actions to appear in the hindlimb and, assuming no change is
vasomotor tone, their magnitude could be compared. Similarly
clonidine given to the animal with the perfused hindlimb would allow
only actions on vasomotor tone to appear.
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The Central Administration Of Clonidine ,
A method of investigating the site of a drugs action is by
selective administration to prospective areas. Regardless of how
achieved the concentration at the site of action will determine both
the intensity and duration of any response. IV administration
(chapter 2) shows that the response to clonidine is very rapid,
implying easy access to the site of action from the blood stream and
that the pharmacological effects appear rapidly.
In the rat the cerebral circulation is derived from the two
internal carotid arteries and the two vertebral arteries which
supply the Circle of Willis through the basilar artery. The origins
of the right and left subclavian arteries differ, the left arises
from the arch of the aorta whilst the right originates from the
common carotid artery. This asymmetry is important in central drug
administration. The vertebrals also give rise to the ventral spinal
artery which runs caudally down the ventral ssurface of spinal cord.
The ventral 3pinal artery is an anastomotic chain formed by a series
of ventral radicular arteries that reach the 3pinal cord along the
spinal nerves. Reports on the importance of the vertebral arteries
in the rat vary. Wellens at al (1976) suggest that the vertebrals in
the rat play no part in supplying blood to any part of the brain.
This study is based upon microsphere, raethacrylate infusions and
IVert administration of alpha-methyldopa. Methacrylate and
microspheres when injected IVert only appeared in the muscle
surrounding the neck. Alpha methyldopa did not show an enhanced
action on blood pressure and heart rate after IVert
administration. The methacrylate study aside the methods and
conclusions appear reasonable. Mitchell %> Himwich (1966) do show a
role for the vertebrals in maintaining cerebral blood flow and
Haywood et al (1930), using injection of biological black dye, show
that the vertebrals supply the brainstem.
Experiments
Administration Of Clonidine By The Following Routes
1 ) Into the internal carotid artery.
2) Into the lateral cerebral ventricle.
3) Into the vertebral artery.
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Methods
1) Intracarotid Clonidine. Administration was accomplished by
inserting a cannula into the external carotid and pushing it to the
bifurcation formed by the internal and external carotid. This
necessitated the removal of the hyoid bone. To restrict the
distribution of clonidine to the internal carotid artery the
occipital and superior thyroid arteries were ligated. Clonidine was
injected against the flow of blood over 40 seconds in 40ul with a
50ul syringe. An alternative approach could involve double
cannulation of the the common carotid, allowing injection into the
carotid, possibly combined with ligation of the occipital, external
carotid and superior thyroid arteries. The ligations would be
optional and would serve to limit drug distribution. Another
approach is to insert a cannula down the right brachial artery to
the common carotid artery, after side branches are tied off injected
drug passes up the right common carotid.
2) Intraventricular Clonidine. A 26 gauge needle was inserted
into the lateral ventricle using a stereotaxic frame and anchored
with dental cement to a screw attached to the skull. Injections were
given in 10ul over 60 seconds. Clonidine was made up in saline and
tests with saline alone showed no cardiovascular changes
accompanying injection. Evans blue dye was injected into the ICV
cannula at the end of the experiment and distribution of dye
throughout the ventricular system was taken as establishing the
correct location of the cannula. Once the technique was mastered all
injections were into the lateral ventricle system and Evans blue
found throughout the ventricular system.
Coordinates from the Bregma 0,0,0 caudal 0.5 mm
lateral 1 .3 mm
depth 5-0 mm
3) Intravertebral Clonidine. Intravertebral administration is
commonly used in cats and dogs but rarely in rats. Haywood et al
(1930) placed a cannula in the left brachial artery with its tip at
the point of separation of the vertebral artery from the subclavian,
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INTRAVERTEBRAL ADMINISTRATION IN THE RAT
Fig. 4.1
Techniques for intravertebral administration of drugs.
Two methods are shown, A that used by the experimenter and B
that more commonly used in cats and used in the rat by Haywood et al
(1980). Solid black indicates the cannula and the stipled areas the
likely pattern of drug distribution.
The asymmetry in the carotid/subclavian arteries is important
in technique A but not in B.
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in an accompanying diagram the cervical and mammary arteries were
shown as being ligated but no mention of the latter is made in the
text. The technique relies upon accurate placing of the cannula tip.
If this is too deep and the injectate will enter the internal
mammmary or co3tocervical arteries, if too shallow and the
vertebral will be missed by the injectate in favour of any unligated
arteries. Details of the surgery were not given. Attempts to utilize
this approach involved the removal of the sternum and large amounts
of muscle. Though Haywood et (1933) used their technique in recovery
experiments. In practice this approach proved difficult surgically
especially when trying to find the mammary artery whilst avoiding
fragile veins. An alternative, see fig 4-1 A. was developed. A
cannula is inserted into the right common carotid artery and all
readily accessible branches of the right subclavian artery ligatei,
the axillary, ascending cervical and cervical. The cervical arteries
are approached through the neck and a curved pair of watch makers
forceps used to loop a tie around them. The axillary artery is
approached as it emerges around the pectoral muscles, some care has
to be taken not to rupture the axillary vein or damage the adjacent
nerves, the '7th and"3th cervical and 1st thoracic.
The approach adopted has advantages over that used by Haywood
et al (1930), the surgery is relatively easy and the exact location
of the cannula tip is not as critical. The main disadvantage is that
the distribution of injected drugs is not confined to the vertebral
artery and will of necessity involve the costocervical and internal
mammary arteries. However failure to adequately ligate one of the
branches of the subclavian artery does not undermine an experiment,
it only increases the spread of drug. Greene (1935) indicates that
the vertebral may arise from the cervical trunk, this would negate
the Haywood et al (1930) approach.
Results
1) Intracarotid Injection Of Clonidine (IC).
See figs 4-2, 4.3 and tables 4-T4-5- Injection of saline had no
effect on blood pressure or heart rate. In the two figures control
animals have undergone the same surgery as those given clonidine IC
but received the clonidine IV. Comparison of the control and IC
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IC Clonidine 2.5 ug/Kg, Comparison With Control 2.5 ug/Kg.
There are no appreciable differences in the blood pressure and heart
rate responses.
The control has undergone the same surgery as the IC and clonidine
is administered IV.
Control N=5, IC N=5
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IC Clonidine 5.0 ug/Kg, Comparison With Control 5.0 ug/Kg.
The blood pressure responses are very similar however the IC group
display a greater fall in heart rate than the control.
The control group received clonidine IV.
Control N=4, IC N=4
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animals shows no difference in the arterial blood pressure
responses. However, at 5 ug/Kg a greater fall in heart rate is seen,
with 2.5 ug/Kg this difference is not found.
2) Intraventricular Clonidine (ICV).
See figs 4.4, 4.5, 4-6, 4-7 and tables 4.T6-3. The fall in
blood pressure is dose dependent over the range studied, 1-10 ug/Kg.
Heart rate changes have not been included in fig 4-4 as ratemeters
were not available in all experiments. ICV administered clonidine
leads to a much reduced onset of action compared to IV
administration. Comparison of the dose response curve with that
following IV injection (see chapter 2) show3 no difference in peak
effects but comparison at a dose of 5 ug/Kg between ICV and animals
prepared for ICV but injected IV shows the former to be more potent,
a surprising result which suggests that the surgery involved in
placing the ICV cannula alters the magnitude of the drug response.
Although the response is dose dependent the time course is
similar over the range of doses used. The only aberration is the
slight pressor effect seen during the 2 mins after the 1 ug/Kg
injection.
3) Intravertebral Clonidine Administration (iVert).
See figs 4.8, 4-9, 4.10a, 4-10b and tables 4-T1-3. 0.25 ug/Kg
of clonidine lowers blood pressure and heart rate when adminstered
into the vertebral artery. Saline similarly administer! has minimal
effects and the quantity of clonidine used has only a small
hypotensive action when administered intravenously. This is clearly
shown in a number of studies where clonidine was alternately
injected IV and IVert.
Tne recovery from a single IVert application of clonidine was
followed in a number of animals, it is faster than that seen after a
equipotent IV application but is by no means dramatic.
Discussion
The major differences appeared in the response to clonidine
when administered by one of four routes, IV, IVert, ICV and IC. The
differences involved the magnitude of response and speed of onset.




ICV Clonidine 1, 2.5, 5, 10 ug/Kg.
Only blood pressure responses are shown as heart ratemeters were not
available for all the experiments.
The onset of action is slow, peaking between fifteen and twenty
minutes.
The response to ICV saline is not shown but is minimal.
1 ug/Kg N=4, 2.5 ug/Kg N=4, 5 ug/Kg N=7, 10 ug/Kg N=4
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Fig. 4.5
ICV Clonidine 5 ug/Kg And Control IV 5 ug/Kg.
Control has an ICV cannula implanted but has clonidine given IV.
ICV is more potent but the timecourse for each differs, see next
graph. Fig. 4.6
The control group were underwent the same surgery as the ICV animals
but were injected IV with clonidine.




























ICV Cienidine and Control Timecourse.
Data on blood pressure and heart rate has been reasessed with
respect to timecourse. For each animal the response at each time has
been recalculated as % of maximum and this data used in plotting the
graph. Clearly IV control animals achieve maximum falls in blood
pressue and heart rate before animals given clonidine ICV.
The failure of graphs to reach 100% maximum arises because not all
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Fig. 4.7
IVert Clonidine Comparison With IVert Saline And IV Control
All animals underwent the same surgery.
The volume of saline is that used for the clonidine injection, and
is given over the same 40 second period as was the IV dose.




















Recording of a single experiment where clonidine or saline were
given IV or IVert. Volume used was 40 ul and the quantity of



























































graph showing recovery and comparison with saline




has a severly retarded onset suggesting that the site of action is
reached only with difficulty. Though more potent the increase does
not match that seen with injection into the ventricular system in
dogs, monkeys and cats where potency greatly increased (Bolme at al
1975) (Schmitt & Schmitt 1968). The abscence of greatly enhanced
potency has been previously noted in the rat (Borkowski et al 1975)
(Finch at al 1977).
That onset is progressive not delayed suggests that the site is
easily reached by a portion of the dose. But if action is at a
single site, which a portion of the dose can reach rapidly, it
becomes hard to explain why the remainder fails to act producing a
rapid supramaximal response. A second site of action that is less
easily attained could be reasonably envisaged.
Following ICV administration a quantity of clonidine, capable
of reducing blood pressure and heart rate when injected
intravenously, is deposited in the ventricular system and judging by
the pattern seen with Evans Blue spreads widely. This not
withstanding the likely initial volume of distribution is very
limited and a much higher concentration within C8F than seen after
IV administration would be anticipated. The importance of this to
the subsequent cardiovascular changes is not shown in this series of
experiments.
IG administration is no more potent than IV injection
in reducing heart rate and blood pressure. This appears to be the
first study undertaken on IC clonidine administration in the rat
although the lack of hypotensive potency has been noted in larger
animals (Gonstantine & McShane 1968) (Laubie et al 1976). A direct
action on baroreceptors, increasing their sensitivity, leading to a
fall in blood pressure may be discounted in the rat, although
reported in other animals. The route of administration would be
expected to result in a high concentration of clonidine around at
least one set of carotid body baroreceptors and any direct actions
would be expected to appear. In this context the greater fall in
heart rate, seen with 5 ug/Kg IC, may be of importance although the
variations between animals were large. It is possible that the
surgery involved in the chosen method of intracarotid administration
may have damaged the carotid sinus baroreceptors.
Intravertebral clonidine is very effective in lowering blood
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pressure and heart rate. This indicates that the new method used to
inject into the vertebral artery enables clonidine to reach an area
involved in blood pressure control- The technique is easy to utilize
requiring about 10 minutes surgery. If time was very pressing
ligation of the branches of the subclavian artery could be ommitted
finally requiring no more surgery than carotid cannulation. In these
studies the branches were ligated when found. This technique could
permit the widespread use of intravertebral injection in the rat,
presently an under-used approach. The use of intravertebral
injection in the cat and dog is common and in most cases nothing is
discovered using a large expensive animal than could not be 3howa in
the rat.
Intravertebral administration of clonidine is the most
effective route of the four used in the rat. This appears to be the
first study of intravertebral clonidine in the rat although a number
of studies have been undertaken in dogs and cats, noting the
hypotensive potency (Sattler & Van Zwieten 1967) (Katie et al 1972)
(Constantine & McShane 1963). Given the potency of this method of
administration only one dose was studied in detail, 0.25 ug/Kg. This
dose when given IV to rats prepared for IVert administration has
almost no action on heart rate or arterial blood pressure. This
means that the the drug induced response is only due to first pass
uptake into areas supplied with blood from the vertebral artery.
That this is the case is not surprising given clonidine's lipophilic
properties, what is surprising is the persistence of the fall in
heart rate and blood pressure, figs 4.10a and 4.10b. The fall in
blood pressure resulting from 0.25 ug/Kg IVert is similar to that
caused by 5 ug/Kg (chapter 1 ) a factor of X20. The return to predose
blood pressure is faster with IVert administration and must
represent the washing out of clonidine from the brain by blood
containing a low level of drug, a measure of clonidine's ability to
move out of the brain. Clearly the drug crosses the blood brain
barrier readily when moving from blood to brain but movement in the
other direction is poor which is strange given the concentration
gradient which may be assumed to exist facilitating net movement.
These results clearly suggest that in the rat the vertebral
arteries deliver blood to the brain, but do not indicate which areas
are supplied. They contradict the conclusions drawn by Wellens et al
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(1976), that the vertebral arteries are not involved in the cerebral
blood supplly. The size of rat used differs markedly, Wellens et al
(1976) used 400-500 gm whilst all the rats used with TVert clonidine
were less than 200 gnis, suggesting an age difference. Alternatively,
Greene (1935), the lability of the circle of Willis in the rat might
reconcile the data.
Given that the quantity of clonidine used when applied
intravenously had only minor effects on the cardiovascular system it
follows that the peak concentration of clonidine appears in the
brain immediately after the end of the slow IVert infusion. The dose
U3ed had no pressor actions, IV adminstration of the same quantity
did not increase arterial pressure, therefore clonidine not passing
into the brain on the first pass is unlikely to 3how any peripheral
vasoconstrictor effects. Thus the onset of the cardiovascular
effects is uncomplicated by baroreflex mediated responses to a
pressor effect and the rate of onset of the response depends solely
upon the hypotensive properties of the drug. The peak reduction in
arterial pressure appears at 10 minutes not at the end of the
infusion and the reduction in heart rate is also much greater after
ten minutes than at the end of the infusion. This indicates that the
mechanism of the cardiovascular response to clonidine in the rat has
a temporal component, possibly representing actions at two or more
different sites.
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Tables for Chapter 4
Animals Prepared for IVert Administration
Blood Pressure mmHg
10 -5 -1 0 1 2 4 6 10 Time
>.23 TV
-0.5 0 0 104.5 -1 .5 -1 -5 0 0 0.5
-0.5 0.5 0 114.5 -1 1 .5 1 .5 1.5 1 .5
0.5 0.5 2 124 -3.5 -3.5 -2 -2 -2.5
0 0 0 119-5 -2 -5 -6.5 -7 -7
0 1 0 112 -2 -1 -1 -2 -1
-2.5 -2.5 0.5 134.5 0 -5.5 -4.5 -4.5 -1
0 0 0 37.5 1 -5 -2 -3.5 -3.5 -2.5
I-n&/K& TV°rt
-2 -1 .5 0.5 111.5 -3.5 -10 -10.5 -10.5 -9
1.5 1 .5 0 126 -14 -15 -15 -1 6 -16.5
3 2 0 113 -26 -25 -24 -24 -22
0 2 1 136.5 -28 -33 -33 -33 -32
0 1 0.5 127.5 -15 -16.5 -16 -17 -18
-1 .5 5.5 -0.5 127.5 2.5 1.5 -1 .5 1 .5 -1 .5
0 0 0 110 0 0 0 0 0
1 .5 1 -1 118.5 0 -0.5 -1 .5 -0.5 -0.5
-1 -1 0 127 0 0 0 0 1
1.5 0 0.5 114-5 -0.5 -0.5 -0.5 -0.5 1 .5
-1 -1 0 123.5 0 -1 .5 2 2 0.5
-1 .5 -2.5 -3 139 -0.5 -3 -0.5 -1 .5 -2.5





-2.5 -5 0 375 -5
iv O ■*■»•••
-5 -2.5 -2.5
0 0 0 393 -5 -7.5 -7.5 -7.5 -10
-5 0 0 400 -6 -7.5 -7.5 -7.5 -7.5
0 0 0 363 -5 -7.5 -10 -10 -10
0 0 0 413 0 0 0 0 -2.5
2.5 2.5 0 423 -5 -5 -12.5 -12.5 -12.5




-37.50 2.5 0 413 -32.5 -35 -32
-2.5 -2.5 0 390 -20 -22.5 -22.5 -25 -22.5
0 -2.5 -2. 5 410 -27.5 -32.5 -32.5 -32.5 -60
-2.5 2.5 0 400 -22.5 -40 -50 -55 -55
-3-5 0 0 413 -15 -32.5 -42.5 -57.5 -57.5
ul IV
10 -15 0 388 0 0 -2.5 2.5 2.5
-2.5 -2.5 0 415 2.5 2.5 2.5 5 2.5
0 0 0 343 0 -2.5 -2.5 -2.5 -2.5
7.5 2.5 2. 5 420 -2.5 -5 -2.5 -2.5 -10
2.5 2.5 0 393 0 0 0 0 0
-7.5 -2.5 0 395 0 0 5 5 5
-5 -2.5 -2. 5 403 -2.5 -5 0 0 -2.5
•12.5 -5 -2. 5 363 0 2.5 5 5 5
The rats were prepared for both IV and IVert adminstration and
were given IVert clonidine (0.25 ug/g), IVert saline (40 ul) or









-10 1 -2.5 2.5 2.5 -3.5 -2. 5
-5 2.5 -3.5 0 2.5 0 -5
-1 0 0 2.5 0 0 0
0 412 390 350 400 413 415
1 -32.5 -20 -30 -22.5 -15 -27. 5
2 -37.5 -22.5 -27.5 -40 -32.5 -32. 5
4 -37 • 5 -22.5 -30 -55 -57.5 -37. 5
6 -35 -25 -27.5 -55 -57.5 -45
10 -32.5 -22.5 -25 -55 -52.5 -60
15 -30 -10 -17.5 -50 -52.5 -55
20 -35 5 -10 -30 -55 -25
25 -35 5 -10 -30 -55 -35
30 -35 10 2.5 -17.5 -52.5 -25
35 -35 15 5 -7.5 -45 -40
40 -37.5 20 15 0 -42.5 -17. 5
45 -37.5 22.5 15 10 -40 -20
mmHg
-10 -1 1 .5 -2 2.5 2 5
-5 -0.5 3 0 2 1 0
-1 0.5 0 -2 1 0.5 0
0 111 .5 126 103 136.5 127.5 135
1 -3.5 -14 -10 -24 -15 -15
2 -10 -15 -3 -33 -16.5 -19
4 -10.5 -15 -3 -32.5 -16 -23
6 -9.5 -16 -3 -32 -16 -25
10 -9 -16.5 -7 -26 -18.5 -27
15 -6. 5 -15 -7 -13 -17.5 -27
20 -6.5 -1 2 -5 -22 -15.5 -17
25 -6.5 -13 -4 -12.5 -15 -15
30 -7 -13.5 -2 -10.5 -15 -15
35 -6 -13.5 -2 -9-5 -11 .5 -15
40 -7.5 -13 1 -10.5 -9 -15
45 -7.5 -14 0 -13.5 -8 -15
The changes in blood pressure and heart rate were followed in
these rats for at least forty five minutes after administration,
rather than for only ten minutes.
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Alternate IV IVert 0.25 ug/Kg Clonidine
Time ,Heart Rate.... R~1 P?»aa on r» o
min min-1 mmHg
-10 -2.5 -5 -5 0 -0.5 0.5 _2 -0.5
-5 -5 -2.5 0 0 -0.5 1 0 1 .5
-1 0 0 0 0 0 0 0 2
IV 0 375 418 400 367.5 104.5 113 119.5 124
1 -5 -5 -6 -5 -1 .5 -2 -2 -3.5
2 -5 -5 -2.5 -7.5 -1 .5 -1 -5 -3.5
4 -5 -5 -7.5 -10 0 -1 =6.5 -2
6 -2.5 -5 -7.5 -10 0 -2 -6.5 -2
8 -2.5 -2.5 -7.5 -10 0.5 -1 -7 -3
IVert 0 -5 -2.5 -7.5 -10 1 .5 -1 -7 -3
1 -52.5 -40 -65 -25 -7.5 -12 -1 6 -18
2 -35 -42.5 -70 -30 -10.5 -13 -1 8.5 -19
4 -35 -45 -67.5 -35 -9.5 -13 -18 -19
6 -32.5 -45 -67.5 -33.5 -10.5 -12 -18 -19
8 -32.5 -40 -60 -32.5 -10 -11 -17 -17
IV 0 -32.5 -40 -57.5 -30 -9.5 -1 1 -1 6 -15
1 -35 -45 -60 -32.5 -11.5 -11 -16.5 -18.5
2 -30 -45 -60 -32.5 -11 .5 -10 -16.5 -17.5
4 -32.5 -40 -60 -32.5 -1 2 -9 -16.5 -16
6 -35 -37 -60 -30 -11.5 -7 -15 -14
3 -32.5 -35 -57.5 -30 -11.5 -6 -14 -11 .5
IVert 0 -32.5 -35 -55 -30 -11.5 -6 -14 -10.5
1 -47.5 -62.5 -37.5 -37.5 -15 -15 -19 -20
2 -47.5 -67.5 -35 -42.5 -13.5 -15.5 -1 8.5 -20
4 -42.5 -65 -32.5 -50 -10 -14 -21 .5 -19
6 -37.5 -57.5 -32.5 -50 -7.5 -14 -24 -1 8
3 -30 -35 -75 -57.5 -7.5 -12 -22 -17.5
10 -25 -55 -72.5 -60 -7.5 -1 2 -22 -16
The rats were prepared for both IV and IVert administration of
clonidine. Clonidine was given initailly IV, then IVert, again IV
and finally IVert again.
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Intracarotid Clonidine (5 ug/Kg) on Heart Rate and Blood Pressure
Heart Rate
mins ...IC. . niin-1 ..... . TV
-5 7 1 -3 1 -3 -6 2 -3
-4 6 0 -2 1 -2 -5 0 -1
-3 5 0 -1 3 -2 -4 3 -1
-2 3 0 -2 0 -2 -2 1 0
-1 0 0 -1 0 0 -2 2 -1
0 390 474 404 410 330 330 400 411
1 -40 -50 -43 -22 -38 -28 -43 -44
2 -46 -67 -55 -26 -42 -32 -43 -46
3 -43 -72 -59 -30 -43 -32 -52 -51
4 -46 -78 -62 -35 -45 -30 -56 -51
6 -46 -34 -65 -45 -52 -30 -61 -56
3 -52 -94 -64 -55 -56 -25 -67 -56
10 -53 -102 -61 -62 -53 -13 -67 -55
15 -68 -106 -53 -54 -53 -16 -53 -42
20 -60 -106 -44 -46 -43 -20 -43 -40
25 -52 -102 -47 -57 -48 -24 -31 -41
30 -53 -94 -43 -53 -35 -33 -24 -33
35 -62 -39 -46 -42 -37 -36 -34 -17
40 -63 -94 -31 -33 -44 -23 -38 -10
45 -63 -94 -39 -40 -40 -23 -23 -16
50 -63 -94 -37 -46 -40 -20 -22 -6
55 -54 -93 -37 -33 -40 -14 -26 -10
Blood Pressure
mmHg
-5 1 -3 5 1 2 -2 1 -2
-4 1 -3 4 0 1 0 1 -1
-3 -1 -2 3 -2 0 1 1 -1
-2 -2 -1 .5 0 -1 0 2 0 -1
-1 -1 0 0 -1 0 -1 0 0
0 99-5 109 101 100 100 117 106 103
1 -4.4 -6 -4 -3 -5.5 -6 -11 -1 0
2 -18 -11.5 -5 -6 -10 -1 1 -10 -1 1
3 -20 -13 -10 -6 -15 -13 -12 -1 2
4 -22 -16.5 -3 -3 -17 -12 -12 -14
6 -25-5 -21 -10 -11 -1 8.5 -12 -13 -1 1
8 -26.5 -20 -10 -9 -22 -1 2 -15 -13
10 -26 -23 -11 -17 -21 -10 -15 -13
15 -19 -22.5 -10 -17 -17 -10 -15 -12
20 -13.5 -21 -10 -15 -18 -13 -13 -15
25 -1 1 -19.5 -12 -15 -15 -15 -9 -15
30 -14-5 -17.5 -13 -3 -13 -19 -10 -15
35 -15 -18 -13 -17 -14 -21 -14 -14
40 -15 -19 -12 -16 -21 -24 -14 -14
45 -13 -12 -13 -13 -19 -24 -13 -17
50 -14 -12 -11 -20 -19 -22 -14 -16
55 -10 -13 -10 -18 -19 -19 -10 -1 8
All the rats were prepared for both IV and IC administration of
clonidine, the tables headed IC denote those receiving clonidine
by that route and the tables headed IV denote those given
clonidine by the alternate route.
Chapter 4.T5






-5 1 3.5 1 .5 -1 -1 -1 3 1 9 0
-4 1 2.5 1 -2 -2 0.5 2 2 9 0
-3 0 -1 .5 1 -1 -1 1 0 2 7 0
-2 0.5 -2.5 0.5 -2 -1 2.5 1 0 5 2
-1 0 -1.5 0 -1 0 0 0 -1 2 0
0 36 34.5 34 85 99 38 101 110 1 20 94
1 -10 -19 -5.5 -6 -6 1.5 0 -7 -1 -16
2 -14 -25 -7 -6 -3 -0.5 -4 -15 -2 -24
3 -14 -27 -6.5 -5 -7 -0.5 -10 -15 -1 -17
4 -14 -25.5 -6.5 7 -5 -2.5 -6 -1 2 -3 -12
6 -15 -25.5 -6.5 -3 3 -4 -1 1 -16 -5 -10
3 -15 -20.4 -6.5 -6 4 -3 -1 5 -1 8 -6 -7
10 -15.5 -11 -5.5 -3 7 -6 -13 -17 -5 -6
15 -13 -13.5 -7 -9 4 -7 -15 -20 -6 -13
20 -9 -11.5 -3.5 -22 2 -2.5 -17 -20 -7 -1 8
25 -9 -13.5 -3.5 -14 2 1 .5 -16 -15 -10 -15
30 -7 -12.5 -3.5 -15 -7 6.5 -12 -20 -3 -1 5
35 -5-5 -6.5 -2.5 -1 8 -9 0.5 0 -23 -7 -18
40 -3.5 -5.5 -3.5 -17 -12 -2.5 -26 -20 -6 -14
45 -7 -3.5 -7 -16 -3 -2 -27 -21 -6 -15
50 -3 -4 -14.5 -15 -3 -3.5 -33 -19 -4 -14
Heart Rate
min--1
-5 -1 10 -4 -12 7 -3 -2 18 16 -3
-4 1 11 -3 -12 7 -5 -5 16 12 -2
-3 0 7 -3 -12 4 -3 -3 3 11 -1
-2 -1 5 -3 -11 0 -3 -2 5 9 -2
-1 -1 3 -1 -4 0 -2 -1 4 3 -2
0 401 359 427 421 336 440 427 452 453 401
1 -27 -25 -29 -17 -37 -19 -5 -27 -17 -5
2 -45 -30 -34 -42 -47 -23 -24 -44 -19 -14
3 -54 32 -33 -21 -49 -26 -30 -50 -19 -1 5
4 -53 -33 -35 -17 -52 -27 -17 -44 -1 8 -13
6 -65 -36 -35 -14 -57 -34 -1 8 -53 -17 -3
3 -63 -39 -57 -14 -60 -41 -30 -53 -27 -15
10 -66 -40 -47 -14 -61 -44 -32 -60 -57 -1 8
15 -53 -40 -47 -13 -66 -55 -41 -59 -51 -26
20 -37 -47 -52 -11 -72 -27 -47 -15 -62 -37
25 -25 -53 -43 -17 -66 10 -56 -27 -47 -42
30 -15 -33 -33 -29 -43 36 -55 -52 -45 -46
35 -1 -9 -37 -32 -37 18 -11 -62 -45 -43
40 5 -15 -32 -31 -6 10 -53 -60 -42 -51
45 14 -23 -41 -25 9 6 -51 -40 -50 -51
50 25 -27 -3 -24 27 -4 -43 -30 -20 -54
Chapter 4.T6
]V Clonidine (5 ug/Kg) on Heart Rate and Blood Pressui
time Heart Rat0
min
-10 2 -6 -9 -3 2 -6 0
-5 3 1 -6 -4 2 -5 0
-4 2 -5 -5 -3 0 1 2
-3 1 -2 -3 -3 0 -2 1
-2 0 1 -3 0 0 1 -1
-1 -2 0 -2 0 -2 2 -2
0 345 433 418 435 345 436 464
1 0 -7 0 0 0 -2 -1
2 -4 -24 -3 -19 -4 -14 -19
3 -6 -43 -5 -33 -9 -25 -35
4 -10 -45 -3 -45 -10 -36 -42
6 -12 -54 -10 -54 -12 -53 -53
3 -15 -62 -15 -64 -19 -66 -67
10 -20 -68 -24 -69 -20 -72 -70
15 -23 -77 -34 -30 -24 -70 -76
20 -29 -76 -49 -90 -30 -71 -37
25 -22 -63 -60 -35 -22 -71 -33
30 -17 -65 -65 -77 -1 8 -71 -91
35 -15 -63 -56 -78 -14 -62 -39
40 -15 -57 -47 -79 -15 -64 -35
45 -17 -47 -42 -79 -1 8 -62 -79
50 -13 -33 -42 -73 -13 -63 -74
55 -9 -27 -40 -71 -10 -65 -72
60 -5 -27 -40 -71 -10 -65 -72
Blood Pressure
-10 0 3 2 2 -2 0 -1
-5 0.5 1 2 2 1 0 -1
-4 0.5 0 1 -1 0 3 -1
-3 -1 1 2 -1 0 2 -1
-2 -1 2 1 -1 0 0 -2
-1 -1 0 1 0 0 0 -1
0 111 103 34 81 111 83 86
1 0 -1 0 1 -1 0 2
2 -3 -2 -3 -1 -4 -1 -2
3 -7 -3 -4 -4 -5 -3 -3
4 -10 -1 1 -5 -6 -12 -5 -9
6 -1 5.5 -15 -6 -3 -20 -9 -16
8 -20 -18 -7 -11 -26 -9 -18
10 -27.5 -20 -7 -10 -26 -10 -17
15 -28.5 -23 -7 -11 -29 -13 -18
20 -30 -23 -7 -13 -30 -14 -18
25 -30 -22 -7 -7 -32 -14 -16
30 -30 -20 -5 -6 -30 -11 -16
35 -31 -17 -4 -4 -31 -11 -16
40 -28.5 -16 -2 1 -28 -9 -15
45 -35 -13 1 1 -25 -9 -1 2
50 -34 -12 2 2 -23 -9 -11
55 -25 -10 2 4 -27 -9 -10
60 -26.5 -1 2 2 2 -26 -9 -10
Chapter 4.T7
ICV Prepared Rat Given Clonidine IV (5 ug/Kg)
time Blood Pressure
J.L*.
10 1 1 1
• • • • •
3 0 0
-5 2 2 1 2 0 0
-4 1 2 1 4 1 0
-3 0.5 2 1 4 0 -2
-2 0.5 0 1 1 0 -2
-1 0 -1 1 1 0 -1
0 124 32 83 113 36 95
1 -1 .5 -20 -3 -3 -4 -14
2 -4 -25 -6 -10 -14 -16
3 -5 -17 -5 -3 -14 -17
4 -5 -1 8 -5 -10 -13 -17
6 -6 -29 -4 -9 -13 -13
8 -10 -29 -5 -13 -13 -18
10 -12.5 -29 -6 -11 -11 -1 8
15 -13.5 -24 -7 -3 -13 -16
20 -14.5 -22 -4 -10 -1 0 -13
25 -16 -18 -3 -9 -9 -13
30 -17.5 -26 1 -11 -3 -14
35 -20.5 -31 0 -11 -9 2
40 -17.5 -31 1 -15 -11 2
45 -17.5 -33 3 -14 -12 5
50 -17.5 -36 10 -12 -13 5
55 -17-5 -36 1 1 -11 -13 5
Heart Rate
1 ... .
1 0 7 17 4 0 -1
-5 7 10 3 0 -1
-4 6 6 2 0 -2
-3 -2 4 1 3 -3
-2 0 1 1 0 -2
-1 -2 2 0 -1 -1
0 378 374 395 375 370
1 -30 -27 -18 -33 -32
2 -35 -31 -24 -43 -44
3 -33 -38 -27 -46 -52
4 -33 -40 -29 -49 -59
5 -38 -45 -32 -51 -62
8 -38 -46 -35 -53 -63
10 -36 -43 -34 -56 -63
15 -24 -51 -27 -53 -67
20 -19 -50 -27 -53 -62
25 -4 -46 -25 -40 -59
30 -6 -36 -35 -32 -55
35 -11 -33 -20 -32 -48
40 -10 -33 -5 -54 -45
45 -13 -33 -10 -32 -42
50 -1 2 -19 -10 -37 -40
55 -11 -15 -9 -37 -41
Chapter 4.T3
ICy Clonidine Effect on Heart Rate and Blood Pressure
time Blood Pressure
min , .1 . Ufr/K/r 0 ^ - n fr /\C fT
-5 0 -1 1 0 1 .5 1 2 1 -5
-4 0 0 1 0.5 0 1 1 1
-3 -0.5 0 1 0 0 1 0 0
-2 -0.5 -1 0.5 -0.5 -1 1 0 0
-1 -0.5 1.5 0 0.5 0.5 1 0 0
0 39-5 81 .5 91 94 87 106 34.5 33
1 1 .5 2.5 1 1 .5 2 -1 0 -2.5
2 1 .5 2 1 1 -5 0 -1 .5 -6 -1
3 1 0 0 0.5 -2 -6 -9 -4
4 0.5 -2 -1 .5 -1 -4 -7.5 -10 -3.5
6 -3 -5.5 -3.5 -4 -8.5 -7 -11 -14
3 -5 -5.5 -4.5 -5 -1 1 .5 -3.5 -14 -15.5
10 -6.5 -7 -6 -6.5 -14 -7.5 -17 -16.5
15 -9-5 -5.5 -7 -7 -18.5 -10 -19 -1 8.5
20 -10 -5 -7 -7.5 -20.5 -9.5 -19 -1 3.5
25 -10 -5 -3 -7.5 -20 -9.5 -17 -19
30 -11 -4.5 -7 -7.5 -19.5 -10 -17 -19
35 " -I'D -4-5 -7.5 -4 -8 -9.5 -14 -1 8
40 -9-5 -4-5 -7.5 -7 -1 6 -10 -13 -16
45 -11 -5 -6.5 -7.5 -1 8 -10 -13 -19
ICV Clonidine (10 ug/Kg) Effect on Heart Rate and Blood Pressure
time Blood Pressure
min mraHg
-5 0 -5 1 -1
-4 1 -1 0 0
-3 0 0 0 0
_2 0 -1 -1 -0.5
-1 0 2 0 0.5
0 129 93 114 95
1 -1 -4 -4 -3
2 -3 -5 -15 -6
3 -5 -9 -18 -11
4 -7 -16 -14 -1 4.5
6 -11 -24 -28 -21
8 -15 -27 -31 -24.5
10 -19 -28 -33 -27
15 -24 -32 -37 -31
20 -29 -27 -33 -31
25 -28 -22 -39 -30
30 -32 -15 -33 -28
35 -31 -11 -33 -27
40 -30 -1 1 -35 -25
Chapter 5- 1
The Autoradiographic Location Of Clonidine
Work presented in the previous chapter shows that the magnitude
of the response to clonidine varies with the route of
administration. This suggests that access to a site of action varies
with the route of administration. Therefore comparison between the
different patterns of distribution and the hypotensive effect could
be helpful in locating clonidine"s site(s) of action. Areas in which
a high concentration is attained with a route of administration
associated with only a small reduction in blood pressure are
unlikely to contain the site of action. Conversely when a large fall
in blood pressure is obtained the site of action is likely to be
contained within regions with high clonidine concentrations.
To pursue this approach a senstive assay for clonidine is
needed. The more sensitive the assay the smaller the tissue samples
required which enhances the spatial resolution. Conway and Jarrott
(1980) used a radioimmunoassay capable of detecting 30 pg of
clonidine which, assuming a dose of clonidine within the hypotensive
range and an even distribution throughout the body, represents a few
milligrams of tissue. A more common approach involves subdividing
the brain into relatively large pieces (Glowinski & Iversen 1966),
clearly this does not provide high spatial resolution. High
resolution can be obtained if a large number of small samples are
taken from known sites. Suitable techniques (Palkovits 1973) exist
but their use is generally confined to removing a small number of
samples. To use an onerous extraction technique in combination with
a complex assay is possible but very time-consuming and therefore
not practicable. This approach was rejected in favour of
autoradiographic location of radiolabelled clonidine which offers
higher spatial resolution than tissue sampling and although time
consuming compares favourably with the alternative approach.
Autoradiography has been previously used to measure the spread
of drugs after central administration (Herz et al 1970, Schubert et
al 1970, Fuxe et al 1963, Grossman & Stumpf 1969).
The studies were primarily concerned with the distribution of
clonidine within the CNS. The prevention of diffusion after death
was considered to be a major problem especially as it was intended
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to look at the time course during the onset of hypotension. The
onset after IV administration is rapid. A. rapid death and the
simultaneous prevention of diffusion is therefore important in
stopping the onset at a known time. This is most easily achieved by
freezing the rat in a hexane/dry ice mixture, the alternative of
removing the brain and then freezing it takes several minutes and is
only applicable if diffusion is unlikely and the onset of action
slow. Sectioning a whole rat requires expensive equipment which is
not widely available. Access was provided by ICI through the CASE
award.
Autoradiography
Autoradiography involves placing a photographic film in close
apposition to tissue containing a radioisotope, the emissions
produce a latent image in the film that is subsequently converted to
a true image during development. The density of silver grains in the
film is a function of the underlying radioactivity. Autoradiography
detects the radioisotope not the remainder of the molecule and
therefore fails to distinguish between the labelled substance and a
metabolite containing the radioisotope. The pharmacokinetics of
clonidine, mentioned in the first chapter, suggest that over the
short post injection times used the majority of the radioactive
marker will be present as clonidine and therefore can be used as
a marker for clonidine.
Two radioisotopes have been incorporated into the clonidine
14 "5
molecule, ^"C and H Both are beta particle emitters but their
1 4
energy spectra differ. The beta particles from C are of higher
energy and travel further in tissue and emulsion. It follows that
the distance between a silver grain and the point of origin of the
14 3
Beta particle is greater for C than H and that the theoretical
1 4
resolution is higher with the latter. Emissions from a C source
s
may travel 10Oum whilst those from H do not exceed 3um. Therefore
14
when a C radioisotope is used the grain density will reflect the
3
section thickness whilst with H no change is apparent when the
depth is increased beyond 3um. Thus with sections of 5-4-Oum, a range
used in whole body autoradiography, variations in thickness between
sections is not reflected in the autoradiogram when using H but can
1 4
be a problem when C is employed.
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X ray films are generally employed when large sections are
studied because the combination of large crystal size, uniformity of
emulsion and ease of use outway the higher resolution obtainable
with liquid emulsions. The loss of resolution is of no importance in
■a
the studies undertaken. The limited penetration of H emissions
greatly reduces the efficiency of autoradiography when X ray films
are used, because they incorporate an antiscratch layer (0.5-1 .Oum)
between the emulsion and the tissue which prevents the majority of
Beta particles reaching the emulsion. As a consequence has been
the radioisotope of choice in whole body autoradiography.
1 4
Although C has been incorporated into the clonidine molecule
it is not supplied by either New England Nuclear or Amersham
-a
International, the major radioisotope manufacturers. H clonidine is
obtainable with a high specific activity permitting the use of doses
in the hypotensive range. The cost is prohibitive when X ray films
are employed. Attempts have been made to increase the utility of
tritium with chromatograms and macroscopic sections:
a) Applying liquid emulsions to the section (Rogers 1959,
Markman 1963, Chamberlain et al 1964). This ensures intimate contact
between tissue and emulsion which increases the number of Beta
particles reaching the latter. Diffusion of soluble substances can
occur, chemography is enhanced and the production of even layers of
emulsion is difficult. Liquid X ray emulsions are not readily
available.
b) Radio flourography. A scintillant generates light on
exposure to Beta particles and a light sensitive film is then used
to detect the latter (Wilson 1959, Farebrother & Creasy 1976).
Exposure at low temperatures further enhances sensitivity (Luthi d
tfaser 1965) as does preexposure of the film to a controlled light
flash (Laskey & Mills 1975). Problems arise with diffusion, non
linearity of the response, reduced resolution and difficulties in
producing low temperatures
c) Tritium sensitive X ray films. Two films have been developed
CEA Verken and Sakura Marg (Makita & Hatuoka 1973), the latter is
■a
not obtainable in the UK and information scarce. The CEA Verken H
film (Larsson & Ullberg 1977a,b Applegren et al 1977) has a
"monolayer" of emulsion applied to one side of the backing, uses
large crystals (1.3 urn), a high silver to gelatin ratio and no
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antiscratch layer. This combination makes this film 12-265 times as
sensitive as the commonly used X ray films when tritium is employed
(Larsson & Ullberg 1977a). The absence of the antiscratch layer
greatly increases the number of beta particles reaching the emulsion
which is itself very sensitive to the low energy emissions of
tritium.
Of the three approaches outlined for increasing the sensitivity




1. Anaesthetized rats injected with a mixture of radioisotope
and unlabelled drug. Tritiated clonidine is supplied in ethanol and
0.001 M HC1. It was redissolved in saline after blowing off the
original solvent with nitrogen. Blood samples taken to determine the
plasma level of radioactivity.
2. Animals killed by immersion in hexane/dry ice (solid carbon
dioxide) mixture -75 °C.
3- Whole animal mounted in a block of carboxymethylcellulose
(wallpaper paste) and stored frozen until sectioned.
4. The frozen block was trimmed. Mounting tape applied to the
cut surface and 20-50 um sections taken with a cryostat (Bright &
Sons) at -20 °C.
5- Sections were freeze dried at -20 C for 48 hrs. in cryostat
cabinet.
6. Sections were removed from cryostat after placing in an air
tight container containing silica gel and were allowed to reach room
temperature before removing.
7- Excess taps removed and talcum powder applied to tissue and
blown off.
8. In a dark room under safe light, Wratten 6B.Mounted sections
were placed in apposition to film and put in a press.
9- A light tight container with film, tissue and press were
left in cold store to expose.
10. Film developed in accordance with manufacturers directions,
4 mins in developer at 20°C.
The whole body autoradiography technique used is predominantly that
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developed hy Ullberg (1954,1977)- The technique prevents diffusion
of clonidine hy rapidly freezing the rat and keeping sections frozen
until they are dehydrated. After cutting, the sections are kept at
-20^0 to allow water to sublime. Condensation onto the cold section
by moisture in the atmosphere on removal from the cryostat is
prevented by bringing the sections to room temperature in a moisture
free environment. It can then be handled safely at room temperature,
although care needs to be taken to prevent the section becoming damp
which would reintroduce diffusion problems.
Cutting was performed on a Bright & Sons cryostat, this is
essentially a powered sledge microtome mounted in a deep freeze, it
is capable of cutting whole body sections of animals up to the size
of small pigs. Prior to cutting the frozen animal was mounted in a
block of carboxymethylcellulose which provides support. The block is
trimmed until the areas of interest are revealed. Sections were cut
between 20 and 30 urn. As tritium was used variations in section
thickness are not reflected in the autoradiogram. Prior to cutting,
adhesive tape is attached to the cut surface of the block and used
to lift the section off the knife face as the sledge is driven
across the knife. The tape (3*1 810) prevents the section breaking up
and is useful in handling as contact with the tissue can be avoided.
After cutting the sections are mounted on frames and kept in
the cryostat cabinet for two days. This allows removal of water by
sublimation without it passing through a liquid phase which would
permit diffusion of clonidine. After removal from the cryostat the
tape is trimmed and talcum powder applied. A powder ladden puff is
shacken above the section and the surplus removed by blowing. This
is done to reduce the adhesive properties of the tape which where it
is not covered by tissue will stick to the film and cause damage on
separation. Talcum powder will adhere to the exposed tape surface
but will be blown off other areas and does not form a layer between
tissue and emulsion that would prevent Beta particles reaching the
latter. A number of sections are mounted on thick paper of similar
dimensions to the film. Film and mounted sections are then
sandwiched between aluminium plates a slightly compressable sheet
and plastic sheets and placed in a press. This when screwed down
brings the film and tissue into close apposition without causing
mechanical damage. Given the poor penetration of H beta particles
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this is important.
Rats of either sex in the range 150-170gm were used. Larger
rats show only marginal increases in brain weight and the increasing
levels of body fat and bone calcification make sectioning more
awkward and require more radioactive clonidine.
Sections from each animal were used to make up one sheet for
auto radiography,
Analysis
The primary method was by eye. It is easy to relate the pattern
of distribution to organs and body tissues. The silver density above
a tissue is not necessarily a linear function of the underlying
radioactivity. A dense tissue reduces the escape of beta particles
and the film/development process is saturable. However comparison of
densities above the same tissue in different animals does reflect
the content of tritium. Some quantification was achieved by removing




3) Lose dependence of clonidine distribution.
4) Effect of a carotid arterial cannula on lateral





1) Positive or negative chemography is the creation or removal
of a latent image by the chemical action of the specimen on the
emulsion. The absence of the traditional antiscratch layer in the
CEA verken film exposes the emulsion directly to the tissue making
chemography a possibility.
Sections from rats prepared in the usual manner but without
clonidine were placed in contact with exposed and unexposed film.
I.V. Clonidine For Autoradiography
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Time From Injection mins
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Fig. 5.1a Left Page
IV Clonidine For Autoradiography
Blood Pressure and Heart Rate Changes
Fig. 5.1b
Distribution Of Clonidine After IV Administration.
Each autoradiogram is taken from a separate animal.
Killed 10 minutes after administration.
Sections in dorso ventral plane around the midline
2.5 ug/Kg Clonidine IV
10 ug/Kg Clonidine IV
5 ug/Kg Clonidine IV
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Fig. 5.1c
Autoradiogram With Labelled Structures

























2) Exposure times. The density of the developed film depends on
the radioactive dose given, the size of animal used and the exposure
time. Tritiated clonidine is expensive and to derive the maximum use
from limited supplies only small doses were given, 40 uCi/rat.
Applegren et al (1977) used 200 uCi/rat but did not mention the size
of animal or exposure time. To determine the exposure time for the
small doses of tritium used sections from one animal were developed
after different exposure times.
3) Dose dependence of clonidine distribution. In the section on
pharmacokinetics in chapter 1 it is suggested that differences in
the reported T1/2s of clonidine may reflect the different doses
employed. Differences could reflect a saturable transport system or
be secondary to the cardiovascular changes attendant upon clonidine
administration. Should they appear over the dose range giving a
hypotensive response this would have to be taken into account.
The standard dose of H clonidine was given together with
unlabelled clonidine to a final dose of either 2.5, 5 or 10 ug/Kg.
One rat received each dose. Dosing was via the jugular vein and
blood pressure was recorded from the right carotid artery. Usually a
femoral artery was used but these three animals were simultaneously
used for the next experiment, the effect of carotid cannulation. The
animals were killed 10 mins after IV clonidine, when the hypotensive
response was fully established.
4) Effect of a carotid artery cannula on lateral distribution
in the head. As mentioned in chapter 2 the pressure recorded from
the central end of a ligated carotid artery is lower than that found
on the cardiac side of the ligation. It is therefore possible that
the blood supply to one side of the head and/or brain may be
compromised by carotid cannulation. As small rats were used it is
more convenient to cannulate a carotid artery than a femoral artery
but is of less use if clonidine distribution is affected.
After killing the heads were removed and sectioned in the
transverse plane whilst the remainder of the body was sectioned in
the rostro-caudal plane.
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5) IV injection. Clonidine distribution does not appear to be
'T.
dose dependant between 2-5-10 ug/Kg. -H clonidine 30 uCi made up to
5 ug/Kg was given IV via the femoral vein and arterial pressure
recorded from the femoral artery. Animals were killed over a range
of times 0.25, 0.5, 1.0, 2.0, 5-0, 10.0, 20.0 and 40.0 mins to look
for changes in distribution over a period covering the onset of the
hypotensive response, hoses were rapidly given as a single bolus.
6) IC Administration. Again 30 uCi of H clonidine was given
with with cold clonidine making a total of 5 ug/Kg. The mode of
delivery was that described in the previous chapter. Animals were
sacrificed at 0.25, 0.5, 1.0, 2.0, 5-0 and 10.0 mins.
7) ICV Administration. 15 uCi of clonidine were administered
in a total of 3 ug/Kg. The quantity of clonidine was reduced to
account the increased hypotensive efficacy of this route and because
distribution was expected to be limited. Animals were sacrificed at
1, 2, 4, 8, 16 and 32 minutes after administration of clonidine.
8) IVert Administration. 15 uCi of clonidine were given by
the method described in the previous chapter. The amount used was
chosen to highlight the areas reached by IVert dosing and does not
reflect the hypotensive potency of this route of administration.
Animals were sacrificed at 1.0, 2.0, 4-0, 8.0 and 16.0 mins.
One further rat was killed at 4-0 mins using the mode of injection
described by Haywood et al (1980).
Results
Pictures taken from the autoradiograms are shorn in this
chapter. They were obtained using the original autoradiogram as a
negative to make a contact print which was in turn contact printed.
This results in a picture showing density as radioactivity in the
same manner as the original. The quality has deteriorated due mostly
to the uneven light source used to make the contact prints.
Rather than show every autoradiogram a few complete
autoradiograms and sections from a number of others have been
included. A summary table showing the results of the
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autoradiographic work and the hypotensive actions of clonidine when
given by different routes appears at the end of this chapter.
1) Chemography. Development of the film showed no evidence of
positive or negative chemography. This is a common result when
freeze drying is the only tissue processing undertaken. It follows
that when yH clonidine is employed the silver grains relate to
radioactivity. Mechanical damage to the film becomes apparent after
development but is easy to relate the mounting tape, finger prints
3
or scratches and can be easily separated from that due to H.
2) Exposure times. Films were developed after 17, 35 and 70
days and the range of densities deemed satisfactory only in those
exposed for the longest time. Seventy days is a long exposure time
for whole body autoradiography but compares favourably with times
used in autoradiography at the electron microscope level. To
increase the number of experiments that could be undertaken the
exposure time was extended to three months and the radioactive do3e
reduced to 30 uCi.
3) Dose dependence of clonidine distribution. Pig. 5-1a shows
the reduction in blood pressure and heart rate in the three rats
used in this section, the effect was dose dependent. Pig. 5-1b shows
a section from each animal in the dorso ventral plane close to the
midline. The pattern of clonidine distribution appears to be similar
in all three animals. High levels of clonidine appear in the bone
marrow of the spinal processes, liver and kidney.
4) Effect of carotid arterial cannula on lateral distribution.
Fig. 5-1e. There appears to be no difference in the concentration
achieved on the right and left side of the brain. Though in the
lacrimal glands and salivary glands a higher concentration is seen
on one side of the head not containing the carotid cannula. The
lower levels appear on the same side as the carotid cannula.
5) IV Administration. Pigs. 5.1b, 5.1c and 5.1d show sections
taken in the dorso ventral plane, Pig. 5-1c is along the midline,
section passes along the spinal cord, and Pig. 5• 1 d taken in the
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same plane but at a distance from the midline. Each has an overlay
used to label some of the more prominant structures.
Fig. 5>2a,b one section from each rat mounted serially on two
sheets to provide an easy comparison of the changes in clonidine
distribution after a bolus IV injection.
Fig. 5.2c,d A. number of heads from each rat were mounted
together. Hie letters on the facing page enable the identification
of each head, 15 sees C is the section at the top of Fig. 5«2c on
the binding side of the page
Brain
Less heavily labelled than the liver. Differences between grey and
white tissue are very marked being lower in white areas, noticeable
in the corpus callosum, cerebellum and in sections along the spinal
cord. This difference persists and can be seen in sections from the
animal killed after 40 mins and that killed at 15 seconds. In a
number of sections the pituitary appears prominantly as does the
pineal body Fig. 5.2c 1 min C. In some an area just below the the
cerebellum and around the floor of the fourth ventricle seems
better labelled than other areas Fig. 5.2c 1 min C.
Heart
In the sections from the animals killed shortly after clonidine
injection the heart muscle appears to be the most heavily labelled
tissue. Within the heart muscle a lower density is apparent, this is
blood within the heart. The different heart muscle thicknesses show
the right and left ventricles, Fig. 5-2a 15 seconds. During the 40
mins covered by the sections the relative density of the heart falls
until it is no longer the most densely labelled tissue.
Liver/Spleen
The liver appears as a very prominant organ in the whole body
sections, in respect of size and clonidine content. Areas of low
density frequently appear in the tissue representing blood vessels
which like blood contained in the heart contains less clonidine than
he surrounding tissue. The pattern of distribution changes within
the liver during the 40 mins covered by the experiment. Initially a
speckled distribution is seen but this rapidly alters, by 5 minutes
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it cannot be readily discerned and later the liver exhibits a
uniform density. The changes seen in the liver are similar to those
in the spleen.
Lungs
The lungs appear caudal and generally dorsal to the heart and the
clonidine content is initially very high but declines over the forty
minutes of this study.
Stomach
The stomach is seen as a ring enclosing an area of low density, the
stomach wall is well labelled especially in the region of wall
thickening, Pig 5•1d- In sections from animals killed later in the
experiment the labelling is starting to extend into the stomach
contents and after forty minutes the stomach contents contain a high
level of clonidine Pig. 5.2b 40 ruins. The plane of this section does
not include a large portion of the stomach, it appears below the
large vein that runs parallel to the spinal cord and caudal to the
liver. In sections showing more of the stomach the radioactivity
does not extend into the centre of the stomach.
Small Intestine
The walls of the intestines are well labelled with clonidine but is
only present in the lumen when no solid materials are present
therein. Later, after 40 mins, clonidine penetrates into solid
material in a similar manner to the stomach.
Feaces
Clonidine does not appear in the contents of the lower parts of the
intestine.
Kidney
Clonidine very rapidly appears in the kidney in high concentrations
and as in most tissues blood vessels containing relatively little
clonidine appear, Pig. 5-1b bottom picture. The marked differences
between the levels in the medulla and cortex abate during the period
of the experiment. The whole body autoradiogram Pig. 5«2b 10 mins
contains a portion of a ureter, just caudal to the kidney running
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towards the rear of the animal, it is above and to the right of a
black dot within the vena cava- The level of clonidine is high.
Bladder
The bladder does not appear in any of the sections shown but does
contain clonidine as early as ten minutes after the IV
administration of clonidine.
Fat/Muscle
Over the period of the experiment the movement of clondine into the
muscle and fat progresses. In the early animals the concentration
appears low and the distribution is uneven later distribution is
much more uniform. In Fig. 5-5a 15 seconds an area of brown fat can
be seen dorsal and slightly rostral to the heart, it is denser than
the surrounding tissue.
Bone
The bone marrow attracts large quantities of clonidine, this
includes the long bones of the legs, spinal processes and ribs. The
tooth pulp also contains high levels of clonidine Fig. 5-2c 5 mins
A. Bone and teeth are almost completely devoid of clonidine.
Salivary and Lacrimal Glands
Clonidine rapidly appears in both these tissues and maintains high
concentrations until the end of the experiment.
6) IC Administration Fig. 5-4a,b,c. This pattern of
distribution is clearly different from that associated with other
routes of administration. Unlike the IV results the distribution is
uneven favouring rostral areas of the brain, even then the
distribution favours the side of the head with the cannulated
internal carotid. The medulla and spinal cord are not reached in
high concentrations. In areas heavily labelled the concentration is
not uniform compared to that after IV administration. Parts of the
head outside the brain are also heavily labelled, primarily areas
well rostral. The distribution between rats differs: in the animal
killed at 30 sees large areas rostral to the medulla were reached





Fig. 5.3a Left Page
Kilied After 4 Minutes
Fig. 5.3b Below
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Injection into right carotid.
Fig. 5.4a Left Page
Killed After 15 Seconds
Fig. 5.4b Over Page Left
Killed After 2 Minutes
Fig. 5.4c Over Page Right
Killed After 30 Seconds
 
 
in that killed at two minutes only a small part of the brain
received clonidine in large amounts, the sections taken at 15
seconds show a greater tranverse spread of clonidine into the
cerebrum than the tissue below.
7) ICV Administration Fig. 5.3a,b,c,d,. Distribution is limited
to areas bordering on the ventricular system and spinal canal and
the concentrations achieved in these areas exceed those associated
with IV adminstration. In other areas only low levels of clonidine
are seen. To facilitate visualizing the distribution an outline of
the head and brain have been superimposed on the sections. The area
bordering on the fourth ventricle is especially prominent. As is
the mass intermedia. Penetration along the spinal cord occurs in all
the animals used. Some of the sections pass along the spinal cord
showing the spinal canal and diffusion outwards. The subarachnoid
space is also reached with ICV administration.
8) IVert Administration Pig. 5-5a,b,c,d,e. The distribution is
not uniform between animals and variable degrees of extracerebral
penetration appear. Within the brain the medulla spinalis, spinal
cord, medulla oblongata, pons are heavily labelled. More rostral
areas have a patchy distribution and clear limits to the penetration
of clonidine are seen. In section from the rat sacrificed at 16 mins
the densities seen are low but higher levels are still apparent in
the spinal cord and medulla. Extracerebral tissues not uniformly
reached: in the 8 minute animal fig. 5-4a only a few areas bodering
on the spinal cord have high concentrations of clonidine whilst
those after 1 and two minutes have large areas labelled. The
extracerebral areas are distinct from those seen with IC
administration and are generally caudal to the medulla.
In one animal the techique of Haywood et al (1980) was used,
the brain was not included in the areas labelled heavily Fig. 5-4d
Discussion
These experiments show that it is possible to locate small
amounts of tritiated clonidine with the new CEA Verken film using
long exposure times. Wo evidence of chemography was found and





Fig. 5.5a Left Page Fig. 5.5e Over Page Right
Killed After 8 Minutes Killed 1 Minute
Fig. 5.5 b
Killed After 2 Minutes
Fig. 5.5c Killed After 4 Minutes
IVert via brachial artery.
Fig. 5.5d
Killed After 16 Minutes
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handling and the use of talcum powder, to reduce the adhesive
properties of the backing tape, reduce damage to the film to an
acceptible level. Separation of sections from the film has been done
underwater, to reduce the light flashes otherwise seen when the
adhesive tape is pulled away from the film. The flashes would
expose the film and can be misinterpreted. Talcum powder avoids
flashing and the destruction of the tissue sections seen with
underwater separation.
The high specific activity (20 Ci/mmol) of tritiated clonidine
permits the use of concentrations of clonidine in the hypotensive
range unlike early studies on clonidine pharmacokinetics (Cho &
Gurry 196 9)-
The use of autoradiography in preference to tissue assay
provides good spatial resolution but the procedure is more invovled
and fewer animals can be used. In this study single animals were
employed, this compares with groups of five used by Conway & Jarrott
(1931) in a pharmacokinetic study on clonidine. The other advantage,
better spatial resolution appart, is that all the body tissues are
available for study and not just those selected for assay. Uneven
distributions within tissues and the limited distribution following
ICV administration would be much harder to establish with tissue
assays but the quantitative data derived from assays is not readily
obtained with autoradiography.
Clonidine does not reach, in equal concentrations, both sides
of the head when a carotid arterial cannula is in place. This
reflects the lower blood pressure seen in the cerebral end of a
ligated carotid artery compared to that found on the cardiac side
(see chapter 2). IIo transverse concentration gradient appeared in
the brain suggesting that the circle of Willis compensates for the
ligated artery. Despite this finding it was decided to record
arterial pressures from a femoral artery and leave both carotids
intact.
The three animals killed at ten minutes after administration of
a range of clonidine doses, though with the same amount of
radioactive clonidine, displayed very similar patterns of
distribution. This means that variations in the quantity of
clonidine injected are not critical and that the amount used could
be adjusted for each route of administration.
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The location of clonidine in the bladder and intestinal tract
follows the known pattern of excretion in the rat ("Rehbinder 1969,
Cho & Curry 1969) in the urine and faeces. As a lipophilic drug
clonidine readily passes in to the intestinal contents and similarly
passes from them into the blood stream when administered orally, the
usual manner. Clonidine is a basic drug and therefore its
accumulation in the stomach will be enhanced. The levels seen in the
stomach are the highest within the intestinal tract which support
this idea. In the abscence of active transport the unionized drug
concentration across a lipid membrane comes rapidly into
equilibrium. The acid pH of the stomach will result in the
ionization of a large proportion of the clonidine present and a
higher concentration than that seen in the blood is achieved within
the stomach. Penetration into the stomach contents appears to
involve diffusion from the stomach wall, this suggests that gastric
motility is low, possibly an anaesthetic effect.
The concentration of clonidine in the blood is lower than that
seen in most tissues, even in the animals killed early in the
experiment.
In the spleen and liver the pattern of distribution changes
during the experiment. Initially it is patchy but this is lost in
the subsequent 5 minutes. A consequence is that calculation of the
T1/2 of clonidine in the liver over this period is misleading as it
refers to the changes throughout the tissue taking no account of
alterations in the pattern of distribution. Similarly the pattern of
distribution alters in fat and muscle.
The initial distribution of clonidine seems to reflect tissue
blood flow, shortly after administration the kidney, liver, heart
and lungs are seen to contain high concentrations of clonidine. This
decreases with time whilst in less well perfused tissues, muscle and
fat, the concentration seems to increase over this period.
Comparison of the tissue concentrations between 2 and 10 minutes
reported by Conway and Jarrott (1930) supports this interpretation,
although not mentioned by the authors. In the lung and heart only
about 50$ of the quantity of clonidine present at 2 mins was
retained after 10 minutes, in contrast muscle and adipose tissue and
muscle retained about 30$.
IV administration achieved high concentrations in some areas,
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pineal body, pituitary and possible parts of the floor of the fourth
ventricle. These areas are considered to have a less well
established blood brain barrier and the resulting higher
concentrations indicate that the blood brain barrier does restrict
the access of clonidine to the remainder of the brain. The
differences between the grey and white matter in the brain and
spinal cord probably reflects the lower blood flow of the latter.
Even in the animal killed 15 seconds after the injection of
clonidine the drug is well established in the brain and the onset of
central actions is not delayed by slow penetration into central
sites. Interestingly the concentration in the brain does not decline
over the first few minutes. Svensson et al (1975) found the central
actions of a small IV injection of clonidine decreased over a few
minutes. In the introduction it was suggested that this could
represent the egress of clonidine from the brain over this time
period. The lipophilicity of clonidine ensures its rapid penetration
into the CNS and as the initial distribution of clonidine appears to
reflect tissue blood flow these two factors would lead to high
central concentrations. The pattern of distribution subsequently
alters ceasing to reflect tissue blood flow and net movement from
the brain might be anticipated with a reduction in central actions.
This would appear as a recovery in blood pressure over the first few
minutes after injection, a pattern of response not encountered.
The pattern of distribution, within and outside, the brain
after IC adminstration varied between animals. However the method of
administration used achieved the desired objective, reaching only a
circumscribed area of the brain. Marked differences appear in the
concentration achieved on each side of the brain which indicates
that each carotid preferentially supplies its own side of the brain.
When one carotid is occluded both sides of the brain are supplied
equally. This could provide a method of delivering drugs to rostral
brain areas without complications with tranverse concentration
gradients. Areas outside the brain would have been reached through
branches of the internal carotid.
ICV clonidine only reaches very limited areas of the brain on
the edge of the ventricular system. This finding was also found by
Chalmers & Wurtman (1971) using noradrenaline, Schubert et al
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(1971) with H fentanyl and differential depletion of central
catecholamines was reported after IGV 60HDA administration (Chalmers
& Reid 1972).
IVert administration of clonidine reaches areas in the caudal
portion of the brain with a preference for the side whose artery was
cannulated. This does not support the findings of Wellens et al
(1976) where the vertebrals were deemed to be of no importance in
the rat. Differences in the size of animal used may reconcile the
two sets of results. The different method used to inject
intravertebrally in the rat does work and is much easier to use than
the technique used in the cat and dog. However other arteries are
involved and it is therefore impossible to say whether it is the
vertebral that supplies areas surrounding the spinal cord. The
pattern of distribution is similar to that reported for the dog and
cat (Wellens et al 1975, Reneman et al 1974)* The greater
concentration found on the side of the cannulated carotid has been
reported (Sherbin-Schepers 1979) Porsius (1930) Porsius & Van
Zwieten (1978). The technique has been improved by ligating the
other vertebral artery (Sherbin-Schepers 1939) and infusing drugs
into both (Porsius 1930), neither has been attempted in the rat and
only ligation seems feasible. In the rat the vertebrals supply the
upper part of the spinal cord, it is unlikely that that this is
invovled in the cardiovascular response since sympathetic
preganglionic cell bodies are not found in this area. The animal
killed sixteen minutes after IVert adminstration of clonidine showed
only slightly raised amounts of clonidine in the medulla and spinal
cord. This may represent escape of clonidine from the brain after
its first pass uptake but seems to have occured much faster than the
recovery in blood pressure reported with this route of
administration (see previous chapter). This is a general problem
with single animals and compounded by the wide variations in
distribution seen between animals. The lability of the rat
cardiovascular system and circle of Willis in particular mentioned
by Greene (1935) may in part explain the differences between
animals.
The different patterns of distribution were correlated with the
differing hypotensive and heart rate-reducing effects, see previous
chapter.
ICV was found to be slightly more potent than IV but in the
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areas reached the concentration appears to greatly exceed that seen
with IV administration and if they include the site of hypotensive
action a much greater fall in blood pressure would be anticipated.
It seems that IC administration does not simply provide another
route of access to a central site of action but lowers blood
pressure through a different mechanism, see discussion in chapter 1 .
IGV administration either fails to reach areas of the brain or
achieves a high concentration and in no area approximates to the
concentrations seen with IV administration. Actions on heart rate
and arterial pressure are similar but cannot stem from an action at
a common site. The periventricular areas reached by ICV dosing will
include those reached following topical clonidine on either the
floor of the fourth ventricle and the ventral surface of the
brainstem. The high levels but relatively poor hypotensive effect
suggests that these areas are unlikely to be involved in the
hypotensive response to IV clonidine and that they represent a
different and unrelated mechanism.
IC administration is no more potent than IV in lowering
arterial blood pressure and heart rate. It follows that areas that
achieve a level of clonidine in excess of that seen with a
equipotent IV dose are not candidates for the hypotensive site of
action. This appears to preclude the forebrain supporting the
conclusions drawn from decerebration experiments.
IVert clonidine concentrates in medullary areas and lowers
blood pressure potently. Higher levels of clonidine are seen in thse
areas than with IV dosing and reflect the size of the IVert dose.
When this is considered it follows that the site of action is
contained within the areas reached after IVert administration.
There is overlap with areas reached after ICV and IVert
administration which can be excluded as potential sites. Similarly
areas reached by both IC and IVert routes are not candidates.
On the basis of differential distribution and hypotensive
potency the central site of clonidino'3 hypotensive and
cardioinhibitory action lies within the medulla but not on the edges
of the ventricles. This conclusion is incompatible with the floor of
the fourth ventricle and area S as sites of action. It is not
suggested that locally applied clonidine, in these two areas, does
not lower blood pressure but that this action is unrelated to the
onap JL j •
effects of IV administration. This in turn is seen as representing
the actions following oral administration. The area S has not been
established in rodents but if a homologous structure exists these
studies argue against its importance.
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* Hypotensive potency compares the ablility of clonidine given by
each route of administration to lower blood pressure and heart rate
with that following IV injection. Numbers greater than 1 indicate
greater potency.
& This is measured semi quantitatively with 0 reflecting a
negligible density and 10 a very high density.
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Plasma Concentrations Of Clonidine
The plasma concentration of clonidine is reported to fall
rapidly after bolus administration (Conway & Jarrott 1930) (Jarrott
& Spector 1978). Reports of the T1/2 of clonidine vary widely, from
tens of minutes to hours (Chapter 1 Pnarmacokinietics). Comparison
with the cardiovascular effects would be interesting. In addition
measurement of the escape of clonidine from the ventricular system
into the circulation would show if this could explain the response
to this method of administration. Applied ICV clonidine exhibits a
slow onset of hypotension and bradycardia. The peak levels slightly
exceed those following IV administration and with injections of 5
ug/Kg the ratio is 1.5:1. It is possible that the slow response
partly involves escape of clonidine from the ventricular system into
the general circulation. This would permit peripheral hypotensive
actions and access to areas of the brain not attainable from the
ventricular system which would appear in addition to any central
actions generated from periventricular areas.
Methods
Collection Of Blood
Arterial blood samples were taken from a femoral arterial
cannula. Short cannulae were employed and sufficient blood to
compensate for dead space allowed to escape before a sample was
collected. Blood escaped under arterial pressure. 500 units of
heparin were given per animal to prevent blood coagulation.
Treatment Of Samples
Blood was centrifuged to separate cells from plasma- 10 ul
plasma samples were made up to 1 ml with water added to 10 ml of
Fisofluor "2" and counted for tritium using a liquid scintillation
counter. Background subtractions were made automatically from blanks
prepared with distilled water instead of plasma. Conversion from
counts per minute to disintegrations per minute was also made
automatically. Counting efficiency was measured with an external
standard.
1) IV Clonidine.
•5Blood from 5 rats given 5 uCi H clondine made up to 5 ug/Kg
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was collected at 0.25,0.5.1,2,5,10.20,40,60 mins. Blood volumes of
30 ul were taken at each time of collection.
2) ICV Clonidine.
Blood was taken from three rats used in the autoradiographic
study reported in the previous chapter. They were killed at 3,16 and
3
32 mins. Each animal had received 15 uCi of H clonidine. Blood was
taken at 0.5,1,2,4,8,12,16,20,25 and 30 mins from the rat killed at
32 mins, up to and including 16 mins for the rat killed at that
earlier time and up to 3 mins from the animal killed at 3 mins.
3) IVert Administration
Blood from one animal used in the autoradiograhy experiments
was collected.
4) Plasma concentrations of clonidine were calculated from the
amount of radioactive clonidine and unlabelled clonidine injected,
the size of the animal and the plasma levels of tritium.
Results
Liquid Scintillation Counting
Background counts were 15*5 DPM, standard error 2.8 (N=6). Counting
efficiency 30-33$.
Blood Samples
No problems were encountered in obtaining arterial blood samples. No
alterations in the blood pressure record accompanied sample
collection. Over the collection period the total blood lost by each
animal would not have exceeded 0.5 mis, about 6$ of the total blood
volume.
1) IV Clonidine Fig. 6.1,2 and Table 6.1
Fig 6.1 shows changes in mean arterial pressure and plasma
tritium concentrations following IV bolus clonidine. Plasma levels
fell precipitously over the first two minutes and stabilized at
about 25$ of the peak level,found at 0.25 mins. Thereafter decline
is slow hardly altering between 10 and 60 mins. The standard errors
fell over the first four plasma samples.
Mean arterial blood pressure follows the usual pattern, briefly
rising then falling rapidly to a maintained level. A slow recovery
appears after twenty minutes.
Once blood pressure and the plasma tritium concentration have
stabalized at 10 minutes the plasma concentration of clonidine is




Plasma Levels And Blood Pressure Changes After IV Clonidine













Plasma Levels Of Clonidine After IV And ICV Administration
N=5 for IV clonidine
3 rats given ICV clonidine
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2) ICV Clonidine Pig. 6.2 and Table 5.1
Fig 6.2 show3 that the plasma concentrations following ICV
administration of clonidine are much below those after IV. The
pattern of change is also different, there is no initial peak and
the concentration is 3table after the first sample.
1) IVert Clonidine Table 6.2
The plasma concentration was initially high and fell very
slowly, a pattern unlike that seen with either ICV or IV
administration. The autoradiograms show that the tritium
concentration in the medulla and spinal cord were only slightly
above those found in rats after IV clonidine administration.
Discussion
The brief hypertensive episode following bolus IV
administration coincides with the peak plasma concentration, both
fall rapidly and at 30 seconds the concentration of tritium in
plasma is less than half that seen at 15 seconds and blood pressure
has fallen to the preteatment level. Thi3 close temporal
relationship suggests that the two are related though it does not
indicate whether a central or peripheral action is involved. The
standard errors of the plasma tritium concentrations fall over the
first few samples. This probably reflects the rapidly altering
concentration which makes the exact timing of samples critical. As a
percentage of the mean concentration the standard error is 10$ at
0.25 seconds and \% between 20 and sixty minutes.
The rapid drop in plasma concentration following IV bolus
injection suggests that the secondary hypertension, reported in
chapter 2, is unlikely to be a direct effect of clonidine on the
vasculature. It may involve catecholamine release and an
interaction with the adrenal gland had been reported in the urethane
anaesthetized and unanaesthetized rat (Zandberg 1977) though the
interaction with the barbiturate anaesthetized rat was reported to
be much smaller in magnitude.
The stable plasma concentrations of clonidine found between
twenty and forty minutes were surprising high, 4 ng/ml, and a
reduction over this period was anticipated. Conway & Jarrott found
T1/2s for most tissues in the range 40-110 mins yet in this study
the plasma T1/2, not calculated, would be very long. The two studies
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are 3imilar in that the same anaesthetic, inactin, was employed.
Conway & Jarrott used a smaller dose of inactin, 100 mg/Kg IP, a
larger dose of clonidine 20 ug/Kg and found the return towards the
pretreatment arterial pressure to be more rapid than seen in this
study. This may explain the discrepancy. An alternative explanation
is that metabolites of clonidine are appearing in the plasma.
Tritium was used as a marker for clonidine and a metabolite
containing tritium would not be detected separatley, inflating the
clonidine concentration. Jarrott & Spector detected 4 hydroxy
clonidine in plasma after 60 minutes, it is the main metabolite of
clonidine in the rat. Depending upon the mechanism of hydroxylation
the tritium might be retained in the metabolite. The metabolite is
not lipophilic and therefore concentrates in blood rather than in
tissues and is may have inflated the later plasma clonidine figures.
This is unlikely to be a problem over the early part of the
experiment as the metabolite was only reported after 60 minutes. In
three of the five rats used in the IV plasma concentration study a
final blood sample was taken at 30 minutes. In each case the
concentration of tritium was higher than that at 60 minutes, the
increase was by about 13^ of the 60 minute concentration. This
suggest that the tritium lablel is retained in a metabolite. This
falls outside the period used in the autoradiographic studies and
does not bring their validity into question.
Since the plasma concentration of tritium does not continue to
fall precipitously after the first 2 minutes the use of cumulative
injections of clonidine is seen to be reasonable.
After IGV clonidine only low concentrations of clonidine appear
in the plasma. The much lower levels seen at 0.5 min reflect the
slow injection of clonidine into the lateral ventricles but the low
steady level probably represents very limited escape from the
ventricular system. The plasma concentrations are about 1/'5 of those
seen after IV administration, once the level has stabilized.
This precludes important peripheral actions for clonidine given
ICV and indicates that most of the administered drug is confined to
the ventricular system. These results confirm those from the
autoradiographical studies. The combination of limited escape and
distribution predominantly in periventricular areas suggests that
the concentration of clonidine in these tissues is very much higher
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than that seen with IV administration. Given IV only 2% of the total
administered resides in the brain (Timmermans et all 1977). Assuming
that the plasma concentrations represent an equilibrium between
tissues and blood and that the clonidine that has escaped from the
ventricular system is also at equilibrium but at 1/5 the IV level.
It follows that around two thirds of the administered clonidine is
still within the CN3, if distributed evenly the concentration would
be thirty times that seen in the brain after IV administration of a
similar quantity. These assumptions are crude and unlikely to be
correct: equilibrium may not exist, ICV clonidine is not evenly
distributed within the CN3 and the amount of clonidine present in
the brain after IV administration are not derived from thse
experiments. However it is likely that the concentration ratio
ICV/IC greatly exceeds 1.5, the hypotensive potency ratio ICV/IV.
Even including peripheral hypotensive mechanisms the two ratios
remain unreconcilable and the CN3 concentration seen with ICV
administration is not reflected by the magnitude of the hypotensive
effect and the areas of the brain reached with ICV administration
are not those acted upon by IV administered clonidine. An action of
IV clonidine on sites near the area 3 or floor of the fourth
ventricle is unlikely and these areas not involved in the usual
response to clonidine.
This conclusion probably applies to other experiments involving
ICV administration and at the least suggests that their conclusions
ought to be viewed cautiously. Very different plasma concentrations
of clonidine follow IVert administration. The reduced rate of fall
of plasma concentration between 0 and 1 min reflects the slower rate
of administration used with IVert, given over 40 seconds, but the
later slow decline indicates a progressive release from the brain.
Porsius & Van Zwieten (1973) compared the plasma concentration of
1 4
C nicotine after IV and IVert administration. Immediately
following IV injection the plasma concentation was high and declined
rapidly, after IVert injection this peak did not appear suggesting
that first pass uptake into the brain occurs. A slow release from a
depot in the brain would account for the abscence of a peak plasma
concentration. The potency of the IVert route and the
autoradiography results indicate that first pass uptake into the
brain tissue is high. The maintenance of the hypotension and
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bradycardia show3 that release from the brainstem is not rapid. Easy
access put poor egress is hard to explain. Clonidine is lipophilic
and would in consequence move readily into the brain during the
first pass when local plasma levels are likely to be very high but
as the plasma level falls so CN3 clonidine concentrations should
follow those of the plasma. The recovery from IVert clonidine is
more rapid than that following IV administration, see previous
chapter. Clonidine is not as lipophilic as thiopentone, a
barbiturate anaesthetic, which rapidly leaves the brain after IV
bolus administration. It initially achieves a high CN3 concentration
because the brain has a high blood flow, measured in ml/gm tissue,
and its effective partition coefficient is 2000. That for clonidine
is between 3 and 9 therefore movements across the blood brain
barrier will not be as rapid. Pentobarbitone and antipyrine have
effective partition coefficients that straddle that of clonidine.
Their penetration half times, from plasma to brain, are 4.0 and 5-8
mins. If this carries over to clonidine and is applicable to
movement out of the brain the recovery from IVert clonidine appears
reasonably in line with its lipophilicity. Initially during the
first pass the plasma/CNS concentration ratio will be very large,
equilibration will not occur but some clonidine will reach the
brain. A3 plasma levels fall the concentration ratio CN3/plasma will
be smaller than that initially moving clonidine into the brain and
movement will in consequence occur more slowly and the recovery from
the hypotensive actions appear slowly, probably in line with brain
concentration.
The plasma levels of tritium after IV administration of H
clonidine declines rapidly over the first two minutes, after
administration continue to decline but more 3lowly between two and
ten minutes and subsequently stabilize. The brief hypertensive
episode corresponds with the peak plasma concentration suggesting
that this is a peripheral action. Clonidine given by the ICV route
escapes very slowly from the CN3 probaby achieving concentrations
greatly in excess of those seen after an equipotent IV injection. In
consequence the site3 of ICV hypotension and bradyardia are
different from those involving IV clonidine, this excludes the area
T1
S and the floor of the fourth ventricle as sites of hypotensive
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action for IV clonidine. IVert clonidine reaches the brain during
the first pass and subsequently slowly leaves the areas reached. The
decline if plasma concentration is slower than with IV which nay
reflect continual release from a depot established during the first
pass.
Plasma Tritium Concentration CPM/Sample
IV Clonidine




























Mean Arterial Pressure mmHg
-5 32 101 102 103 104
-2 80.5 102 102.5 104 103
-1 81 100 102.5 104 103
0.25 103 145 122 145 131
0.5 73 100 93 120 103
1 .0 72.5 39 93 97 92
2.0 63 37 39 95 35
5-0 65-5 74 37 95 33
10.0 63 69 36 92 82
20.0 63 72.5 35 92 76
30.0 63 72 87 95 77.5
40.0 66 74 35 100 77
50.0 70 76 37 99 75
60.0 70 76 37 99 75
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1 .0 257 248 229 2753
2.0 267 265 235 1831
4.0 245 237 201 1270
6.0 809
3.0 214 224 201 763
10.0 567
12.0 220 224 330
14.0 479




* The DPM figures given are calculated from the quantities of tritium
given and have been normalised for 6 uCi/animal and 10 ul plasma
samples.
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Conclusions And Suggestions For Further Work
The inactin anaesthetized rat is a useful model for
cardiovascular research, it maintains a stable blood pressure and
heart rate, shows reflex responses to asphyxia, vasodilator and
vasopressor drugs and responds to clonidine with a reduction in
heart rate, peripheral resistance and mean arterial blood pressure.
The initial reduction in peripheral resistance occurs through a
reduction in sympathetic nerve tone, 3hown by a novel hindlimb
perfusion designed to separate acute nervous and blood born
responses. This showed that clonidine exerted a central action in
this preparation as the reduction in sympathetic vasoconstrictor
activity outlasted the brief pressor response to IV clonidine. The
clonidine induced reduction in heart rate involves sympathetic tone
to the heart and no evidence was obtained for resting vagal tone or
clonidine induced bradycardia involving vagal tone.
Clonidine was administered by four different routes IV, IC, ICV
and IVert and the intensity and time course of the responses
compared. IV administration leads to a rapid dose dependant
reduction in both heart rate and blood pressure. Responses with IC
injection are similar to IV. ICV is slightly more potent in lowering
both heart rate and blood pressure but the effect appears slowly,
peaking at 10-20 minutes. IVert is some twenty times more potent
than IV. Tne onset of activity is fast and the recovery more rapid
than that seen after IV.
A. comparison was made of the distribution of clonidine after
each route of administration to establish potential sites for the
hypotensive and heart rate reducing actions. IV administration
resulted in an even distribution throughout the brain. IC was
concentrated in rostral brain areas. ICV to areas bordering on the
ventricular sytem including the spinal cord. IVert, the most
efficacous route, resulted in high concentrations in the medulla,
pons, medulla spinalis and areas slightly rostral to these
locations. This clearly shows that the vertebral arteries are
important in delivering blood to the brainstem. The autoradiographic
experiments and measurement of plasma concentrations clearly
indicate that, when given ICV, clonidine reaches concentrations in
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part3 of the brain far in excess of those achieved with IV
administration. In consequence it is proposed that ICV injection is
not lowering blood pressure and heart rate by the same mechanism as
IV clonidine. This implies that the area S and floor of the fourth
ventricle are not the sites of action involved in the clinical
response to clonidine. Clonidine IVert is active in doses likely to
achieve similar concentrations in the brainstem to those found after
IV administration. The prior exclusion of areas bordering the
ventricular system shows the site of action to lie within the
medulla or pons but its location is not readily reached from the
ventricular system.
It is possible that no one site of action explains the
cardiovascular effects of clonidine. The inability to locate a
single site would confirm this but as yet unsufficient data exists.
This study clearly indicates that the use of ICV administration
to deliver drugs to the brain, bypassing the blood brain barrier,
does not provide equal access to all areas of the CN3. This techique
has been widely employed often without sufficient precautions with
regard to spread of drug and local concentration.
Further Work
The pursuit of the 3ite of action of clonidine with local
injection and autoradiography appears promising. It would be useful
in clarifying the role of the area S and floor of the fourth
3
ventricle as sites of action. Topical application of H clonidine
would be expected to reveal concentrations greatly in excess of
those seen with IV administration. Similarly the hypothalamic and
spinal sites could be readily investigated. Tbe study would then
require microinjections of suitably small quantities of clonidine
into likely central sites. Likely areas would include those
containing alpha 2 adrenoceptors and areas associated with
cardiovascular control. A method of locating potential sites would
be to U3e retrograde staining techniques to follow autonomic
efferents into the CH3, then repeat the retrograde work from the
sites previously identified, in practice mapping cardiovascular
pathways. Using autoradiography to establish the resulting
distribution and concentration. That the hypotensive effect could be
achieved, with local concentrations in the range seen with TV
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administration, would be taken as the definitive test of putative
sites of action. The study would then proceed with intracellular
microelectrode examination and iontophoresis to establish the
pharmacological requirements for action at the site.
An autoradiographic study on the distribution of histamine H2
antagonists after ICV administration would be interesting.
Indicating the areas of the brain required for the reduction in the
hypotensive effect of clonidine and the concentrations achieved. The
latter is of interest in establishing whether the histamine H2
antagonists are present in concentrations associated with histamine
antagonism or whether another action is involved. Further studies
with cats might establish the reasons for the failure to show
antagonism in this species. A possible cause might be alterations in
the distance from the ventricular surface of the relevant site of
action occuring with increased brain size.
The work of Zaimis on peripheral hypotensive actions of
clonidine should be pursued particularly with respect to longterm
changes in vascular reactivity. Chronic administration could be
managed with clonidine added to drinking water and the development
of hypotension followed with tail cuff blood pressure measurements.
Comparison of isolated tissue responses to nerve stimulation and
exogenous drug application could be used to chart alterations in
tissue reactivity. The efficacy of treatments too low to alter
arterial blood pressure might provide an insight into the anti
migraine properies of clonidne, they appear almost uninvestigated.
They seam to utilise quantities of clonidine below the hypotensive
threshold.
Clonidine has a peripheral action on presynaptic receptors but
their importance has been questioned. The lack of peripheral
vasoconstictor effects mediated through alpha 2 adrenoceptors is
surprising and deserves investigation. Peripheral alpha 2
adrenoceptors have been located in the vasculature and mediate
vasoconstriction. Clonidine is believed to act centrally on the same
type of receptor. It should follow that hypotenisive and
hypertensive actions would appear over the same dose range. However
higher concentrations appear to be required for peripheral
vasoconstriction. A plausible approach could involve perfusing a
neurally intact hindlimb with a perfusate containing clonidine. Both
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changes in hindlimb vascular resistance to stimuli evoking reflex
alterations, carotid occlusion, asphyxia vasoactive drugs, and
changes in the resting resistance could be investigated. A further
development would require cross perfusing the limb from a second
animal and administration of clonidine to the donor. A comparison
between the hypotensive effect and alterations in the responsiveness
of the hindlirab to reflexes causing changes in vasoconstrictor tone
would highlight peripheral and central effects.
Quantitative autoradiography could be employed in catecholamine
turnover experiments to increase their spatial resolution, by
loading with tritiated noradrenaline and looking at the rate of
decline during various manipulations. If care was taken to control
afferent inputs during clonidine treatment the effects on different
catecholamine containing nuclei could be investigated.
Finally further work on the differential effects of clonidine
on autonomic efferents would be interesting, particularly the action
on muscle vasodilator nerves and different vagal fibres. Clonidine
lowers vagal drive to the stomach but increases cardiac vagal tone.
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"Pulseless" Roller Pump
Roller pumps are inherently pulsatile. They operate by
occluding flexible tubing and as the roller rotates fluid is pushed
forward. The rollers and the race, the area supporting the tubing
when it is in contact with the rollers, are so designed that at
least one roller always occludes the tubing. Occlusion is sufficient
to maintain different pressures on either side of the roller.
Pulsations arise from a change in the rate of fluid delivery. The
major cause is roller engagement and disengagement. As a roller
disengages the tubing returns to its original dimensions. The
increase in volume briefly reduces the forward flow of fluid and a
drop in pressure downstream of the pump results. Engagement of a
roller has the opposite effect upstream of the pump.
In cardiovascular physiology roller pumps are often used to
perfuse a isolated limbs or organs and the pressure generated
dowastream of the pump is taken as a measure of resistance. When the
pumping rate is constant a change in pressure does represent a
change in resistance but roller pump3 are pulsatile. The size of the
associated pressure change depends upon the compliance of the
system. However tissues and receptors respond differently to
pulsatile and non pulsatile pressures (Cox & Bagshaw 1930, Spickler
at al 1967) making non pulsatile or controlled pulsatile perfusions
desirable. A common method of reducing pressure pulsations is to
increase artificially the compliance of the system using a side arm
containing air. The column of air changes volume during pulsations
damping them, the degree of damping depending on the volume of air
in the side arm. Damping reduces the frequency response of system
which is undesirable and makes the experimental imposition of
pulsations more difficult. However if the compliance of the perfused
tissue changes, but not the resistance to flow, the size of any
pressure pulsation al30 changes thereby altering the conditions of
the perfusion. A balance has to be struck between frequency response
and the accepted level of pulsation. Clearly a reduction in the
inherent pulsatility of roller pump3 used for circulatory perfusion
experiments is desirable.
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Potential Causes Of Eulsations
1) Engagement and disengagement of rollers.
As mentioned above the rollers cause pulsations, the volume involved
depends upon the diameter of the roller and the degree to which the
tubing is compressed. The magnitude and duration of the oressure
pulse further reflects time over which the volume change occurs. If
rapid the pulse will be brief but intense and if prolonged smaller
but of greater duration, an inverse relationship. It follows that
variations between rollers will cause different pressure pulses.
Examination of the Watson Marlow pump (MRHE 200) shows variations
in the diameter of rollers and variations in the distance from the
centre of rotation which lead to the generation by each roller of a
different sized pulse.
2) Tubing not lying in the plane of roller rotation.
As the roller moves it pushes fluid ahead. The volume displaced by a
given rotation is the length of tubing under the roller X the
internal diameter. Therefore if the tubing is at an angle to the
plane of rotation of the rollers the volume pumped is not the
distance moved by the roller multiplied by the internal diameter of
the tubing. It becomes an function of the angle from the plane of
rotation. If the tubing is free to move the angle will alter
unpredictably and alterations in flow arise.
3) C hang es in rate of pumping.
A change in the speed of the pump will cause a change in fluid
output. This may arise during one cylce of engagement, pumping and
disengagement if the torque of the motor is insufficient. In the
Watson "darlow pump this occurs at low speeds during engagement of
the roller with the tubing.
Solutions
1) Removal of differences between rollers.
Ideally the rollers should be located symmetrically around the
centre of the motor spindle but in practice symmetry is achieved
around the centre of the roller holder. In the Watson Marlow pumps
the roller holder is attached to the motor spindle by a grub screw.
Appendix 1 . d
When tightened this moves the rollers relative to the motor spindle
and the symmetrical arrangement is lost. A new roller holder that
attaches to the motor spindle by friction was made, this preserves
symmetry by ensuring that the centre of the roller holder and the
spindle are the same.
New rollers were made from brass to high tolerances and their
effective diameter measured during rotation on the motor spindle.
The effective diameter is the distance from the centre of the motor
spindle to the edge of the roller. This is not the distance from the
centre of the motor spindle to the centre of rotation of each roller
plus half the diameter of the roller because this omits any
difference between the individual roller spindle and the centre hole
of the roller which reduces the effective size of the latter.
Differences between rollers in postion on the pump were +_ one
thousandth of one inch.
2) Alterations to the race.
If disengagement of the roller from the tubing occurred slowly
with a constant rate of change in volume of the latter pulsations
from this cause would be eliminated. The race was redesigned
accordingly.
This requires that the disengagement arc is equivalent to the
pumping arc. In the Watson Marlow as one roller disengages the
following roller is fully engaged, this is required for the
maintenance of different pressures on each side of the Dump. It was
decided to make operation of the pump "pulseless" for engagement and
disengagement. The new design has a roller leaving the race for the
whole of the pumping arc, therefore the following roller has to be
in contact with the race to maintain the seal. When one roller has
just completely left the tubing the following roller is about to
start disengaging and the next roller must be fully engaged. In turn
its following roller is beginning to engage. Four rollers are then
close to the tubing. This is difficult to arrange with three rollers
as the pumping arc is then 1 /5 each rotation and the required
disengagement and engagement arc 2/5 of a rotation of the motor
spindle. A six roller pump was decided upon, giving a roller tubing
contact arc of 1/2 a rotation. Increasing the number of rollers
leads to more pulses per rotation but reduces the size of the race,
making construction easier. Increasing the number of rollers
Roller Disengaged Tubing Open
■ Pumping Arc "
Fig. Al.l
Redesigned Race j
a. In the new race the rollers disengage over 1/6 of a complete
cycle, similarly pumping occurs over 1/6 of a cycle.
b. Graph showing the increase in the distance, from the centre of
rotation, of the race during the disengagement cycle. It is not
linear, see line on graph, and is intended to produce uniform change
in the volume of the tubing throughout the cycle.






















































Pump with pressure transducer and clamp downstream. The clamp is
used to increase the resistance to flow of the tubing and permit the
development of pressure.
Fig. kU3
Operation Of Old And New Systems.
Set up without damping the old, Watson Marlow race and rollers
produce large changes in pre33ure downstream of the pump. These
range from below 0 mmHg to above 200 mmHg, both are off scale, when
a mean pressure of 95 mmHg is developed. In the top left trace the
solid parts of the trace show the mean pressure developed, recorded
with the preamplifier set to mean, The pressure pulses to their left
occur in the same circumstances exccept that the preamplifier was
operating undamped. To keep pressures positive the sytem was damped
with an air filled side arm between the pump and transducer.
The new design is displayed in each mode and illustrates the
advantages of the redesigned system.
' The traces were all made with the 3ame pump speed and different
pressures were produced by altering the resistance in the outflow
tubing.
Appendix 1 .4
employed makes uniformity of construction more difficult. Six was
accepted as a compromise between the size of race and number of
rollers.
Redesign of the race
A micrometer was used to push a roller against the tubing,
reading the micrometer gave the movement of the roller. Changes in
the internal volume of the tubing were measured by displacement of
water along a thin bore polythene tube attached to the roller
tubing. This allowed accurate measurement of volume changes. The
relationship between volume displaced and roller movement was used
to redesign the race. The new race was intended to cause uniform
changes in internal tube diameter throughout the engagement and
disengagement cycle, Fig A1.2a,b.
Redesigned Rollers
The diameter of the rollers affects the volume displaced within
the tubing. Similarly the greater the internal diameter of the
tubing the greater the volume displaced by a given size of roller.
A small roller with small bore tubing would lead to a small
displacement of volume. With the unaltered race where disengagement
is rapid a small pressure pulse would result. However the volume
pumped by one rotation would be reduced, requiring a higher pump
3peed. In consequence the volume change would occur over a shorter
period, tending to negate the advantage. A redesigned race would
reduce the rate of change of tube internal volume. The degree of
pressure damping required to cope with a large number of small
pulses is less than that required for a smaller number of large
pulses, depending upon the size of pulse not their frequency.
The decision about tube size was determined by the particular
pump available. The range of speeds over which it produced a
constant speed of rotation and the range of pumping rates required
forced the adoption of 1.6 mm internal diameter tubing.
A roller size of 6.55 mm was adopted. As the diameter of the
roller is reduced the volume that it displaces on contact with the
tubing does fall in a linear manner. The size chosen is smaller than
that used by Watson Harlow and is a convenient size for machining.
To reduce lateral movement of the tubing the rollers were
provide with flanges, limiting the tubing to a groove just wider
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than its external diameter-
Measurement Of Pressure Pulse During Pumping
The output of the pump was attached with a sidearm to a
pressure transducer and the tubing constricted downstream of the
transducer with a clamp, Fig A1.2. The clamp restricts fluid
outflow and allows generation of pressure changes. The test system
ha3 no damping except that provided by the elasticity of the tubing.
Switches between the Watson Marlow race and rollers and the altered
equipment were made without altering the clamp.
Results
Tne new race and rollers are a marked improvement over those
supplied by Watson Marlow but have not entirely eliminated the
problem of pulsations, A1.3* The variations between individual
rollers has been reduced but still exist, the residual pulse
associated with disengagement is different for each roller.
Disadvantages
The race is specific for one size of tubing, internal and
external diameter are involved in the design. A range of races are
required if a variety of tubing is to be employed. Slight variations
occur in different batches of tubing, degrading the operation of the
race.
Further Possible Improvements
The rollers and their housing were made to the highest
tolerances feasible in the departmental workshop and further
improvements in this direction are unlikely.
When adjusting the race, varying the distance from the rollers
to achieve the minimum pulse, a critical point is reached where
further movement away results in a drop in pressure with 3ome
rollers. Due to failure of the engaged roller to sufficiently
compress the tubing and make a seel. This occurs when the pulsation
associated with other rollers is positive. Increasing the
compression of the tubing by the roller might effect a reduction,
redesinging the race.
The use of a roller pump with a lower speed, permitting the use
of wider bore tubing. This would enable easier construction of the
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race, with 1.5 ram tubing the cutting equipment was operating at its
limits.
In use the tubing does not lie unraoving against the race but is
stretched by each roller as it passes and recoils afterwards. The
design of the race was based upon a static model of roller tubing
interaction and did not take this into account. Reducing the
friction between the tubing and roller might reduce this problem.
Reducing the diameter of the rollers. The volume displaced by a
roller when opposed to the tubing is a function of the the its
diameter. This is a possible approach and would necessitate buildind
new rollers and a new race.
The type of tubing may be of importance, its compliance. Soft
tubing will be stretched by the rollers and recoil to a greater
extent than stiff tubing. However the conetact of a roller on stiff







Circuit Diagram Of Control Box.
In essence a differential amplifier with buffered inputs from the
transducer and a reference voltage. The amplified difference between
the two determines the control voltage which in,turn alters the pump
speed, which tends to reduce the discrepancy between them.
Switch SI selects either an internal or external reference voltage.
Switch S2 alters the polarity of the differential amplifier output.
This enables the use of the system to infuse vasodilating drugs,
when the measured blood pressure exceeds that set by the reference
voltage the rate of infusion is increased, with a vasoconstricting
drug the reverse is required.
The amplifiers are standard 741 operational amplfiers, powered from
+ 15 volts, not shown on diagram.
The gain of the differential amplifier was set to 400.
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Feedback Controller For Watson Marlow Roller Pump
The speed of the pump can be altered by altering the input
voltage on a socket at the rear of the machine. Therefore by taking
the pressure from a transducer downstream of the pump and passing it
through a differential amplifier the pressure generated may be
controlled a the second, reference voltage, input to the amplifier,
Fig A.1.4. The greater the difference in the two voltages the greater
the amplifier output and the faster the pump runs. The gain of the
amplifier determines how closely the pressure generated follows the
second input to the amplifier. If the pressure at the transducer
alters the feedback loop operates to return the pressure the
original level.
The output voltage of the feedback controller varies from 0-14
volts.
Uses Of System
1) Infusion of drugs.
The pump wa3 attached to a solution of either glyceryl trinitrate or
phenylephrine and connected to a vein. The pressure transducer
measures arterial pressure, Fig 41.5a. The system was intended to
provide maintained changes in blood pressure by using the feedback
loop to alter the rate of infusion of a vasoactive substance.
Altering the reference voltage selected the pressure to be achieved,
A1.6c.
The system worked sometimes but the fast reponse time of the
feedback system and the slower response of the animal to changes in
infusion rate led to oscillations in pressure and infusion rate. A
fall in pressure leads to an increase in the rate of infusion which
after a delay raises pressure which in turn reduces the infusion
rate leading to a drop in pressure etc. Further at any time only a
vasodilator or vasoconstrictor can be used, restricting changes in
blood pressure to increases or decreases.
A reduction in the response time of the feedback loop with large
capacitors on the output of the differential amplifier reduced the
oscillations.
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2) Constant pressure souroe
Leaving the referenoe voltage unchanged makes the system operate as
a constant pressure source for use in perfusions, Fig A.1 . 5b• Changes
in resistance are shown by alterations in the control voltage
driving the pump, A1.6a.
3) Variable pressure source
Fig A1.4c. The input to the pump was attached to the cardiac end of
the common carotid artery and the output to the central end of both
common carotids. The head and baroreceptor3 receive a pressure
determined by the control voltage, \1.6b. The intention was to
investigate changes in heart rate associated with blood pressure at
the brain and baroreceptors. With rises in pressure heart rate falls
and so does blood pressure recorded from the femoral artery. The
surgery involved is not too onerous and the preparation was intended
to supercede studies on heart rate where TV vasoconstrictor or
vasodilator drugs are used to alter afferent input and evoke a
reflex response.
Once a "pulseless" roller pump that required little oressure damping
had been made a signal generator could replace the reference
voltage, permitting the generation of static and dynamic pressures
at high frequency.
4) Flowmeter
If a pressure transducer downstream of the pump has its output fed
into the reference voltage input of the differential amplifier the
pressure generated downstream will follow that upstream of the pump.
Fig A1.41. The control voltage to the pump than becomes a measure
of pumping rate or blood flow of a tissue perfused perfused tissue.
A solution for those not having sophisticated flow meters.
Tnis approach has not been used and is therefore speculative.
At the time when this system was being considered Mohram published a
paper (1930) which has many similarites. The pump used has four
rollers and is designed to reduce only pulsations downstream of the
pump. The size of tubing used, 0.25 inch, makes manufacture of a







Applications Of The Control Box.
Illustrated by different applications in an animal hindlimb.
T - pressure transducer
R - reference voltage input in the feedback controller.
a) Infusion of drugs.
When the blood pressure falls below the level set by the
reference voltage the pump is activated and a vasoconsting drug
infused. To operate with vasodilating drugs the inverting switch in
the feedback controller must be activated, the pump is activated
when blood pressure rise3 above the required level.
b) Constant pressure perfusion.
Alterations in vascular resistance are recorded by the pressure
transducer and the feedback controller alters the pumping rate
accordingly.
c) Variable pressue source.
A3 in b) except that the reference voltage is varied which in
turn changes the resulting pressure.
d) Flowmeter.
t, a second tranducer, measures arterial pressure which is used
as the reference voltage. Thereby causing the perfusion pressure to
follow. The control voltage driving the pump is a measure of the
pumping rate and therefore perfusion rate at the ambient arterial






























The feedback controller in operation
a) The panel on the left has the pump operating at a constant rate
perfusing a carotid artery. IV PHE increases arterial pressure and
after a delay, accounted for by the volume in the external circuit,
carotid pressure al30 rises. In the right panel the feedback
controller is operating as a constant pressure source and no
increase incarotid pressure occurs, instead the control voltage
falls preventing the pressure rise. A pressure increase of 30 mmHg
in the left panel is reduced to 3 mmHg.
b) Variable pressure source. The carotid artery is perfused and
alterations in the reference voltage are used to change the carotid
pressure. The control voltage increases with each pressure step and
arterial pressure, recorded from the femoral artery falls. Arterial
pressure changes are assumed to occur through the baroreceptors
which were intact.
Appendix 1.













PHE was given as a vasoconstrictor.
At the first * on the baseline the pump was turned on. Until then
the changes in control voltage have no effect. At each subsequent *
the reference voltage was altered, seen as a step change in the
control voltage, either up or down. After the last * the controller
was switched off.
Oscillations in arterial pressure are the major problem. A change in
infusion rate in not immediately reflected in pressure changes and
the delay allows oscillations to appear, further pressure does no
rapidly drop when the infusio rate drops, tl/2 of PHE. The pump
speeds up, pressure rises after a delay, pump slows attempting to
reach a steady state infusion, but pressure overshoots the pump
stops, infusion rate falls and the pump again speeds up which
restarts the cycle. Slowing the rate of change in the control
voltage should permit the attainment of a steady state. This
arrangement is not applicable where acute pressure changes are
required but is likely to be of use when steady pressures are
required over a long period.
Neurophysiologies! Spike Discriminator And Counter
The naurophysiological spike discriminator was designed to
separate action potentials from noise, distinguish between action
potentials and measure frequency. Frequency is determined by
counting the number of action potentials in a given period rather
than the reciprocal of the interval between action potentials. The
discriminator was intended to increase the yield from experiments
involving nerve recording by permitting analysis of single units
within a multiunit record. It differs from commercial equipment,
which was not available, through the inol\i3ion of a time window in
the gating mechanism and the provision of a multiplexed output
displaying the operation of the gate. Fig A2.1 shows a block diagram
of the machine and fig A2.2 its operation.
Input/Gain
Provides a high input impedance, 2 «1 ohms, and a variable DC
gain of X 1/2 - 15- Signals within the range +14 volts are accepted
at the input.
Gate
The gate consists of two reference voltages, V1 and V2, and a
time window, T2. To generate an output pulse, P2, the incoming
signal must exceed V1 but not V2 and recross V1 within the time
window. When V1 is exceeded there is a period T1 within which an
output pulse cannot be generated and a subsequent period T2 within
which a pulse may be generated. This permits senarate analysis of
action potentials of different duration or amplitude. Fig A2.2-5
show the gate in operation.
Multiplexer
The multiplexer has a single output into which V1 , V2 or signal
are sequentially connected. As switching between inputs is at a high
frequency the operation of the gate can be viewed on one channel of
an oscilloscope. The switching cycle is V1-signal-V2-signal and the
switching frequency 100khz therefore in 1 millisecond the signal is
shows fifty times for 10 microseconds and V1 and V2 twentyfive times
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Fig A2.1 Block Diagram of Spike Discriminator
The gate is the central component, accepting the incoming signal
from the input/gains stage ani seniing signals to the counters and
multiplexer.
Fig A2.2 The Operation Of The Gate
A. variable test pulse (3) is applied to the gate whilst V1 , V2 and
T2 and held constant.
S signal leaving the input/gain stage.
V1 lower reference voltage. The gap in V1 corresponds to the
time gate T2Hysteresis is apparent.
V2 lower reference voltage.
«C1 output from the lower voltage comparator.
P2 output from the gate, goes high when the signal falls within
the apperture set by V1 , V2 and T2. It is initiated when S drops
below V1 . P2 is also apparent a3 a gap in the V2 trace.
Five separate traces are displayed A-S. They were taken from an
oscilloscope.
A. 3 exceeds V1 but not V2 and falls within T2 and P2 is
generated, note hysteresis in V1 and the gap3 in V1 and V2.
B. 3 is shortened and falls outside T2 and fails to generate
P2.
C. S is extended and falls outside T2 and fails to generate p2.
D. 3 exceeds V2 which prevents the generation of P2.
3. 3 falls below V1 and no output is produced.
In four of the five examples no output pulse appears.
fvopanuix. < . c.
During T2 ths signal is displayed at the expense of V1 creating
a gap in V1 corresponding to the time gate and similarly P2 switches
V2 off in favour of the signal, indicating that an output pulse has
been generated. Fig A2.9*
The gate may be made to appear static on an oscilloscope by
using the output from the V1 comparator to initiate each sweep.
Analog Output
The number of output pulses from the gate are counted and
passed into a ten bit, 0-1025, digital to analog converter giving an
analog voltage output compatible with an oscilloscope or pen
recorder. The analog output is updated at the end of each counting
period, alternatively a ramp stepping once for each pulse and
resetting to zero at the end of each period is available. Fig A2.9-
10.
Digital Output
A four digit, 0-999, LTD display gives a numerical count
corresponding to the analog output.
Timing
An oscillator provides a wide range of counting periods. 0.1-10
seconds, and reference frequencies for calibrating the analog
output.
Power Supply












i_. 1 msec 1 volt
Fig A2.3-4 Operation Of The Gate With Action Potentials.
In each case the action potential falls within VI, V2 and T2 and an
output pulse is generated. The time gate is apparent as a gap in the
VI trace and the gap in V2 indicates that a pulse P2 has been
generated. In Fig A2.4 P2 is displayed .








, ■ 1 msec [ 0.1 volt
Fig A2.5 The Gate Operating With A Multiunit Nerve Recording.
The trace shows a multiunit record containing three action
potentials of different height. Only the first falls between VI and
V2 and leads to the production of P.
, , 0.5msec L 1volt
Fig A2.6 Operation Of The Time Gate With Action Potentials.
The same action potential is shown in A and B but in B the time gate
has been extended, causing S to fall below VI outside the time gate.
Only in A is P2 generated.
The oscilloscoope sweep is triggered from the lower voltage
comparator output CI. This means that in successive sweeps the
postion of the gate on the oscilloscope remains unaltered.
Appendix 2
Technical Details
This section explains the detailed operation of each portion of
the apparatus and contains circuit diagrams. To make the circuit
diagrams intelligible power supply connections and earthing have
been ommitted.
Input/Gain
Components 3/4 343 A Quad 741 operational amplifier
Three 741 operational amplifiers are U3ed to providing an input
buffer, a variable D.C. inverted gain amplifier and an inverting
unity gain buffer restoring the polariity of the signal presented to
the comparators and multiplexer.
Gate
Fig A2.11
Components 2 x 74DS123 Dual monostable
74D313 Dual schmitt trigger
74LS74 Dual D type flip flop
2 x LM748c Operational amplifier
The gate produces an output pulse when the incoming signal
falls within the voltage and time windows set by the experimenter.
When V1 is exceeded the output of comparator C1 changes and
initiates a pulse from the monostable M1, the falling edge of which
activates N2 whose pulse duration provides the time window T2. The
period between 71 being crossed and the start of T2 and the duration
of T2 are set using variable resistors on the front of the machine.
When V1 is recrossed P1 is generated from M3 which in turn activates
M4 if it is within T2 and 72 ha3 not been exceeded. If 72 is crossed
the D type flip flop is cleared, altering the output logic level
which through the NAND gates prevents P1 reaching M4 and the
generation of an output pulse, P2. T3 resets the D type flip flop as
it simultaneously attempts to trigger *14 but the delay involved in
the NAND chain prevents the reseting allowing 14 to be triggered if
72 has been exceeded.
743c operational amplifiers were used as comparators in
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preference to LM71 0 or LM'319 comparators as the expected maximum
frequency of incoming spikes is in the kilo rather than megahertz
range and the very fast response time of the comparators renders
them prone to triggering from high frequency signals unrelated to
action potentials. 74L313 Schmitt triggers were used to increase the
switching speed of the LM748s making a secure interface with TTL
components. The 01 comparator incorporates hysteresis, this reduces
the V1 after the incoming signal exceeds the 71 thereby preventing
oscillation in the comparator output when the signal and reference
are of similar magnitude.
The chain of HAND gates prevents P1 reaching M4 when the upoer
voltage comparator or time gate have been violated.
The 741*3123 monostables, used to generate the time gate, are
retriggerable and the timing period starts anew whenever V1 is
exceeded. This prevents triggering from a signal falling inside the
time gate initiated by the proceeding pulse. The connection between
M1 and the CLR input on M2 operates to terminate T2 if it is still
active, making the time gate fully retriggerable.
The reference voltages, V1 and 72, are derived from
potentiometers connected between earth and a 12 7 saner diode
stabilized supply.
An output from C1 is provided externally and is used to
initiate sweeps of the oscilloscope displaying the gate, this
produces a static display of the gate with action potentials
superimposed. This is useful in setting the time gate and for
viewing each action potential.
Multiplexer
Fig A2.12
Components HSF 4052 Dual 4 channel anlog multiplexer
1/2 74LS13 Dual schmitt trigger
74LS10 Triple three input HAND
1/2 74LS73 Dual JK flip flop
LM310 High 3peed voltage follower
The 74LS13 is wired as an oscillator whose output is passed
into a 2 bit binary divider and used to determine which of the four
inputs to the analog multiplexer are connected to the voltage
Fig. A7
0.1 msec -| volt
0.1 msec L 0.1 volt
Fig. A8
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Fig A2.7-3 The Operation Of The Multiplexer
The multiplexer functions by sequentially switching V1,V2 and S into
a single output. The clock, CLK, controls the switching.
In these two - oscilloscope displays the time base is of sufficient
speed to show switching between the three signals. At a slower speed
the gaps in each signal are not apparent, Fig A2.2-5.
In Fig A2.'7 gaps in V1 and V2 and hysteresis of V1 are not shown.
In Fig A2.8 the switching out of V1 in favour of S during T2 and of
V2 during T2 is seen. This enables the operator to view the
operation of the gate on a single channel oscilloscope. Hysteresis
is also apparent.
follower output. The oscillator output pulses are not symmetrical
ani cannot therefore be used to produce switching periods of equal
duration necessitating the U3e of a two bit divider. Input B of the
multiplexer opens either inputs 1 or 3 to the output regardless of
the state of A and as the nerve recording is connected to both it is
displayed for 50$ of the time in 2 1/4 periods. In addition the
nerve recording is displayed during T2 at the expense of V1 and
during P2 at the expense of V2, this is controlled by the 3 triple
NAND gates. The switching in of the signal creates apparent gaps in
the reference voltages increasing the information available to the
operator. When the output of the multiplexer is displayed on an
oscilloscope the following are displayed;
1) Serve recording
2) Lower reference voltage
3) Upper reference voltage
4) Time Gate
5) Whether the signal has triggered an output pulse
6) Hysteresis on the lower reference voltage
The multiplexer output is passed into LM310, a high sneed




Components 74LS73 Dual -JK flip flop
74LS74 Dual D type flip flop
2 x 74LS93 4 bit binary counter
2 x 74LS75 Quad D type flip flop
AD7520 10 bit digital/analog convertor
747 Dual 741 operational amplifier
The 74LS73 and 74LS93s form a ten bit binary counter into which
output pulses from the gate are fed. At the end of each counting
period the D type flip flops are clocked transferring the counts to




Fig A2.9-10 The Analog Output.
In Fig A2.9 the signal is of vagal afferents in the rat showing
cardiac modulation in their discharge.
Analog output
Stimulus
Fig A2.10 shows a thermosensitive unit in a chicken beak.
It responds to a temperature ramp and hold of 32-46°
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digital input. The counting cycle is completed when the binary
counter is cleared. The reference voltage for the D/A convertor is
provided by a twelve volt zener diode and adjusted with a variable
resistor which is used to set a 0-1 Ov outnut range on the D/A
convertor giving individual steps of approximately 10 millivolts.
Digital Counter
Fig A2.14
Components R3 537-024 Four digit multiplexed LED display
7217 C?40S Four decade counter driver
The 7217 counter driver contains all the components required to
count over four decades, store the counts and drive a multiplexed
display. Timing is provided by the timing section.
Timing
Fig A2.15
Components 4x 74L390 Decade counter
74123 Dual Monostable
1/2 74LS13 Schmitt trigger
74L30Q Quad 2 input N4ND
A 1000 fiz oscillator is built around the 74LS13 3chmitt trigger
and the output frequency adjusted U3ing the 0-500 ohm variable
resistor. The decade counters connected sequentially divide the
output from the oscillator and switches 31 and S2 permit selection
of the required counting period or test frequency.
Each cycle involves counting pulses, storing the counts on D
type flip flops and clearing the counters. The output from 31
initiates the timing pulses, CK1 and CX2, which are generated by the
sequential triggering of the 2 monostables. Storage of the counts
occurs at the end of CK1 which is long enough, 60usec, to allow
counting of pulses occuring prior to the start of GK1 . CK2, 280usec,
clears all counters. During the storage'clear interval the 741300
prevents pulses reaching the counters and causing an aberrant analog
and digital output, the interuption of counting for a total of 340
usee in each cycle means that 1 pulse in 300 is lost with a counting
period of 0.1 second.
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The switch 52 selects freqencies in place of pulses derived
form the gate and is used to calibrate the analog ouput.
An input through BC103 allows an external non TTL signal to
determine the counting period.
Fig A2.ll Circuit Diagram Of The Gate.
Multiplexer
IE
Fig A2.12 Circuit Diagram Of The Multiplexer
7 4L800
Fig A2.15 Circuit Diagram Of The Timing.
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The cardiovascular actions of clonidine in the inactin-anaesthetized rat
By J. Adler. Department of Physiology, Royal (Dick) School of Veterinary Studies,
University of Edinburgh, Edinburgh EH9 1QH
In the inactin (130 tng/kg i.p.), thiobutabarbitone, anaesthetized rat clonidine i.v.
rapidly causes a prolonged bradycardia and hypotension after a brief hypertension.
Pretreatment with atenolol (1 mg/kg) or atropine (1 mg/kg) show that heart rate is
under sympathetic but not vagal control and that clonidine-induced bradycardia is
only apparent in the presence of sympathetic tone.
Clonidine after atenolol pretreat ment causes a fall in blood pressure without further
bradycardia indicating an action on the vasculature. This is confirmed using a standard
leurally intact hindlimb perfusion.
A modified 'delayed' hindlimb perfusion with a large extracorporeal circuit was
rsed, blood born actions arc delayed by the time taken to negotiate the extracorporeal
hrcuit whilst neurally mediated actions are immediately apparent. Clonidine, Fig.
I, causes an immediate vasodilatation and a delayed vasoconstriction resulting in a
let vasodilatation. The immediate neurally mediated vasodilatation outlasts the brief
iressor response to i.v. clonidine and is therefore not solely a compensatory response.
The delayed response to clonidine is pressor and no evidence for a peripheral
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Fig. 1. The cardiovascular effects of i.v. clonidine on the 'delayed' hindlimb perfusion.
Schmitt, Schmitt, Boisser, Guidicelli & Fichelle (1968) showed that clonidine
jduced sympathetic nerve activity and these results show a fall in peripheral
isistance resulting from reduced nerve activity.
Supported by SRC CASE Studentship with ICI. .
2
REFERENCES
Pichler. i. & Kobinger, W. (1978). Eur. J. Pharmacol. 52, 287-295.
schmitt, H., SCHMITT, H., BOISSER, J. R., GtJIDICELLI, J. F. & FlCHELLE, J. (1968). Eur. J.
Pharmacol. 2, 340-346.
[From the Proceedings of the Physiological Society, 16-17 July 1982
Journal of Physiology, 332, 68 -69/']
An autoradiographic study into the site of action of clonidine in the rat
By J. Adler. Department of Physiology, Royal (Dick) School of Veterinary Studies,
University of Edinburgh, Edinburgh EH9 1QH
In the anaesthetized rat clonidine causes a fall in blood pressure and bradycardia
through a predominantly central action (Schmitt, Schmitt, Boissier, Guidicelli &
Fichele, 1968). The site of action is not unequivocally established.
In these experiments clonidine was administered to 150-170 g inactin-anaesthetized
rats (thiobutabarbitone 130 mg/kg i.p.) by a variety of routes and the hypotensive
potency and resulting distribution of clonidine studied. Diffusible substance auto¬
radiography with tritiated clonidine (Amersham) and the LKB tritium-sensitive film
were used to locate the injected clonidine.
Intravertebral administration was achieved by retrograde injection into the right
common carotid artery after ligation of all accessible branches of the right subclavian
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Fig. 1. Clonidine, 0-25 /ig/kg, administration in an anaesthetized rat with an intravertebral,
femoral venous and arterial cannulae. Injections in 40 y\. over 40 sec.
into the lateral ventricle, internal carotid artery or femoral vein were of similar
potency although intraventricular injection resulted in a greatly reduced onset of
action. The autoradiograms show that intravenously administered clonidine distri¬
butes evenly over the c.n.s. whilst other routes lead to high concentrations in different
areas: intraventricular in areas bordering on the ventricular system and spinal canal,
intracarotid in areas rostral to the medulla, intravertebral in the medulla, upper
segments of the spinal cord, pons and caudal portions of the cerebellum. This suggests
that in the rat the locus of clonidine's antihypertensive action is within the medulla
ar pons but not on the borders of the ventricular system.
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